<!DOCTYPE html><html lang="en" class="bg-surface-base antialiased"><head><meta charSet="utf-8"/><meta name="viewport" content="width=device-width, initial-scale=1, interactive-widget=resizes-content"/><link rel="stylesheet" href="/_next/static/css/62c4caba71dfda84.css" nonce="MDFkNTc1MWYtZjA5OC00YWU2LWJmZGQtOTJjODZlMmExY2I0" data-precedence="next"/><link rel="stylesheet" href="/_next/static/css/eb3d87f98fe1565f.css" nonce="MDFkNTc1MWYtZjA5OC00YWU2LWJmZGQtOTJjODZlMmExY2I0" data-precedence="next"/><link rel="stylesheet" href="/_next/static/css/1b5e561215938d4d.css" nonce="MDFkNTc1MWYtZjA5OC00YWU2LWJmZGQtOTJjODZlMmExY2I0" data-precedence="next"/><link rel="stylesheet" href="/_next/static/css/0227d069a630d414.css" nonce="MDFkNTc1MWYtZjA5OC00YWU2LWJmZGQtOTJjODZlMmExY2I0" data-precedence="next"/><link rel="stylesheet" href="/_next/static/css/f87fff2ab93d05a7.css" nonce="MDFkNTc1MWYtZjA5OC00YWU2LWJmZGQtOTJjODZlMmExY2I0" data-precedence="next"/><link rel="preload" as="script" fetchPriority="low" nonce="MDFkNTc1MWYtZjA5OC00YWU2LWJmZGQtOTJjODZlMmExY2I0" href="/_next/static/chunks/webpack-e121ed42680f327e.js"/><script src="/_next/static/chunks/78a669d9-e7993486b22c4915.js" async="" nonce="MDFkNTc1MWYtZjA5OC00YWU2LWJmZGQtOTJjODZlMmExY2I0"></script><script src="/_next/static/chunks/40c4a5a7-abdabb07419d1cfc.js" async="" nonce="MDFkNTc1MWYtZjA5OC00YWU2LWJmZGQtOTJjODZlMmExY2I0"></script><script src="/_next/static/chunks/2230-f7c87dc9fa57c408.js" async="" nonce="MDFkNTc1MWYtZjA5OC00YWU2LWJmZGQtOTJjODZlMmExY2I0"></script><script src="/_next/static/chunks/main-app-536d4b8fca62396a.js" async="" nonce="MDFkNTc1MWYtZjA5OC00YWU2LWJmZGQtOTJjODZlMmExY2I0"></script><script src="/_next/static/chunks/63f0ec43-8ee6a76d70472249.js" async="" nonce="MDFkNTc1MWYtZjA5OC00YWU2LWJmZGQtOTJjODZlMmExY2I0"></script><script src="/_next/static/chunks/7670-7326298c9856172b.js" async="" nonce="MDFkNTc1MWYtZjA5OC00YWU2LWJmZGQtOTJjODZlMmExY2I0"></script><script src="/_next/static/chunks/282-691fffb366e24ca5.js" async="" nonce="MDFkNTc1MWYtZjA5OC00YWU2LWJmZGQtOTJjODZlMmExY2I0"></script><script src="/_next/static/chunks/7515-336759ef5dad2b52.js" async="" nonce="MDFkNTc1MWYtZjA5OC00YWU2LWJmZGQtOTJjODZlMmExY2I0"></script><script src="/_next/static/chunks/927-34e2a6da3e15e26b.js" async="" nonce="MDFkNTc1MWYtZjA5OC00YWU2LWJmZGQtOTJjODZlMmExY2I0"></script><script src="/_next/static/chunks/5855-243eeca8f0e4cabd.js" async="" nonce="MDFkNTc1MWYtZjA5OC00YWU2LWJmZGQtOTJjODZlMmExY2I0"></script><script src="/_next/static/chunks/4393-1c8dff25ec904469.js" async="" nonce="MDFkNTc1MWYtZjA5OC00YWU2LWJmZGQtOTJjODZlMmExY2I0"></script><script src="/_next/static/chunks/2225-454cf9f44775e7ce.js" async="" nonce="MDFkNTc1MWYtZjA5OC00YWU2LWJmZGQtOTJjODZlMmExY2I0"></script><script src="/_next/static/chunks/7618-43536a8fb0dd3bfe.js" async="" nonce="MDFkNTc1MWYtZjA5OC00YWU2LWJmZGQtOTJjODZlMmExY2I0"></script><script src="/_next/static/chunks/app/page/%5Bslug%5D/layout-55a344716dd57c44.js" async="" nonce="MDFkNTc1MWYtZjA5OC00YWU2LWJmZGQtOTJjODZlMmExY2I0"></script><script src="/_next/static/chunks/7720-3a1e7e411adba2d3.js" async="" nonce="MDFkNTc1MWYtZjA5OC00YWU2LWJmZGQtOTJjODZlMmExY2I0"></script><script src="/_next/static/chunks/7086-1f1c4891d766e04f.js" async="" nonce="MDFkNTc1MWYtZjA5OC00YWU2LWJmZGQtOTJjODZlMmExY2I0"></script><script src="/_next/static/chunks/app/page/%5Bslug%5D/not-found-69a3edc7db5749d6.js" async="" nonce="MDFkNTc1MWYtZjA5OC00YWU2LWJmZGQtOTJjODZlMmExY2I0"></script><script src="/_next/static/chunks/app/global-error-4d07d20223cd4b4c.js" async="" nonce="MDFkNTc1MWYtZjA5OC00YWU2LWJmZGQtOTJjODZlMmExY2I0"></script><script src="/_next/static/chunks/8208b75a-a48e5a4507a0de91.js" async="" nonce="MDFkNTc1MWYtZjA5OC00YWU2LWJmZGQtOTJjODZlMmExY2I0"></script><script src="/_next/static/chunks/5497-ab85ef3ea59dd353.js" async="" nonce="MDFkNTc1MWYtZjA5OC00YWU2LWJmZGQtOTJjODZlMmExY2I0"></script><script src="/_next/static/chunks/6281-c6e84786dade3614.js" async="" nonce="MDFkNTc1MWYtZjA5OC00YWU2LWJmZGQtOTJjODZlMmExY2I0"></script><script src="/_next/static/chunks/2660-d983a7f287e89f18.js" async="" nonce="MDFkNTc1MWYtZjA5OC00YWU2LWJmZGQtOTJjODZlMmExY2I0"></script><script src="/_next/static/chunks/5002-9735c25beda556ba.js" async="" nonce="MDFkNTc1MWYtZjA5OC00YWU2LWJmZGQtOTJjODZlMmExY2I0"></script><script src="/_next/static/chunks/3655-6717081f7512305a.js" async="" nonce="MDFkNTc1MWYtZjA5OC00YWU2LWJmZGQtOTJjODZlMmExY2I0"></script><script src="/_next/static/chunks/8945-e4e3cf487f5e27c7.js" async="" nonce="MDFkNTc1MWYtZjA5OC00YWU2LWJmZGQtOTJjODZlMmExY2I0"></script><script src="/_next/static/chunks/9214-a10614844a67ba31.js" async="" nonce="MDFkNTc1MWYtZjA5OC00YWU2LWJmZGQtOTJjODZlMmExY2I0"></script><script src="/_next/static/chunks/4789-2080f6497f78b5b6.js" async="" nonce="MDFkNTc1MWYtZjA5OC00YWU2LWJmZGQtOTJjODZlMmExY2I0"></script><script src="/_next/static/chunks/app/layout-226f2bd71acf9f9e.js" async="" nonce="MDFkNTc1MWYtZjA5OC00YWU2LWJmZGQtOTJjODZlMmExY2I0"></script><script src="/_next/static/chunks/24cf1b50-159cca90b09285e0.js" async="" nonce="MDFkNTc1MWYtZjA5OC00YWU2LWJmZGQtOTJjODZlMmExY2I0"></script><script src="/_next/static/chunks/9ffa21ba-c069766d809bd4c7.js" async="" nonce="MDFkNTc1MWYtZjA5OC00YWU2LWJmZGQtOTJjODZlMmExY2I0"></script><script src="/_next/static/chunks/600-9a9fcafaaa6c1c4c.js" async="" nonce="MDFkNTc1MWYtZjA5OC00YWU2LWJmZGQtOTJjODZlMmExY2I0"></script><script src="/_next/static/chunks/5448-2a3cfd853d899c9a.js" async="" nonce="MDFkNTc1MWYtZjA5OC00YWU2LWJmZGQtOTJjODZlMmExY2I0"></script><script src="/_next/static/chunks/8-8ca70ca619d8e099.js" async="" nonce="MDFkNTc1MWYtZjA5OC00YWU2LWJmZGQtOTJjODZlMmExY2I0"></script><script src="/_next/static/chunks/app/page/%5Bslug%5D/page-540a27b6839afde5.js" async="" nonce="MDFkNTc1MWYtZjA5OC00YWU2LWJmZGQtOTJjODZlMmExY2I0"></script><script src="/_next/static/chunks/app/error-4a29e9399afba038.js" async="" nonce="MDFkNTc1MWYtZjA5OC00YWU2LWJmZGQtOTJjODZlMmExY2I0"></script><script src="/_next/static/chunks/app/not-found-dd95690acf732f18.js" async="" nonce="MDFkNTc1MWYtZjA5OC00YWU2LWJmZGQtOTJjODZlMmExY2I0"></script><meta name="next-size-adjust" content=""/><title>Grokipedia</title><meta name="description" content="Grokipedia is an open source, comprehensive collection of all knowledge."/><link rel="icon" type="image/x-icon" href="/favicon.ico" sizes="48x48"/><link rel="icon" href="/images/icon-dark.png" media="(prefers-color-scheme: light)" type="image/png"/><link rel="icon" href="/images/icon-light.png" media="(prefers-color-scheme: dark)" type="image/png"/><link rel="apple-touch-icon" href="/icon-192x192.png"/><link rel="manifest" href="/manifest.webmanifest"/><meta name="robots" content="index, follow"/><meta name="googlebot" content="index, follow, max-snippet:-1"/><meta property="og:title" content="Grokipedia"/><meta property="og:description" content="Grokipedia is an open source, comprehensive collection of all knowledge."/><meta property="og:url" content="https://grokipedia.com"/><meta property="og:site_name" content="Grokipedia"/><meta property="og:locale" content="en_US"/><meta property="og:type" content="website"/><meta property="og:image" content="https://grokipedia.com/icon-512x512.png"/><meta property="og:image:width" content="512"/><meta property="og:image:height" content="512"/><meta property="og:image:alt" content="Grokipedia"/><meta name="twitter:card" content="summary"/><meta name="twitter:creator" content="@Grokipedia"/><meta name="twitter:title" content="Grokipedia"/><meta name="twitter:description" content="Grokipedia is an open source, comprehensive collection of all knowledge."/><meta name="twitter:image" content="https://grokipedia.com/icon-512x512.png"/><title>Boehringer Ingelheim</title><meta name="description" content="Boehringer Ingelheim is a privately held, research-driven biopharmaceutical company headquartered in Ingelheim am Rhein, Germany. Founded in 1885 by Albert Boehringer initially as a chemicals manufacturer producing tartaric acid and baking powder, it has grown into a global enterprise focused on developing innovative therapies for human and animal health. The company&#x27;s independence from public markets allows a long-term perspective on research and development, with annual R&amp;D investments..."/><meta name="author" content="system"/><link rel="manifest" href="/manifest.webmanifest"/><meta name="keywords" content="BI, Boehringer"/><meta name="robots" content="index, follow"/><meta name="googlebot" content="index, follow, max-snippet:-1"/><link rel="canonical" href="https://grokipedia.com/page/Boehringer_Ingelheim"/><meta property="og:title" content="Boehringer Ingelheim"/><meta property="og:description" content="Boehringer Ingelheim is a privately held, research-driven biopharmaceutical company headquartered in Ingelheim am Rhein, Germany. Founded in 1885 by Albert Boehringer initially as a chemicals manufacturer producing tartaric acid and baking powder, it has grown into a global enterprise focused on developing innovative therapies for human and animal health. The company&#x27;s independence from public markets allows a long-term perspective on research and development, with annual R&amp;D investments..."/><meta property="og:url" content="https://grokipedia.com/page/Boehringer_Ingelheim"/><meta property="og:site_name" content="Grokipedia"/><meta property="og:locale" content="en"/><meta property="og:image" content="https://grokipedia.com/icon-512x512.png"/><meta property="og:image:width" content="512"/><meta property="og:image:height" content="512"/><meta property="og:image:alt" content="Boehringer Ingelheim"/><meta property="og:type" content="article"/><meta property="article:modified_time" content="1970-01-21T09:19:42.740Z"/><meta name="twitter:card" content="summary"/><meta name="twitter:creator" content="@Grokipedia"/><meta name="twitter:title" content="Boehringer Ingelheim"/><meta name="twitter:description" content="Boehringer Ingelheim is a privately held, research-driven biopharmaceutical company headquartered in Ingelheim am Rhein, Germany. Founded in 1885 by Albert Boehringer initially as a chemicals manufacturer producing tartaric acid and baking powder, it has grown into a global enterprise focused on developing innovative therapies for human and animal health. The company&#x27;s independence from public markets allows a long-term perspective on research and development, with annual R&amp;D investments..."/><meta name="twitter:image" content="https://grokipedia.com/icon-512x512.png"/><link rel="icon" href="/favicon.ico" type="image/x-icon" sizes="16x16"/><meta name="sentry-trace" content="ee8bcdc0634cc5b31c130f23112e5c73-81f3724daedb8d98-1"/><meta name="baggage" content="sentry-environment=production,sentry-public_key=5f2258f71198ee26a355127af230c3a6,sentry-trace_id=ee8bcdc0634cc5b31c130f23112e5c73,sentry-org_id=4508179396558848,sentry-transaction=GET%20%2Fpage%2F%5Bslug%5D,sentry-sampled=true,sentry-sample_rand=0.29113310936921066,sentry-sample_rate=1"/><script src="/_next/static/chunks/polyfills-42372ed130431b0a.js" noModule="" nonce="MDFkNTc1MWYtZjA5OC00YWU2LWJmZGQtOTJjODZlMmExY2I0"></script></head><body class="flex h-[100svh] w-full flex-col __variable_13c637 __variable_8a0ba0 __variable_779740 __variable_2484fd __variable_525cc3 __variable_13486b"><div hidden=""><!--$--><!--/$--></div><script nonce="MDFkNTc1MWYtZjA5OC00YWU2LWJmZGQtOTJjODZlMmExY2I0">((a,b,c,d,e,f,g,h)=>{let i=document.documentElement,j=["light","dark"];function k(b){var c;(Array.isArray(a)?a:[a]).forEach(a=>{let c="class"===a,d=c&&f?e.map(a=>f[a]||a):e;c?(i.classList.remove(...d),i.classList.add(f&&f[b]?f[b]:b)):i.setAttribute(a,b)}),c=b,h&&j.includes(c)&&(i.style.colorScheme=c)}if(d)k(d);else try{let a=localStorage.getItem(b)||c,d=g&&"system"===a?window.matchMedia("(prefers-color-scheme: dark)").matches?"dark":"light":a;k(d)}catch(a){}})("class","theme","dark",null,["light","dark"],null,true,true)</script><header class="h-16 bg-surface-base fixed top-0 z-50 w-full"><div class="hidden h-full grid-cols-[1fr_3fr_1fr] items-center gap-4 !py-0 md:grid max-w-full py-6 px-4 w-full mx-auto"><div class="-ml-2 justify-self-start"><a class="cursor-pointer" href="/"><svg width="200" height="auto" viewBox="0 0 955 225" fill="none" xmlns="http://www.w3.org/2000/svg"><path d="M99.6937 159.214C90.008 159.214 81.5652 157.414 74.3652 153.814C67.1652 150.214 61.5509 144.986 57.5223 138.129C53.5794 131.271 51.608 123.043 51.608 113.443C51.608 103.843 53.5794 95.4857 57.5223 88.3714C61.5509 81.2572 67.1652 75.7286 74.3652 71.7857C81.6509 67.8429 90.1794 65.8714 99.9509 65.8714C103.208 65.8714 106.679 66.1286 110.365 66.6429C114.051 67.0714 117.222 67.6714 119.879 68.4429C121.508 68.8714 123.008 69.2572 124.379 69.6C125.751 69.9429 127.122 70.1143 128.494 70.1143C129.522 70.1143 130.551 69.9857 131.579 69.7286C131.751 73.5 131.922 77.4 132.094 81.4286C132.265 85.4572 132.522 89.6572 132.865 94.0286C131.065 94.2857 129.565 94.3714 128.365 94.2857C126.651 86.4 123.522 80.5714 118.979 76.8C114.437 72.9429 108.394 71.0143 100.851 71.0143C94.8509 71.0143 89.708 72.1286 85.4223 74.3572C81.2223 76.5 77.7937 79.4572 75.1366 83.2286C72.5652 87 70.6794 91.3714 69.4794 96.3429C68.2794 101.229 67.6794 106.457 67.6794 112.029C67.6794 120.171 68.9223 127.371 71.408 133.629C73.8937 139.886 77.6652 144.814 82.7223 148.414C87.8652 151.929 94.2937 153.686 102.008 153.686C104.408 153.686 107.065 153.471 109.979 153.043C112.894 152.529 115.679 151.757 118.337 150.729V134.529C118.337 131.871 118.208 129.814 117.951 128.357C117.779 126.814 117.222 125.7 116.279 125.014C115.422 124.329 114.008 123.857 112.037 123.6C110.151 123.257 107.537 122.957 104.194 122.7C103.937 121.329 103.937 119.957 104.194 118.586C105.994 118.586 108.179 118.629 110.751 118.714C113.322 118.714 115.894 118.757 118.465 118.843C121.122 118.843 123.308 118.843 125.022 118.843C127.679 118.843 130.722 118.8 134.151 118.714C137.665 118.629 140.665 118.586 143.151 118.586C143.322 119.871 143.322 121.2 143.151 122.571C139.637 123 137.108 123.429 135.565 123.857C134.022 124.286 133.079 125.143 132.737 126.429C132.394 127.714 132.222 129.9 132.222 132.986V137.1C132.222 141.129 132.308 144.514 132.479 147.257C132.737 150 132.951 151.971 133.122 153.171C121.208 157.2 110.065 159.214 99.6937 159.214ZM148.19 157.414C147.933 156.043 147.933 154.714 148.19 153.429C151.105 153.257 153.248 153 154.619 152.657C155.99 152.229 156.89 151.371 157.319 150.086C157.748 148.8 157.962 146.743 157.962 143.914V115.114C157.962 111.771 157.79 109.286 157.448 107.657C157.19 106.029 156.376 104.914 155.005 104.314C153.719 103.629 151.49 103.071 148.319 102.643C148.062 101.443 148.062 100.329 148.319 99.3C151.748 98.6143 155.09 97.8429 158.348 96.9857C161.605 96.0429 165.033 94.8429 168.633 93.3857L170.819 94.1572V105.471C176.819 97.8429 182.948 94.0286 189.205 94.0286C192.205 94.0286 194.433 94.8429 195.89 96.4714C197.348 98.0143 198.076 99.7714 198.076 101.743C198.076 104.057 197.305 105.857 195.762 107.143C194.219 108.343 192.462 108.943 190.49 108.943C188.862 108.943 187.233 108.514 185.605 107.657C184.062 106.8 182.905 105.471 182.133 103.671C179.219 103.671 176.605 104.829 174.29 107.143C172.062 109.371 170.948 111.986 170.948 114.986V142.629C170.948 145.971 171.119 148.371 171.462 149.829C171.89 151.286 172.919 152.229 174.548 152.657C176.262 153 179.005 153.257 182.776 153.429C182.948 154.629 182.948 155.957 182.776 157.414C179.862 157.414 176.862 157.371 173.776 157.286C170.69 157.2 167.519 157.157 164.262 157.157C161.09 157.157 158.262 157.2 155.776 157.286C153.376 157.371 150.848 157.414 148.19 157.414ZM229.285 158.829C223.028 158.829 217.542 157.5 212.828 154.843C208.199 152.1 204.599 148.371 202.028 143.657C199.457 138.857 198.171 133.371 198.171 127.2C198.171 120.514 199.499 114.686 202.157 109.714C204.899 104.743 208.714 100.886 213.599 98.1429C218.485 95.4 224.099 94.0286 230.442 94.0286C236.699 94.0286 242.142 95.4 246.771 98.1429C251.399 100.886 254.999 104.657 257.571 109.457C260.142 114.257 261.428 119.7 261.428 125.786C261.428 132.043 260.057 137.7 257.314 142.757C254.657 147.729 250.928 151.671 246.128 154.586C241.328 157.414 235.714 158.829 229.285 158.829ZM212.699 125.657C212.699 134.4 214.114 141.343 216.942 146.486C219.857 151.543 224.185 154.071 229.928 154.071C235.414 154.071 239.614 151.671 242.528 146.871C245.442 141.986 246.899 135.471 246.899 127.329C246.899 118.671 245.442 111.771 242.528 106.629C239.614 101.486 235.371 98.9143 229.799 98.9143C224.314 98.9143 220.071 101.271 217.071 105.986C214.157 110.7 212.699 117.257 212.699 125.657ZM267.394 157.414C267.308 157.071 267.265 156.729 267.265 156.386C267.265 156.043 267.265 155.7 267.265 155.357C267.265 155.014 267.265 154.714 267.265 154.457C267.265 154.114 267.308 153.771 267.394 153.429C270.308 153.257 272.451 153 273.822 152.657C275.194 152.229 276.094 151.371 276.522 150.086C276.951 148.8 277.165 146.743 277.165 143.914V79.5C277.165 76.8429 276.908 74.8714 276.394 73.5857C275.965 72.2143 274.979 71.2714 273.437 70.7572C271.979 70.1572 269.751 69.7286 266.751 69.4714C266.665 69.1286 266.622 68.8286 266.622 68.5714C266.622 68.3143 266.622 68.0572 266.622 67.8C266.622 67.4572 266.622 67.1572 266.622 66.9C266.622 66.6429 266.665 66.3429 266.751 66C270.179 65.5714 273.694 64.9286 277.294 64.0714C280.894 63.1286 284.579 61.8429 288.351 60.2143L290.537 60.9857C290.451 62.8714 290.365 65.0143 290.279 67.4143C290.279 69.8143 290.279 72.4286 290.279 75.2572V122.957C291.308 122.957 292.165 122.786 292.851 122.443C293.537 122.1 294.094 121.757 294.522 121.414C294.694 121.243 295.037 120.943 295.551 120.514C296.065 120 296.965 119.1 298.251 117.814C299.537 116.529 301.379 114.6 303.779 112.029C306.008 109.543 307.765 107.614 309.051 106.243C310.422 104.786 311.108 103.586 311.108 102.643C311.108 101.957 310.508 101.4 309.308 100.971C308.194 100.457 306.651 100.157 304.679 100.071C304.594 99.7286 304.551 99.3857 304.551 99.0429C304.551 98.7 304.551 98.3572 304.551 98.0143C304.551 97.6714 304.551 97.3286 304.551 96.9857C304.551 96.6429 304.594 96.3 304.679 95.9572C306.394 95.9572 308.537 96 311.108 96.0857C313.765 96.1714 316.122 96.2143 318.179 96.2143C319.208 96.2143 320.665 96.2143 322.551 96.2143C324.522 96.1286 326.494 96.0857 328.465 96.0857C330.437 96.0857 331.894 96.0857 332.837 96.0857C332.922 96.4286 332.965 96.7714 332.965 97.1143C333.051 97.4572 333.094 97.8 333.094 98.1429C333.094 98.4857 333.051 98.8286 332.965 99.1714C332.965 99.4286 332.922 99.7286 332.837 100.071C328.379 100.157 324.608 101.271 321.522 103.414C318.437 105.471 315.479 107.914 312.651 110.743L303.394 120L321.137 143.4C323.022 145.886 324.565 147.857 325.765 149.314C327.051 150.686 328.422 151.671 329.879 152.271C331.337 152.871 333.351 153.257 335.922 153.429C336.094 154.629 336.094 155.957 335.922 157.414C334.808 157.414 333.137 157.371 330.908 157.286C328.765 157.2 325.379 157.157 320.751 157.157C320.065 157.157 319.037 157.157 317.665 157.157C316.294 157.157 315.008 157.243 313.808 157.414C313.808 156.471 313.294 155.186 312.265 153.557C311.237 151.843 310.422 150.6 309.822 149.829C309.565 149.4 308.922 148.5 307.894 147.129C306.865 145.671 305.622 144 304.165 142.114C302.794 140.143 301.379 138.171 299.922 136.2C298.465 134.143 297.137 132.343 295.937 130.8C294.994 129.514 294.094 128.529 293.237 127.843C292.465 127.071 291.479 126.686 290.279 126.686V142.629C290.279 145.971 290.408 148.371 290.665 149.829C291.008 151.286 291.737 152.229 292.851 152.657C294.051 153 295.851 153.257 298.251 153.429C298.422 154.714 298.422 156.043 298.251 157.414C296.022 157.414 293.665 157.371 291.179 157.286C288.779 157.2 286.165 157.157 283.337 157.157C280.594 157.157 277.894 157.2 275.237 157.286C272.579 157.371 269.965 157.414 267.394 157.414ZM369.34 157.414C366.94 157.414 364.454 157.371 361.883 157.286C359.311 157.2 356.526 157.157 353.526 157.157C350.783 157.157 347.997 157.2 345.169 157.286C342.426 157.371 339.769 157.414 337.197 157.414C336.94 156.043 336.94 154.714 337.197 153.429C340.111 153.257 342.254 153 343.626 152.657C344.997 152.229 345.897 151.371 346.326 150.086C346.754 148.8 346.969 146.743 346.969 143.914V115.114C346.969 111.771 346.84 109.286 346.583 107.657C346.326 106.029 345.511 104.914 344.14 104.314C342.854 103.629 340.583 103.071 337.326 102.643C337.069 101.443 337.069 100.329 337.326 99.3C341.097 98.6143 344.697 97.7572 348.126 96.7286C351.554 95.7 354.854 94.5857 358.026 93.3857L360.211 94.1572C360.126 96.8143 360.04 99.3 359.954 101.614C359.954 103.929 359.954 106.114 359.954 108.171V142.629C359.954 145.971 360.126 148.371 360.469 149.829C360.897 151.286 361.754 152.229 363.04 152.657C364.411 153 366.511 153.257 369.34 153.429C369.597 154.714 369.597 156.043 369.34 157.414ZM343.626 71.5286C343.626 69.0429 344.483 66.9429 346.197 65.2286C347.997 63.5143 350.14 62.6572 352.626 62.6572C355.026 62.6572 357.083 63.5143 358.797 65.2286C360.597 66.9429 361.497 69 361.497 71.4C361.497 73.6286 360.64 75.6857 358.926 77.5715C357.211 79.3714 355.026 80.2714 352.369 80.2714C349.969 80.2714 347.911 79.4143 346.197 77.7C344.483 75.9857 343.626 73.9286 343.626 71.5286ZM372.678 188.914C372.592 187.543 372.592 186.214 372.678 184.929C375.678 184.757 377.864 184.457 379.235 184.029C380.607 183.6 381.464 182.743 381.807 181.457C382.235 180.257 382.45 178.286 382.45 175.543V115.114C382.45 111.771 382.278 109.286 381.935 107.657C381.678 106.029 380.864 104.914 379.492 104.314C378.207 103.629 375.978 103.071 372.807 102.643C372.635 101.443 372.635 100.329 372.807 99.3C376.321 98.6143 379.75 97.8 383.092 96.8572C386.435 95.9143 389.907 94.7572 393.507 93.3857L395.307 94.2857C395.221 96.4286 395.178 98.2714 395.178 99.8143C395.178 101.271 395.178 102.686 395.178 104.057C398.521 100.543 401.821 98.0143 405.078 96.4714C408.335 94.8429 411.807 94.0286 415.492 94.0286C420.892 94.0286 425.435 95.4429 429.121 98.2714C432.892 101.1 435.764 104.786 437.735 109.329C439.707 113.871 440.692 118.8 440.692 124.114C440.692 130.371 439.321 136.157 436.578 141.471C433.921 146.7 430.192 150.9 425.392 154.071C420.592 157.243 415.021 158.829 408.678 158.829C406.192 158.829 403.835 158.614 401.607 158.186C399.378 157.843 397.278 157.329 395.307 156.643V174C395.307 177.343 395.564 179.743 396.078 181.2C396.592 182.657 397.707 183.557 399.421 183.9C401.135 184.329 403.835 184.629 407.521 184.8C407.607 186.171 407.607 187.543 407.521 188.914C404.607 188.914 401.65 188.871 398.65 188.786C395.735 188.7 392.521 188.657 389.007 188.657C385.664 188.657 382.792 188.7 380.392 188.786C377.992 188.871 375.421 188.914 372.678 188.914ZM395.178 146.1C398.864 151.414 403.75 154.071 409.835 154.071C414.121 154.071 417.507 152.871 419.992 150.471C422.564 148.071 424.407 144.943 425.521 141.086C426.721 137.229 427.321 133.157 427.321 128.871C427.321 124.586 426.764 120.386 425.65 116.271C424.535 112.157 422.692 108.771 420.121 106.114C417.635 103.371 414.207 102 409.835 102C404.607 102 399.721 104.529 395.178 109.586V146.1ZM477.335 158.829C471.25 158.829 466.107 157.414 461.907 154.586C457.707 151.757 454.493 147.986 452.264 143.271C450.121 138.471 449.05 133.2 449.05 127.457C449.05 121.543 450.164 116.057 452.393 111C454.707 105.943 458.05 101.871 462.421 98.7857C466.793 95.6143 472.107 94.0286 478.364 94.0286C485.907 94.0286 491.778 96.3 495.978 100.843C500.264 105.3 502.407 111.086 502.407 118.2C502.407 119.057 502.364 119.829 502.278 120.514C502.278 121.114 502.235 121.629 502.15 122.057L461.65 121.671C461.65 122.014 461.65 122.314 461.65 122.571C461.65 130.971 463.578 137.571 467.435 142.371C471.293 147.171 476.693 149.571 483.635 149.571C489.464 149.571 495.207 147.686 500.864 143.914C501.721 144.943 502.364 145.929 502.793 146.871C495.507 154.843 487.021 158.829 477.335 158.829ZM462.035 116.914L488.65 116.4C488.735 116.229 488.778 116.014 488.778 115.757C488.778 115.414 488.778 115.2 488.778 115.114C488.778 110.486 487.75 106.629 485.693 103.543C483.721 100.457 480.764 98.9143 476.821 98.9143C473.135 98.9143 469.921 100.414 467.178 103.414C464.435 106.414 462.721 110.914 462.035 116.914ZM559.644 158.957L557.587 158.057L557.073 149.186C554.073 152.443 550.987 154.886 547.816 156.514C544.73 158.057 541.302 158.829 537.53 158.829C532.216 158.829 527.544 157.414 523.516 154.586C519.573 151.671 516.53 147.9 514.387 143.271C512.244 138.643 511.173 133.629 511.173 128.229C511.173 121.971 512.502 116.271 515.159 111.129C517.902 105.986 521.716 101.871 526.602 98.7857C531.573 95.6143 537.359 94.0286 543.959 94.0286C545.93 94.0286 547.987 94.2 550.13 94.5429C552.273 94.8 554.502 95.2714 556.816 95.9572V79.5C556.816 76.8429 556.559 74.8714 556.044 73.5857C555.53 72.2143 554.502 71.2714 552.959 70.7572C551.502 70.1572 549.273 69.7286 546.273 69.4714C546.016 68.3572 546.016 67.2 546.273 66C549.702 65.5714 553.216 64.9286 556.816 64.0714C560.416 63.1286 564.102 61.8429 567.873 60.2143L570.059 60.9857C569.973 62.8714 569.887 65.0143 569.802 67.4143C569.802 69.8143 569.802 72.4286 569.802 75.2572V139.029C569.802 142.286 569.93 144.729 570.187 146.357C570.445 147.986 571.216 149.143 572.502 149.829C573.787 150.429 575.973 150.986 579.059 151.5C579.316 152.614 579.316 153.771 579.059 154.971C575.63 155.486 572.287 156.043 569.03 156.643C565.773 157.243 562.644 158.014 559.644 158.957ZM556.944 106.886C553.259 101.829 548.416 99.3 542.416 99.3C536.502 99.3 532.044 101.486 529.044 105.857C526.044 110.143 524.544 116.1 524.544 123.729C524.544 128.186 525.144 132.471 526.344 136.586C527.544 140.7 529.516 144.086 532.259 146.743C535.002 149.4 538.644 150.729 543.187 150.729C548.93 150.729 553.516 148.243 556.944 143.271V106.886ZM615.699 157.414C613.299 157.414 610.813 157.371 608.242 157.286C605.67 157.2 602.885 157.157 599.885 157.157C597.142 157.157 594.356 157.2 591.527 157.286C588.785 157.371 586.127 157.414 583.556 157.414C583.299 156.043 583.299 154.714 583.556 153.429C586.47 153.257 588.613 153 589.985 152.657C591.356 152.229 592.256 151.371 592.685 150.086C593.113 148.8 593.327 146.743 593.327 143.914V115.114C593.327 111.771 593.199 109.286 592.942 107.657C592.685 106.029 591.87 104.914 590.499 104.314C589.213 103.629 586.942 103.071 583.685 102.643C583.427 101.443 583.427 100.329 583.685 99.3C587.456 98.6143 591.056 97.7572 594.485 96.7286C597.913 95.7 601.213 94.5857 604.385 93.3857L606.57 94.1572C606.485 96.8143 606.399 99.3 606.313 101.614C606.313 103.929 606.313 106.114 606.313 108.171V142.629C606.313 145.971 606.485 148.371 606.827 149.829C607.256 151.286 608.113 152.229 609.399 152.657C610.77 153 612.87 153.257 615.699 153.429C615.956 154.714 615.956 156.043 615.699 157.414ZM589.985 71.5286C589.985 69.0429 590.842 66.9429 592.556 65.2286C594.356 63.5143 596.499 62.6572 598.985 62.6572C601.385 62.6572 603.442 63.5143 605.156 65.2286C606.956 66.9429 607.856 69 607.856 71.4C607.856 73.6286 606.999 75.6857 605.285 77.5715C603.57 79.3714 601.385 80.2714 598.727 80.2714C596.327 80.2714 594.27 79.4143 592.556 77.7C590.842 75.9857 589.985 73.9286 589.985 71.5286ZM665.837 158.571C660.18 158.571 656.623 155.743 655.165 150.086C649.08 155.914 642.865 158.829 636.523 158.829C632.151 158.829 628.423 157.543 625.337 154.971C622.337 152.314 620.837 148.671 620.837 144.043C620.837 132.729 632.365 125.614 655.423 122.7C655.423 120.643 655.423 118.543 655.423 116.4C655.508 114.257 655.551 111.986 655.551 109.586C655.551 106.586 654.437 104.271 652.208 102.643C650.065 100.929 647.451 100.071 644.365 100.071C642.137 100.071 640.251 100.414 638.708 101.1C638.708 103.071 638.28 105.086 637.423 107.143C636.565 109.2 635.365 110.957 633.823 112.414C632.365 113.786 630.565 114.471 628.423 114.471C626.537 114.471 625.037 113.957 623.923 112.929C622.894 111.814 622.38 110.486 622.38 108.943C622.38 106.886 623.323 104.957 625.208 103.157C627.18 101.271 629.665 99.6857 632.665 98.4C635.665 97.0286 638.794 95.9572 642.051 95.1857C645.308 94.4143 648.223 94.0286 650.794 94.0286C653.965 94.0286 656.88 94.6286 659.537 95.8286C662.28 96.9429 664.465 98.6572 666.094 100.971C667.808 103.2 668.665 105.986 668.665 109.329C668.665 111.386 668.623 114.086 668.537 117.429C668.451 120.686 668.365 124.2 668.28 127.971C668.28 131.657 668.237 135.171 668.151 138.514C668.065 141.857 668.023 144.557 668.023 146.614C668.023 149.357 669.223 150.729 671.623 150.729C673.165 150.729 675.523 150.214 678.694 149.186C679.037 149.614 679.251 150.086 679.337 150.6C679.508 151.114 679.637 151.586 679.723 152.014C677.58 154.329 675.308 156 672.908 157.029C670.594 158.057 668.237 158.571 665.837 158.571ZM655.165 146.614L655.423 127.329C647.537 128.357 642.094 130.029 639.094 132.343C636.18 134.657 634.723 137.614 634.723 141.214C634.723 144.214 635.494 146.529 637.037 148.157C638.665 149.7 640.68 150.471 643.08 150.471C644.623 150.471 646.337 150.129 648.223 149.443C650.194 148.757 652.508 147.814 655.165 146.614Z" fill="currentColor"></path><rect x="715" y="65" width="195" height="105" rx="52.5" fill="currentColor" fill-opacity="0.05"></rect><path d="M767.529 142.875L754.049 107.938H762.552L769.309 127.582C769.705 128.812 770.078 130.032 770.43 131.24C770.781 132.449 771.078 133.559 771.32 134.569H771.616C771.858 133.559 772.144 132.449 772.473 131.24C772.825 130.032 773.198 128.812 773.594 127.582L780.186 107.938H788.689L775.472 142.875H767.529ZM810.856 143.633C806.901 143.633 803.528 142.71 800.737 140.865C797.969 138.997 795.871 136.305 794.442 132.79C793.014 129.252 792.3 124.989 792.3 120.001V118.255C792.3 113.245 793.014 108.982 794.442 105.467C795.871 101.929 797.969 99.2373 800.737 97.3916C803.528 95.5239 806.901 94.5901 810.856 94.5901C814.789 94.5901 818.129 95.5129 820.875 97.3586C823.644 99.2043 825.731 101.907 827.138 105.467C828.566 109.004 829.28 113.267 829.28 118.255V120.001C829.28 124.989 828.577 129.252 827.171 132.79C825.764 136.327 823.677 139.019 820.908 140.865C818.162 142.71 814.811 143.633 810.856 143.633ZM810.889 136.382C813.064 136.382 814.877 135.789 816.327 134.602C817.799 133.416 818.898 131.658 819.623 129.329C820.348 126.978 820.711 124.066 820.711 120.595V117.694C820.711 114.223 820.337 111.311 819.59 108.96C818.865 106.609 817.777 104.84 816.327 103.654C814.877 102.445 813.064 101.841 810.889 101.841C808.714 101.841 806.879 102.434 805.385 103.621C803.912 104.785 802.792 106.554 802.023 108.927C801.276 111.278 800.902 114.201 800.902 117.694V120.595C800.902 124.044 801.287 126.945 802.056 129.296C802.825 131.647 803.945 133.416 805.418 134.602C806.89 135.789 808.714 136.382 810.889 136.382ZM838.988 143.205C838 143.205 837.099 142.985 836.286 142.545C835.495 142.106 834.879 141.491 834.44 140.7C834.001 139.909 833.781 139.019 833.781 138.03C833.781 137.019 834.001 136.118 834.44 135.327C834.879 134.536 835.495 133.921 836.286 133.482C837.099 133.042 838 132.823 838.988 132.823C839.977 132.823 840.867 133.042 841.658 133.482C842.449 133.921 843.064 134.536 843.504 135.327C843.943 136.118 844.163 137.019 844.163 138.03C844.163 139.019 843.943 139.909 843.504 140.7C843.064 141.491 842.449 142.106 841.658 142.545C840.867 142.985 839.977 143.205 838.988 143.205ZM857.365 142.875V104.511L846.39 111.663V103.357L858.453 95.3481H865.802V142.875H857.365Z" fill="currentColor"></path></svg></a></div><div class="mx-auto flex w-full"><button class="focus-visible:ring-ring inline-flex items-center justify-center gap-x-2 whitespace-nowrap text-sm font-medium transition-colors focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 border-input text-primary hover:border-primary/15 border hover:bg-overlay-hover py-2 max-w-full px-3 shadow-none sm:w-80 focus-visible:z-1 mx-auto h-full w-full rounded-full bg-surface-l1" type="button"><div class="flex items-center justify-between sm:w-full gap-4"><div class="flex items-center justify-start gap-2"><span class="inline-flex items-center justify-center p-0 m-0 w-4 h-4 text-muted" data-namespace="@xai/icons" data-slot="icon"><svg xmlns="http://www.w3.org/2000/svg" fill="currentColor" viewBox="0 0 24 24" aria-hidden="true" class="w-4 h-4" focusable="false" style="fill:currentColor"><path d="m18.031 16.617 4.283 4.282-1.415 1.415-4.282-4.283A8.96 8.96 0 0 1 11 20c-4.968 0-9-4.032-9-9s4.032-9 9-9 9 4.032 9 9a8.96 8.96 0 0 1-1.969 5.617m-2.006-.742A6.98 6.98 0 0 0 18 11c0-3.867-3.133-7-7-7s-7 3.133-7 7 3.133 7 7 7a6.98 6.98 0 0 0 4.875-1.975z"></path></svg></span><p class="text-sm text-muted hidden sm:block">Search</p></div><span class="hidden sm:block"><div class="bg-foreground/10 text-muted inline-flex items-center rounded-md px-1 py-0.5 text-center font-sans text-xs font-normal tracking-widest rtl:space-x-reverse"><span>âŒ˜</span><span class="text-xs">K</span></div></span></div></button></div><div class="flex items-center gap-2 justify-self-end"><button class="focus-visible:ring-ring inline-flex items-center justify-center gap-x-2 whitespace-nowrap rounded-full text-sm font-medium transition-colors focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary hover:bg-overlay-hover px-4 py-2 w-9 h-9 flex-shrink-0" type="button" id="radix-_R_7apfiumdb_" aria-haspopup="menu" aria-expanded="false" data-state="closed"><span class="inline-flex items-center justify-center p-0 m-0 w-6 h-6 rotate-0 scale-100 transition-all dark:-rotate-90 dark:scale-0" data-namespace="@xai/icons" data-slot="icon"><svg xmlns="http://www.w3.org/2000/svg" fill="currentColor" viewBox="0 0 24 24" aria-hidden="true" class="w-6 h-6" focusable="false" style="fill:currentColor"><path d="M12 18a6 6 0 1 1 0-12 6 6 0 0 1 0 12m0-2a4 4 0 1 0 0-8 4 4 0 0 0 0 8M11 1h2v3h-2zm0 19h2v3h-2zM3.515 4.929l1.414-1.414L7.05 5.636 5.636 7.05zM16.95 18.364l1.414-1.414 2.121 2.121-1.414 1.414zm2.121-14.85 1.414 1.415-2.121 2.121-1.414-1.414zM5.636 16.95l1.414 1.414-2.121 2.121-1.414-1.414zM23 11v2h-3v-2zM4 11v2H1v-2z"></path></svg></span><span class="inline-flex items-center justify-center p-0 m-0 w-6 h-6 absolute rotate-90 scale-0 transition-all dark:rotate-0 dark:scale-100" data-namespace="@xai/icons" data-slot="icon"><svg xmlns="http://www.w3.org/2000/svg" fill="currentColor" viewBox="0 0 24 24" aria-hidden="true" class="w-6 h-6" focusable="false" style="fill:currentColor"><path d="M10 7a7 7 0 0 0 12 4.9v.1c0 5.523-4.477 10-10 10S2 17.523 2 12 6.477 2 12 2h.1A6.98 6.98 0 0 0 10 7m-6 5a8 8 0 0 0 15.062 3.762A9 9 0 0 1 8.238 4.938 8 8 0 0 0 4 12"></path></svg></span><span class="sr-only">Toggle theme</span></button></div></div><div class="flex h-full items-center md:hidden justify-between max-w-full py-6 px-4 w-full mx-auto pt-8"><div class="flex items-center"><div class="-ml-2"><button class="focus-visible:ring-ring inline-flex items-center justify-center gap-x-2 whitespace-nowrap rounded-full text-sm font-medium transition-colors focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary hover:bg-overlay-hover h-9 w-9" type="button" aria-label="Toggle table of contents"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-list h-6 w-6"><path d="M3 12h.01"></path><path d="M3 18h.01"></path><path d="M3 6h.01"></path><path d="M8 12h13"></path><path d="M8 18h13"></path><path d="M8 6h13"></path></svg></button></div><a class="cursor-pointer" href="/"><svg width="160" height="auto" viewBox="0 0 955 225" fill="none" xmlns="http://www.w3.org/2000/svg"><path d="M99.6937 159.214C90.008 159.214 81.5652 157.414 74.3652 153.814C67.1652 150.214 61.5509 144.986 57.5223 138.129C53.5794 131.271 51.608 123.043 51.608 113.443C51.608 103.843 53.5794 95.4857 57.5223 88.3714C61.5509 81.2572 67.1652 75.7286 74.3652 71.7857C81.6509 67.8429 90.1794 65.8714 99.9509 65.8714C103.208 65.8714 106.679 66.1286 110.365 66.6429C114.051 67.0714 117.222 67.6714 119.879 68.4429C121.508 68.8714 123.008 69.2572 124.379 69.6C125.751 69.9429 127.122 70.1143 128.494 70.1143C129.522 70.1143 130.551 69.9857 131.579 69.7286C131.751 73.5 131.922 77.4 132.094 81.4286C132.265 85.4572 132.522 89.6572 132.865 94.0286C131.065 94.2857 129.565 94.3714 128.365 94.2857C126.651 86.4 123.522 80.5714 118.979 76.8C114.437 72.9429 108.394 71.0143 100.851 71.0143C94.8509 71.0143 89.708 72.1286 85.4223 74.3572C81.2223 76.5 77.7937 79.4572 75.1366 83.2286C72.5652 87 70.6794 91.3714 69.4794 96.3429C68.2794 101.229 67.6794 106.457 67.6794 112.029C67.6794 120.171 68.9223 127.371 71.408 133.629C73.8937 139.886 77.6652 144.814 82.7223 148.414C87.8652 151.929 94.2937 153.686 102.008 153.686C104.408 153.686 107.065 153.471 109.979 153.043C112.894 152.529 115.679 151.757 118.337 150.729V134.529C118.337 131.871 118.208 129.814 117.951 128.357C117.779 126.814 117.222 125.7 116.279 125.014C115.422 124.329 114.008 123.857 112.037 123.6C110.151 123.257 107.537 122.957 104.194 122.7C103.937 121.329 103.937 119.957 104.194 118.586C105.994 118.586 108.179 118.629 110.751 118.714C113.322 118.714 115.894 118.757 118.465 118.843C121.122 118.843 123.308 118.843 125.022 118.843C127.679 118.843 130.722 118.8 134.151 118.714C137.665 118.629 140.665 118.586 143.151 118.586C143.322 119.871 143.322 121.2 143.151 122.571C139.637 123 137.108 123.429 135.565 123.857C134.022 124.286 133.079 125.143 132.737 126.429C132.394 127.714 132.222 129.9 132.222 132.986V137.1C132.222 141.129 132.308 144.514 132.479 147.257C132.737 150 132.951 151.971 133.122 153.171C121.208 157.2 110.065 159.214 99.6937 159.214ZM148.19 157.414C147.933 156.043 147.933 154.714 148.19 153.429C151.105 153.257 153.248 153 154.619 152.657C155.99 152.229 156.89 151.371 157.319 150.086C157.748 148.8 157.962 146.743 157.962 143.914V115.114C157.962 111.771 157.79 109.286 157.448 107.657C157.19 106.029 156.376 104.914 155.005 104.314C153.719 103.629 151.49 103.071 148.319 102.643C148.062 101.443 148.062 100.329 148.319 99.3C151.748 98.6143 155.09 97.8429 158.348 96.9857C161.605 96.0429 165.033 94.8429 168.633 93.3857L170.819 94.1572V105.471C176.819 97.8429 182.948 94.0286 189.205 94.0286C192.205 94.0286 194.433 94.8429 195.89 96.4714C197.348 98.0143 198.076 99.7714 198.076 101.743C198.076 104.057 197.305 105.857 195.762 107.143C194.219 108.343 192.462 108.943 190.49 108.943C188.862 108.943 187.233 108.514 185.605 107.657C184.062 106.8 182.905 105.471 182.133 103.671C179.219 103.671 176.605 104.829 174.29 107.143C172.062 109.371 170.948 111.986 170.948 114.986V142.629C170.948 145.971 171.119 148.371 171.462 149.829C171.89 151.286 172.919 152.229 174.548 152.657C176.262 153 179.005 153.257 182.776 153.429C182.948 154.629 182.948 155.957 182.776 157.414C179.862 157.414 176.862 157.371 173.776 157.286C170.69 157.2 167.519 157.157 164.262 157.157C161.09 157.157 158.262 157.2 155.776 157.286C153.376 157.371 150.848 157.414 148.19 157.414ZM229.285 158.829C223.028 158.829 217.542 157.5 212.828 154.843C208.199 152.1 204.599 148.371 202.028 143.657C199.457 138.857 198.171 133.371 198.171 127.2C198.171 120.514 199.499 114.686 202.157 109.714C204.899 104.743 208.714 100.886 213.599 98.1429C218.485 95.4 224.099 94.0286 230.442 94.0286C236.699 94.0286 242.142 95.4 246.771 98.1429C251.399 100.886 254.999 104.657 257.571 109.457C260.142 114.257 261.428 119.7 261.428 125.786C261.428 132.043 260.057 137.7 257.314 142.757C254.657 147.729 250.928 151.671 246.128 154.586C241.328 157.414 235.714 158.829 229.285 158.829ZM212.699 125.657C212.699 134.4 214.114 141.343 216.942 146.486C219.857 151.543 224.185 154.071 229.928 154.071C235.414 154.071 239.614 151.671 242.528 146.871C245.442 141.986 246.899 135.471 246.899 127.329C246.899 118.671 245.442 111.771 242.528 106.629C239.614 101.486 235.371 98.9143 229.799 98.9143C224.314 98.9143 220.071 101.271 217.071 105.986C214.157 110.7 212.699 117.257 212.699 125.657ZM267.394 157.414C267.308 157.071 267.265 156.729 267.265 156.386C267.265 156.043 267.265 155.7 267.265 155.357C267.265 155.014 267.265 154.714 267.265 154.457C267.265 154.114 267.308 153.771 267.394 153.429C270.308 153.257 272.451 153 273.822 152.657C275.194 152.229 276.094 151.371 276.522 150.086C276.951 148.8 277.165 146.743 277.165 143.914V79.5C277.165 76.8429 276.908 74.8714 276.394 73.5857C275.965 72.2143 274.979 71.2714 273.437 70.7572C271.979 70.1572 269.751 69.7286 266.751 69.4714C266.665 69.1286 266.622 68.8286 266.622 68.5714C266.622 68.3143 266.622 68.0572 266.622 67.8C266.622 67.4572 266.622 67.1572 266.622 66.9C266.622 66.6429 266.665 66.3429 266.751 66C270.179 65.5714 273.694 64.9286 277.294 64.0714C280.894 63.1286 284.579 61.8429 288.351 60.2143L290.537 60.9857C290.451 62.8714 290.365 65.0143 290.279 67.4143C290.279 69.8143 290.279 72.4286 290.279 75.2572V122.957C291.308 122.957 292.165 122.786 292.851 122.443C293.537 122.1 294.094 121.757 294.522 121.414C294.694 121.243 295.037 120.943 295.551 120.514C296.065 120 296.965 119.1 298.251 117.814C299.537 116.529 301.379 114.6 303.779 112.029C306.008 109.543 307.765 107.614 309.051 106.243C310.422 104.786 311.108 103.586 311.108 102.643C311.108 101.957 310.508 101.4 309.308 100.971C308.194 100.457 306.651 100.157 304.679 100.071C304.594 99.7286 304.551 99.3857 304.551 99.0429C304.551 98.7 304.551 98.3572 304.551 98.0143C304.551 97.6714 304.551 97.3286 304.551 96.9857C304.551 96.6429 304.594 96.3 304.679 95.9572C306.394 95.9572 308.537 96 311.108 96.0857C313.765 96.1714 316.122 96.2143 318.179 96.2143C319.208 96.2143 320.665 96.2143 322.551 96.2143C324.522 96.1286 326.494 96.0857 328.465 96.0857C330.437 96.0857 331.894 96.0857 332.837 96.0857C332.922 96.4286 332.965 96.7714 332.965 97.1143C333.051 97.4572 333.094 97.8 333.094 98.1429C333.094 98.4857 333.051 98.8286 332.965 99.1714C332.965 99.4286 332.922 99.7286 332.837 100.071C328.379 100.157 324.608 101.271 321.522 103.414C318.437 105.471 315.479 107.914 312.651 110.743L303.394 120L321.137 143.4C323.022 145.886 324.565 147.857 325.765 149.314C327.051 150.686 328.422 151.671 329.879 152.271C331.337 152.871 333.351 153.257 335.922 153.429C336.094 154.629 336.094 155.957 335.922 157.414C334.808 157.414 333.137 157.371 330.908 157.286C328.765 157.2 325.379 157.157 320.751 157.157C320.065 157.157 319.037 157.157 317.665 157.157C316.294 157.157 315.008 157.243 313.808 157.414C313.808 156.471 313.294 155.186 312.265 153.557C311.237 151.843 310.422 150.6 309.822 149.829C309.565 149.4 308.922 148.5 307.894 147.129C306.865 145.671 305.622 144 304.165 142.114C302.794 140.143 301.379 138.171 299.922 136.2C298.465 134.143 297.137 132.343 295.937 130.8C294.994 129.514 294.094 128.529 293.237 127.843C292.465 127.071 291.479 126.686 290.279 126.686V142.629C290.279 145.971 290.408 148.371 290.665 149.829C291.008 151.286 291.737 152.229 292.851 152.657C294.051 153 295.851 153.257 298.251 153.429C298.422 154.714 298.422 156.043 298.251 157.414C296.022 157.414 293.665 157.371 291.179 157.286C288.779 157.2 286.165 157.157 283.337 157.157C280.594 157.157 277.894 157.2 275.237 157.286C272.579 157.371 269.965 157.414 267.394 157.414ZM369.34 157.414C366.94 157.414 364.454 157.371 361.883 157.286C359.311 157.2 356.526 157.157 353.526 157.157C350.783 157.157 347.997 157.2 345.169 157.286C342.426 157.371 339.769 157.414 337.197 157.414C336.94 156.043 336.94 154.714 337.197 153.429C340.111 153.257 342.254 153 343.626 152.657C344.997 152.229 345.897 151.371 346.326 150.086C346.754 148.8 346.969 146.743 346.969 143.914V115.114C346.969 111.771 346.84 109.286 346.583 107.657C346.326 106.029 345.511 104.914 344.14 104.314C342.854 103.629 340.583 103.071 337.326 102.643C337.069 101.443 337.069 100.329 337.326 99.3C341.097 98.6143 344.697 97.7572 348.126 96.7286C351.554 95.7 354.854 94.5857 358.026 93.3857L360.211 94.1572C360.126 96.8143 360.04 99.3 359.954 101.614C359.954 103.929 359.954 106.114 359.954 108.171V142.629C359.954 145.971 360.126 148.371 360.469 149.829C360.897 151.286 361.754 152.229 363.04 152.657C364.411 153 366.511 153.257 369.34 153.429C369.597 154.714 369.597 156.043 369.34 157.414ZM343.626 71.5286C343.626 69.0429 344.483 66.9429 346.197 65.2286C347.997 63.5143 350.14 62.6572 352.626 62.6572C355.026 62.6572 357.083 63.5143 358.797 65.2286C360.597 66.9429 361.497 69 361.497 71.4C361.497 73.6286 360.64 75.6857 358.926 77.5715C357.211 79.3714 355.026 80.2714 352.369 80.2714C349.969 80.2714 347.911 79.4143 346.197 77.7C344.483 75.9857 343.626 73.9286 343.626 71.5286ZM372.678 188.914C372.592 187.543 372.592 186.214 372.678 184.929C375.678 184.757 377.864 184.457 379.235 184.029C380.607 183.6 381.464 182.743 381.807 181.457C382.235 180.257 382.45 178.286 382.45 175.543V115.114C382.45 111.771 382.278 109.286 381.935 107.657C381.678 106.029 380.864 104.914 379.492 104.314C378.207 103.629 375.978 103.071 372.807 102.643C372.635 101.443 372.635 100.329 372.807 99.3C376.321 98.6143 379.75 97.8 383.092 96.8572C386.435 95.9143 389.907 94.7572 393.507 93.3857L395.307 94.2857C395.221 96.4286 395.178 98.2714 395.178 99.8143C395.178 101.271 395.178 102.686 395.178 104.057C398.521 100.543 401.821 98.0143 405.078 96.4714C408.335 94.8429 411.807 94.0286 415.492 94.0286C420.892 94.0286 425.435 95.4429 429.121 98.2714C432.892 101.1 435.764 104.786 437.735 109.329C439.707 113.871 440.692 118.8 440.692 124.114C440.692 130.371 439.321 136.157 436.578 141.471C433.921 146.7 430.192 150.9 425.392 154.071C420.592 157.243 415.021 158.829 408.678 158.829C406.192 158.829 403.835 158.614 401.607 158.186C399.378 157.843 397.278 157.329 395.307 156.643V174C395.307 177.343 395.564 179.743 396.078 181.2C396.592 182.657 397.707 183.557 399.421 183.9C401.135 184.329 403.835 184.629 407.521 184.8C407.607 186.171 407.607 187.543 407.521 188.914C404.607 188.914 401.65 188.871 398.65 188.786C395.735 188.7 392.521 188.657 389.007 188.657C385.664 188.657 382.792 188.7 380.392 188.786C377.992 188.871 375.421 188.914 372.678 188.914ZM395.178 146.1C398.864 151.414 403.75 154.071 409.835 154.071C414.121 154.071 417.507 152.871 419.992 150.471C422.564 148.071 424.407 144.943 425.521 141.086C426.721 137.229 427.321 133.157 427.321 128.871C427.321 124.586 426.764 120.386 425.65 116.271C424.535 112.157 422.692 108.771 420.121 106.114C417.635 103.371 414.207 102 409.835 102C404.607 102 399.721 104.529 395.178 109.586V146.1ZM477.335 158.829C471.25 158.829 466.107 157.414 461.907 154.586C457.707 151.757 454.493 147.986 452.264 143.271C450.121 138.471 449.05 133.2 449.05 127.457C449.05 121.543 450.164 116.057 452.393 111C454.707 105.943 458.05 101.871 462.421 98.7857C466.793 95.6143 472.107 94.0286 478.364 94.0286C485.907 94.0286 491.778 96.3 495.978 100.843C500.264 105.3 502.407 111.086 502.407 118.2C502.407 119.057 502.364 119.829 502.278 120.514C502.278 121.114 502.235 121.629 502.15 122.057L461.65 121.671C461.65 122.014 461.65 122.314 461.65 122.571C461.65 130.971 463.578 137.571 467.435 142.371C471.293 147.171 476.693 149.571 483.635 149.571C489.464 149.571 495.207 147.686 500.864 143.914C501.721 144.943 502.364 145.929 502.793 146.871C495.507 154.843 487.021 158.829 477.335 158.829ZM462.035 116.914L488.65 116.4C488.735 116.229 488.778 116.014 488.778 115.757C488.778 115.414 488.778 115.2 488.778 115.114C488.778 110.486 487.75 106.629 485.693 103.543C483.721 100.457 480.764 98.9143 476.821 98.9143C473.135 98.9143 469.921 100.414 467.178 103.414C464.435 106.414 462.721 110.914 462.035 116.914ZM559.644 158.957L557.587 158.057L557.073 149.186C554.073 152.443 550.987 154.886 547.816 156.514C544.73 158.057 541.302 158.829 537.53 158.829C532.216 158.829 527.544 157.414 523.516 154.586C519.573 151.671 516.53 147.9 514.387 143.271C512.244 138.643 511.173 133.629 511.173 128.229C511.173 121.971 512.502 116.271 515.159 111.129C517.902 105.986 521.716 101.871 526.602 98.7857C531.573 95.6143 537.359 94.0286 543.959 94.0286C545.93 94.0286 547.987 94.2 550.13 94.5429C552.273 94.8 554.502 95.2714 556.816 95.9572V79.5C556.816 76.8429 556.559 74.8714 556.044 73.5857C555.53 72.2143 554.502 71.2714 552.959 70.7572C551.502 70.1572 549.273 69.7286 546.273 69.4714C546.016 68.3572 546.016 67.2 546.273 66C549.702 65.5714 553.216 64.9286 556.816 64.0714C560.416 63.1286 564.102 61.8429 567.873 60.2143L570.059 60.9857C569.973 62.8714 569.887 65.0143 569.802 67.4143C569.802 69.8143 569.802 72.4286 569.802 75.2572V139.029C569.802 142.286 569.93 144.729 570.187 146.357C570.445 147.986 571.216 149.143 572.502 149.829C573.787 150.429 575.973 150.986 579.059 151.5C579.316 152.614 579.316 153.771 579.059 154.971C575.63 155.486 572.287 156.043 569.03 156.643C565.773 157.243 562.644 158.014 559.644 158.957ZM556.944 106.886C553.259 101.829 548.416 99.3 542.416 99.3C536.502 99.3 532.044 101.486 529.044 105.857C526.044 110.143 524.544 116.1 524.544 123.729C524.544 128.186 525.144 132.471 526.344 136.586C527.544 140.7 529.516 144.086 532.259 146.743C535.002 149.4 538.644 150.729 543.187 150.729C548.93 150.729 553.516 148.243 556.944 143.271V106.886ZM615.699 157.414C613.299 157.414 610.813 157.371 608.242 157.286C605.67 157.2 602.885 157.157 599.885 157.157C597.142 157.157 594.356 157.2 591.527 157.286C588.785 157.371 586.127 157.414 583.556 157.414C583.299 156.043 583.299 154.714 583.556 153.429C586.47 153.257 588.613 153 589.985 152.657C591.356 152.229 592.256 151.371 592.685 150.086C593.113 148.8 593.327 146.743 593.327 143.914V115.114C593.327 111.771 593.199 109.286 592.942 107.657C592.685 106.029 591.87 104.914 590.499 104.314C589.213 103.629 586.942 103.071 583.685 102.643C583.427 101.443 583.427 100.329 583.685 99.3C587.456 98.6143 591.056 97.7572 594.485 96.7286C597.913 95.7 601.213 94.5857 604.385 93.3857L606.57 94.1572C606.485 96.8143 606.399 99.3 606.313 101.614C606.313 103.929 606.313 106.114 606.313 108.171V142.629C606.313 145.971 606.485 148.371 606.827 149.829C607.256 151.286 608.113 152.229 609.399 152.657C610.77 153 612.87 153.257 615.699 153.429C615.956 154.714 615.956 156.043 615.699 157.414ZM589.985 71.5286C589.985 69.0429 590.842 66.9429 592.556 65.2286C594.356 63.5143 596.499 62.6572 598.985 62.6572C601.385 62.6572 603.442 63.5143 605.156 65.2286C606.956 66.9429 607.856 69 607.856 71.4C607.856 73.6286 606.999 75.6857 605.285 77.5715C603.57 79.3714 601.385 80.2714 598.727 80.2714C596.327 80.2714 594.27 79.4143 592.556 77.7C590.842 75.9857 589.985 73.9286 589.985 71.5286ZM665.837 158.571C660.18 158.571 656.623 155.743 655.165 150.086C649.08 155.914 642.865 158.829 636.523 158.829C632.151 158.829 628.423 157.543 625.337 154.971C622.337 152.314 620.837 148.671 620.837 144.043C620.837 132.729 632.365 125.614 655.423 122.7C655.423 120.643 655.423 118.543 655.423 116.4C655.508 114.257 655.551 111.986 655.551 109.586C655.551 106.586 654.437 104.271 652.208 102.643C650.065 100.929 647.451 100.071 644.365 100.071C642.137 100.071 640.251 100.414 638.708 101.1C638.708 103.071 638.28 105.086 637.423 107.143C636.565 109.2 635.365 110.957 633.823 112.414C632.365 113.786 630.565 114.471 628.423 114.471C626.537 114.471 625.037 113.957 623.923 112.929C622.894 111.814 622.38 110.486 622.38 108.943C622.38 106.886 623.323 104.957 625.208 103.157C627.18 101.271 629.665 99.6857 632.665 98.4C635.665 97.0286 638.794 95.9572 642.051 95.1857C645.308 94.4143 648.223 94.0286 650.794 94.0286C653.965 94.0286 656.88 94.6286 659.537 95.8286C662.28 96.9429 664.465 98.6572 666.094 100.971C667.808 103.2 668.665 105.986 668.665 109.329C668.665 111.386 668.623 114.086 668.537 117.429C668.451 120.686 668.365 124.2 668.28 127.971C668.28 131.657 668.237 135.171 668.151 138.514C668.065 141.857 668.023 144.557 668.023 146.614C668.023 149.357 669.223 150.729 671.623 150.729C673.165 150.729 675.523 150.214 678.694 149.186C679.037 149.614 679.251 150.086 679.337 150.6C679.508 151.114 679.637 151.586 679.723 152.014C677.58 154.329 675.308 156 672.908 157.029C670.594 158.057 668.237 158.571 665.837 158.571ZM655.165 146.614L655.423 127.329C647.537 128.357 642.094 130.029 639.094 132.343C636.18 134.657 634.723 137.614 634.723 141.214C634.723 144.214 635.494 146.529 637.037 148.157C638.665 149.7 640.68 150.471 643.08 150.471C644.623 150.471 646.337 150.129 648.223 149.443C650.194 148.757 652.508 147.814 655.165 146.614Z" fill="currentColor"></path><rect x="715" y="65" width="195" height="105" rx="52.5" fill="currentColor" fill-opacity="0.05"></rect><path d="M767.529 142.875L754.049 107.938H762.552L769.309 127.582C769.705 128.812 770.078 130.032 770.43 131.24C770.781 132.449 771.078 133.559 771.32 134.569H771.616C771.858 133.559 772.144 132.449 772.473 131.24C772.825 130.032 773.198 128.812 773.594 127.582L780.186 107.938H788.689L775.472 142.875H767.529ZM810.856 143.633C806.901 143.633 803.528 142.71 800.737 140.865C797.969 138.997 795.871 136.305 794.442 132.79C793.014 129.252 792.3 124.989 792.3 120.001V118.255C792.3 113.245 793.014 108.982 794.442 105.467C795.871 101.929 797.969 99.2373 800.737 97.3916C803.528 95.5239 806.901 94.5901 810.856 94.5901C814.789 94.5901 818.129 95.5129 820.875 97.3586C823.644 99.2043 825.731 101.907 827.138 105.467C828.566 109.004 829.28 113.267 829.28 118.255V120.001C829.28 124.989 828.577 129.252 827.171 132.79C825.764 136.327 823.677 139.019 820.908 140.865C818.162 142.71 814.811 143.633 810.856 143.633ZM810.889 136.382C813.064 136.382 814.877 135.789 816.327 134.602C817.799 133.416 818.898 131.658 819.623 129.329C820.348 126.978 820.711 124.066 820.711 120.595V117.694C820.711 114.223 820.337 111.311 819.59 108.96C818.865 106.609 817.777 104.84 816.327 103.654C814.877 102.445 813.064 101.841 810.889 101.841C808.714 101.841 806.879 102.434 805.385 103.621C803.912 104.785 802.792 106.554 802.023 108.927C801.276 111.278 800.902 114.201 800.902 117.694V120.595C800.902 124.044 801.287 126.945 802.056 129.296C802.825 131.647 803.945 133.416 805.418 134.602C806.89 135.789 808.714 136.382 810.889 136.382ZM838.988 143.205C838 143.205 837.099 142.985 836.286 142.545C835.495 142.106 834.879 141.491 834.44 140.7C834.001 139.909 833.781 139.019 833.781 138.03C833.781 137.019 834.001 136.118 834.44 135.327C834.879 134.536 835.495 133.921 836.286 133.482C837.099 133.042 838 132.823 838.988 132.823C839.977 132.823 840.867 133.042 841.658 133.482C842.449 133.921 843.064 134.536 843.504 135.327C843.943 136.118 844.163 137.019 844.163 138.03C844.163 139.019 843.943 139.909 843.504 140.7C843.064 141.491 842.449 142.106 841.658 142.545C840.867 142.985 839.977 143.205 838.988 143.205ZM857.365 142.875V104.511L846.39 111.663V103.357L858.453 95.3481H865.802V142.875H857.365Z" fill="currentColor"></path></svg></a></div><div class="flex items-center gap-1"><button class="focus-visible:ring-ring inline-flex items-center justify-center gap-x-2 whitespace-nowrap rounded-full text-sm font-medium transition-colors focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary hover:bg-overlay-hover px-4 py-2 w-9 h-9 flex-shrink-0 [&amp;_svg]:!w-5" type="button" id="radix-_R_aipfiumdb_" aria-haspopup="menu" aria-expanded="false" data-state="closed"><span class="inline-flex items-center justify-center p-0 m-0 w-6 h-6 rotate-0 scale-100 transition-all dark:-rotate-90 dark:scale-0" data-namespace="@xai/icons" data-slot="icon"><svg xmlns="http://www.w3.org/2000/svg" fill="currentColor" viewBox="0 0 24 24" aria-hidden="true" class="w-6 h-6" focusable="false" style="fill:currentColor"><path d="M12 18a6 6 0 1 1 0-12 6 6 0 0 1 0 12m0-2a4 4 0 1 0 0-8 4 4 0 0 0 0 8M11 1h2v3h-2zm0 19h2v3h-2zM3.515 4.929l1.414-1.414L7.05 5.636 5.636 7.05zM16.95 18.364l1.414-1.414 2.121 2.121-1.414 1.414zm2.121-14.85 1.414 1.415-2.121 2.121-1.414-1.414zM5.636 16.95l1.414 1.414-2.121 2.121-1.414-1.414zM23 11v2h-3v-2zM4 11v2H1v-2z"></path></svg></span><span class="inline-flex items-center justify-center p-0 m-0 w-6 h-6 absolute rotate-90 scale-0 transition-all dark:rotate-0 dark:scale-100" data-namespace="@xai/icons" data-slot="icon"><svg xmlns="http://www.w3.org/2000/svg" fill="currentColor" viewBox="0 0 24 24" aria-hidden="true" class="w-6 h-6" focusable="false" style="fill:currentColor"><path d="M10 7a7 7 0 0 0 12 4.9v.1c0 5.523-4.477 10-10 10S2 17.523 2 12 6.477 2 12 2h.1A6.98 6.98 0 0 0 10 7m-6 5a8 8 0 0 0 15.062 3.762A9 9 0 0 1 8.238 4.938 8 8 0 0 0 4 12"></path></svg></span><span class="sr-only">Toggle theme</span></button><button class="focus-visible:ring-ring inline-flex items-center justify-center gap-x-2 whitespace-nowrap rounded-full text-sm font-medium transition-colors focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary hover:bg-overlay-hover h-9 w-9" type="button"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-search h-5 w-5"><circle cx="11" cy="11" r="8"></circle><path d="m21 21-4.3-4.3"></path></svg></button></div></div></header><div class="bg-surface-base fixed right-0 top-16 z-50 h-[calc(100vh-4rem)] w-full transform border-l transition-transform duration-300 ease-in-out sm:w-1/2 md:hidden translate-x-full"><div class="flex flex-col gap-4 p-4"><div class="flex flex-row gap-2"><button class="focus-visible:ring-ring inline-flex items-center gap-x-2 whitespace-nowrap text-sm font-medium transition-colors focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 border-input text-primary hover:border-primary/15 border hover:bg-overlay-hover py-2 max-w-full shadow-none sm:w-80 h-10 w-full justify-start rounded-full bg-surface-l1 px-4" type="button"><div class="flex items-center justify-between sm:w-full gap-4"><div class="flex items-center justify-start gap-2"><span class="inline-flex items-center justify-center p-0 m-0 w-4 h-4 text-muted" data-namespace="@xai/icons" data-slot="icon"><svg xmlns="http://www.w3.org/2000/svg" fill="currentColor" viewBox="0 0 24 24" aria-hidden="true" class="w-4 h-4" focusable="false" style="fill:currentColor"><path d="m18.031 16.617 4.283 4.282-1.415 1.415-4.282-4.283A8.96 8.96 0 0 1 11 20c-4.968 0-9-4.032-9-9s4.032-9 9-9 9 4.032 9 9a8.96 8.96 0 0 1-1.969 5.617m-2.006-.742A6.98 6.98 0 0 0 18 11c0-3.867-3.133-7-7-7s-7 3.133-7 7 3.133 7 7 7a6.98 6.98 0 0 0 4.875-1.975z"></path></svg></span><p class="text-sm text-muted hidden sm:block">Search</p></div><span class="hidden sm:block"><div class="bg-foreground/10 text-muted inline-flex items-center rounded-md px-1 py-0.5 text-center font-sans text-xs font-normal tracking-widest rtl:space-x-reverse"><span>âŒ˜</span><span class="text-xs">K</span></div></span></div></button></div></div></div><div><div class="min-[1350px]:grid min-[1350px]:grid-cols-[1fr_3fr_1fr]"><nav class="bg-surface-base hidden h-[calc(100vh-4rem)] overflow-y-auto px-6 pb-32 min-[1350px]:sticky min-[1350px]:top-16 min-[1350px]:block scrollbar-none [-ms-overflow-style:none] [scrollbar-width:none] [&amp;::-webkit-scrollbar]:hidden [overscroll-behavior:contain] pt-8"><ul class="space-y-2 text-sm"><li style="padding-left:0rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#boehringer-ingelheim" class="transition-opacity hover:opacity-100 opacity-50">Boehringer Ingelheim</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#history" class="transition-opacity hover:opacity-100 opacity-50">History</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#founding-and-early-years-18851945" class="transition-opacity hover:opacity-100 opacity-50">Founding and Early Years (1885â€“1945)</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#post-war-reconstruction-and-expansion-19461999" class="transition-opacity hover:opacity-100 opacity-50">Post-War Reconstruction and Expansion (1946â€“1999)</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#globalization-and-key-acquisitions-20002015" class="transition-opacity hover:opacity-100 opacity-50">Globalization and Key Acquisitions (2000â€“2015)</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#strategic-partnerships-and-recent-developments-2016present" class="transition-opacity hover:opacity-100 opacity-50">Strategic Partnerships and Recent Developments (2016â€“present)</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#ownership-and-governance" class="transition-opacity hover:opacity-100 opacity-50">Ownership and Governance</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#family-owned-structure" class="transition-opacity hover:opacity-100 opacity-50">Family-Owned Structure</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#leadership-and-decision-making" class="transition-opacity hover:opacity-100 opacity-50">Leadership and Decision-Making</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#business-segments" class="transition-opacity hover:opacity-100 opacity-50">Business Segments</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#human-pharmaceuticals-division" class="transition-opacity hover:opacity-100 opacity-50">Human Pharmaceuticals Division</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#animal-health-division" class="transition-opacity hover:opacity-100 opacity-50">Animal Health Division</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#research-and-development" class="transition-opacity hover:opacity-100 opacity-50">Research and Development</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#rd-investment-and-strategy" class="transition-opacity hover:opacity-100 opacity-50">R&amp;D Investment and Strategy</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#major-collaborations-and-innovations" class="transition-opacity hover:opacity-100 opacity-50">Major Collaborations and Innovations</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#clinical-pipeline-highlights" class="transition-opacity hover:opacity-100 opacity-50">Clinical Pipeline Highlights</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#key-products" class="transition-opacity hover:opacity-100 opacity-50">Key Products</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#established-human-pharma-products" class="transition-opacity hover:opacity-100 opacity-50">Established Human Pharma Products</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#prominent-animal-health-products" class="transition-opacity hover:opacity-100 opacity-50">Prominent Animal Health Products</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#operations-and-global-footprint" class="transition-opacity hover:opacity-100 opacity-50">Operations and Global Footprint</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#manufacturing-and-research-sites" class="transition-opacity hover:opacity-100 opacity-50">Manufacturing and Research Sites</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#workforce-and-operational-efficiency" class="transition-opacity hover:opacity-100 opacity-50">Workforce and Operational Efficiency</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#financial-performance" class="transition-opacity hover:opacity-100 opacity-50">Financial Performance</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#revenue-growth-and-key-metrics" class="transition-opacity hover:opacity-100 opacity-50">Revenue Growth and Key Metrics</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#rd-and-capital-expenditures" class="transition-opacity hover:opacity-100 opacity-50">R&amp;D and Capital Expenditures</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#legal-and-regulatory-challenges" class="transition-opacity hover:opacity-100 opacity-50">Legal and Regulatory Challenges</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#patent-disputes-and-competition-issues" class="transition-opacity hover:opacity-100 opacity-50">Patent Disputes and Competition Issues</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#product-liability-and-safety-litigation" class="transition-opacity hover:opacity-100 opacity-50">Product Liability and Safety Litigation</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#government-pricing-and-regulatory-conflicts" class="transition-opacity hover:opacity-100 opacity-50">Government Pricing and Regulatory Conflicts</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#references" class="transition-opacity hover:opacity-100 opacity-50">References</a></li></ul></nav><div class="relative top-16 pb-32 pt-8 px-4 md:px-8"><div class="mx-auto max-w-[850px]"><button data-state="closed" type="button" class="flex items-center"><div class="text-fg-tertiary mb-2 flex cursor-help items-center gap-2 text-sm"><span class="inline-flex items-center justify-center p-0 m-0" data-namespace="@xai/icons" data-slot="icon" style="height:16px;width:16px"><svg xmlns="http://www.w3.org/2000/svg" fill="none" viewBox="0 0 33 33" aria-hidden="true" class="" focusable="false" style="fill:currentColor;height:16px;width:16px"><path fill="currentColor" d="m13.237 21.04 11.082-8.19c.543-.4 1.32-.244 1.578.38 1.363 3.288.754 7.241-1.957 9.955-2.71 2.714-6.482 3.31-9.93 1.954l-3.765 1.745c5.401 3.697 11.96 2.782 16.059-1.324 3.251-3.255 4.258-7.692 3.317-11.693l.008.009c-1.365-5.878.336-8.227 3.82-13.031q.123-.17.247-.345l-4.585 4.59v-.014L13.234 21.044M10.95 23.031c-3.877-3.707-3.208-9.446.1-12.755 2.446-2.449 6.454-3.448 9.952-1.979L24.76 6.56c-.677-.49-1.545-1.017-2.54-1.387A12.465 12.465 0 0 0 8.675 7.901c-3.519 3.523-4.625 8.94-2.725 13.561 1.42 3.454-.907 5.898-3.251 8.364-.83.874-1.664 1.749-2.335 2.674l10.583-9.466"></path></svg></span><span>Fact-checked by Grok<!-- --> <!-- -->4 days ago</span></div></button><article class="text-[16px]"><h1 id="boehringer-ingelheim" class="group relative mb-2 scroll-mt-24 font-serif text-[2.125em] font-semibold tracking-[-1px] [&amp;:not(:first-child)]:mt-14" node="[object Object]">Boehringer Ingelheim<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h1>
<span class="mb-4 block break-words text-[1em] leading-7"><br/>
Boehringer Ingelheim is a privately held, research-driven biopharmaceutical company headquartered in Ingelheim am Rhein, Germany.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_80qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_a0qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[2]</sup> Founded in 1885 by Albert Boehringer initially as a chemicals manufacturer producing tartaric acid and baking powder, it has grown into a global enterprise focused on developing innovative therapies for human and animal health.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_e0qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[3]</sup> The company&#x27;s independence from public markets allows a long-term perspective on research and development, with annual R&amp;D investments exceeding â‚¬5 billion.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_i0qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[4]</sup> In 2023, Boehringer Ingelheim achieved net sales of â‚¬25.6 billion (USD 27.7 billion), driven by growth in key products like Jardiance in human pharmaceuticals and strong performance in animal health, while employing over 53,000 people across more than 130 countries.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_m0qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[4]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_o0qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[5]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">The firm has faced various legal challenges typical of the pharmaceutical industry, including settlements for off-label promotion of drugs like Aggrenox and antitrust allegations related to patent listings, though these have not fundamentally altered its operational focus on innovation.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_41abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[6]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_61abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[7]</sup></span>
<h2 id="history" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">History<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<h3 id="founding-and-early-years-18851945" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Founding and Early Years (1885â€“1945)<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">
In 1885, Albert Boehringer (1861â€“1939), a pharmacist trained in Heidelberg and Munich, acquired a small tartar refining factory in the Rhine-Hessian village of Nieder-Ingelheim, Germany, for 7,000 marks.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_62qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[8]</sup> On July 31, the enterprise was registered in the commercial register as C.H. Boehringer Sohn, honoring his grandfather, with initial operations commencing August 1 employing 28 workers to produce tartaric acid salts for pharmaceutical and food applications, including baking powder and carbonated beverages.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_a2qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[9]</sup> The factory&#x27;s location near the Rhine facilitated raw material imports like wine lees, essential for tartaric acid extraction.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_e2qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[10]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">By 1893, the company was renamed C.H. Boehringer Sohn to reflect its chemical focus, and production expanded to include lactic acid alongside tartaric derivatives, capitalizing on rising demand from the burgeoning food industry.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_43abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[8]</sup> In 1895, Boehringer secured its first patent for Boeson, a baking powder utilizing lactic acid, marking an early commercial innovation that boosted revenue and established the firm&#x27;s reputation in applied chemistry.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_83abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[8]</sup> The late 1890s saw initial forays into pharmaceuticals, with research into active substances like morphine and codeine from opium, leveraging the company&#x27;s expertise in organic acids to isolate alkaloids for medical use.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_c3abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[11]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">World War I disrupted operations in 1914, requiring Albert Boehringer to oversee a medical supply entity for the German war economy while his nephew Robert assumed daily management; production shifted toward wartime needs, yet research persisted.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_43qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[11]</sup> Post-war recovery in the 1920s involved rebuilding and international expansion, with subsidiaries established in Austria and Italy by the 1930s.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_83qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[8]</sup> Albert Boehringer&#x27;s death in 1939 preceded World War II&#x27;s outbreak, during which numerous employees were conscripted into the Wehrmacht and facilities adapted for war-relevant chemicals and pharmaceuticals, though core R&amp;D continued uninterrupted despite Allied bombings.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_c3qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[8]</sup> By 1945, the company had weathered two global conflicts, maintaining family ownership and a foundation in chemical-pharmaceutical manufacturing.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_g3qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[12]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7"></span>
<h3 id="post-war-reconstruction-and-expansion-19461999" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Post-War Reconstruction and Expansion (1946â€“1999)<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Following the end of World War II, Boehringer Ingelheim resumed operations at its Ingelheim plant on May 28, 1945, after closure on March 16 amid Allied occupation, establishing a procurement department to secure raw materials amid shortages.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_45abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[9]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_65abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[13]</sup> In 1946, the company re-established Dr. Karl Thomae GmbH in Biberach an der Riss with 70 employees, launching the analgesic Thomapyrin, and founded CELA Landwirtschaftliche Chemikalien GmbH for pesticide production.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_a5abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[9]</sup> By 1948, Germany&#x27;s monetary reform facilitated economic recovery, enabling the establishment of the first foreign subsidiary, Bender &amp; Co. GmbH in Vienna, and Olivin for cosmetic sales; the company was removed from Allied war reparations lists in June 1949.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_e5abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[14]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_g5abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[13]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">International expansion accelerated in the 1950s, with subsidiaries founded in Spain (1953), Italy (1955), Brazil (1956), Argentina (1957), and Canada (1958), followed by Japan and the UK (1961), Mexico (1962), France (1968), and the US (1971, initially in New York and later Ridgefield, Connecticut).<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_45qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[14]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_65qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[13]</sup> Employee numbers quadrupled from pre-war levels by 1955, coinciding with the launch of the Animal Health division through a collaboration with Pfizer to market Terramycin.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_a5qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[14]</sup> Key product introductions included Buscopan for gastrointestinal disorders (1951), Persantin for coronary heart disease (1959), Bisolvon as a respiratory expectorant (1963), Atrovent for respiratory diseases (1975), Asasantin for thromboses (1977), Mexitil and Mucosolvan (1979), Actilyse as the first thrombolytic (1987), and Alveofact for neonatal respiratory distress (1989).<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_e5qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[14]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Leadership transitioned with Dr. Wilhelm Boehringer and Hubertus Liebrecht joining the board in 1967; Liebrecht became chairman in 1971 following Wilhelm&#x27;s death in 1975, guiding the firm through global growth while maintaining family ownership.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_46abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[14]</sup> Structural changes included forming C. H. Boehringer Sohn as the German holding in 1981 and Boehringer Ingelheim International GmbH for overseas operations; the Boehringer Ingelheim Fonds was established in 1983 to support biomedical research.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_86abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[14]</sup> The 1985 centenary marked 22,000 employees and DM 4.5 billion in sales, with R&amp;D staff exceeding 3,000 and annual investment reaching DM 500 million by then.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_c6abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[14]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_e6abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[13]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">In the 1990s, focus shifted to unified management, designating Biberach as the research center and Ingelheim for production (1993), alongside the &quot;Value through Innovation&quot; mission (1994).<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_46qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[15]</sup> Product advancements included Combivent for chronic obstructive pulmonary disease (1995), Viramune for reducing HIV mother-to-child transmission, Alna/Flomax for benign prostatic hyperplasia, and Mobec as an antirheumatic (all 1996), and Micardis for hypertension (1999).<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_86qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[15]</sup> Sales reached DM 9.94 billion (approximately $5.07 billion) in 1999, bolstered by the acquisition of Ben Venue Laboratories in Bedford, Ohio, and a new organizational structure under Boehringer Ingelheim Pharma KG.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_c6qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[13]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_e6qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[15]</sup></span>
<h3 id="globalization-and-key-acquisitions-20002015" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Globalization and Key Acquisitions (2000â€“2015)<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">In the early 2000s, Boehringer Ingelheim advanced its globalization through substantial infrastructure investments in Germany, serving as hubs for international operations. The Boehringer Ingelheim Center was inaugurated in 2000 as the new global headquarters in Ingelheim, centralizing administrative, research, and corporate functions to support worldwide activities.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_47qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[15]</sup> In 2002, a new active ingredient plant opened in Ingelheim to bolster pharmaceutical production capacity amid growing global demand. By 2003, the company allocated over â‚¬255 million to expand biopharmaceutical facilities in Biberach, culminating in the inauguration of the G 104 production site for biologics.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_87qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[15]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">A pivotal acquisition occurred in 2004 when Boehringer Ingelheim purchased STEAG microparts GmbH, a German micro-technology specialist, renaming it Boehringer Ingelheim microParts GmbH and basing it in Dortmund to manufacture components for the RespimatÂ® soft inhaler device.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_48abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[15]</sup> This move enhanced production capabilities for respiratory therapeutics, a core area of international expansion. Subsequent investments in Dortmund followed, including â‚¬70 million in 2007 for an atomization factory to increase RespimatÂ® output and â‚¬100 million in 2014 to elevate annual production to 44 million units, reflecting sustained commitment to scaling global supply chains.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_88abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[16]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Further globalization efforts included U.S. expansion via the acquisition of Amgen&#x27;s biomanufacturing facility in Fremont, California, around 2010, which supported biologics production and added over 300,000 square feet of capacity; this underpinned more than $350 million in 2011 U.S. projects for research and manufacturing.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_48qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[17]</sup> In 2009, a â‚¬64 million investment led to the inauguration of the PUROS production site in Ingelheim for innovative anticoagulants, generating 60 new positions.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_88qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[16]</sup> By 2012, the company opened the European Research Center for animal vaccines in Hanover, focusing on farm animal diseases to strengthen its veterinary division&#x27;s global reach. These initiatives drove net sales to â‚¬14.8 billion by 2015, with currency-adjusted growth of 4.1%, fueled by international markets and therapeutic advancements.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_c8qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[18]</sup></span>
<h3 id="strategic-partnerships-and-recent-developments-2016present" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Strategic Partnerships and Recent Developments (2016â€“present)<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">In 2017, Boehringer Ingelheim completed a significant asset swap with Sanofi, acquiring the French company&#x27;s animal health subsidiary Merial for an effective value of approximately â‚¬12 billion while transferring its consumer healthcare business to Sanofi.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_49qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[19]</sup> This transaction, initially agreed in June 2016, bolstered Boehringer Ingelheim&#x27;s animal health portfolio with established products such as NexGardÂ® for flea and tick control and FrontlineÂ® for parasite prevention, establishing Lyon, France, as a major hub for the division.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_89qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[15]</sup> The deal required regulatory divestitures, including the sale of certain vaccine assets to Elanco in October 2016 to address antitrust concerns.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_c9qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[20]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">The company pursued immuno-oncology advancements through targeted collaborations, launching a strategic partnership with Sarah Cannon Research Institute in September 2016 to develop novel therapies, which expanded in October 2017 to investigate combination treatments for lung and other cancers.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4aabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[21]</sup> <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8aabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[22]</sup> Concurrently, Boehringer Ingelheim initiated a long-term collaboration with ViraTherapeutics in 2017 to engineer oncolytic viruses for tumor-targeted immune activation, culminating in the full acquisition of the Austrian biotech firm to integrate its VSV-GP platform into the oncology pipeline.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_caabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[23]</sup> <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_gaabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[24]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Acquisitions accelerated in the 2020s to enhance capabilities in oncology and immunology. In December 2020, Boehringer Ingelheim acquired Swiss firm NBE-Therapeutics for its tumor-targeted immune cell engager technology and German biotech Labor Dr. Merk &amp; Kollegen for dermatology expertise.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4aqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[15]</sup> This was followed by the September 2021 purchase of Abexxa Biologics to advance cancer immunology research via novel protein targets.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8aqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[25]</sup> In July 2025, the company acquired Saiba Animal Health, a Zurich-based developer of pet vaccines and therapeutics, to expand its veterinary offerings.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_caqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[26]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Recent developments emphasize high-potential modalities like antibody-drug conjugates (ADCs) and extended-release therapies. In January 2025, Boehringer Ingelheim partnered with Synaffix for ADC technology access across multiple oncology targets, alongside deals with Sosei Heptares (now Nxera Pharma) and the Broad Institute for mental health drug discovery.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4babav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[27]</sup> August 2025 saw the acquisition of a preclinical oncology program from Accent Therapeutics targeting epigenetic regulation.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8babav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[28]</sup> In May 2025, a multi-year collaboration with Tempus leveraged AI and multimodal data to advance the cancer pipeline.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_cbabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[29]</sup> July 2025 brought a potential $1 billion deal with Re-Vana Therapeutics for extended-release ocular implants to minimize injection frequency in eye diseases.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_gbabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[30]</sup> October 2025 featured a licensing agreement with AimedBio for an ADC asset, with milestones up to $991 million, continuing the focus on precision oncology.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_kbabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[31]</sup> These initiatives supported 6.3% sales growth in the first half of 2025, driven by human pharmaceuticals and animal health.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_obabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[32]</sup></span>
<h2 id="ownership-and-governance" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Ownership and Governance<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<h3 id="family-owned-structure" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Family-Owned Structure<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Boehringer Ingelheim is structured as a privately held <em>Kommanditgesellschaft</em> (KG), a form of German limited partnership that vests controlling interest in family partners while allowing for professional management and limited liability for other stakeholders. This legal form, under which the company operates as C.H. Boehringer Sohn AG &amp; Co. KG, has preserved full family ownership since its founding in 1885 by Albert Boehringer, avoiding public listing and external shareholder influence.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8cqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[33]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_acqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[13]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Ownership is distributed among descendants of the founding Boehringer family and interconnected families, including the von Baumbach lineage through historical marriages and inheritance, with the fourth generation now holding stakes. Key figures such as Chairman and CEO Hubertus von Baumbach, a great-grandson of the founder, exemplify family involvement in oversight, though day-to-day operations are delegated to a professional Board of Managing Directors.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4dabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[34]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_6dabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[35]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8dabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[36]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">This family-controlled model prioritizes long-term strategic independence, enabling sustained investments in research and developmentâ€”totaling approximately â‚¬5.95 billion in 2023â€”without quarterly profit pressures typical of publicly traded peers. The structure supports a unified governance approach, where family shareholders influence major decisions via supervisory bodies, fostering continuity across generations while maintaining operational autonomy.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4dqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[37]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_6dqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[38]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8dqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[39]</sup></span>
<h3 id="leadership-and-decision-making" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Leadership and Decision-Making<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Boehringer Ingelheim operates under a family-owned governance model where the Shareholders&#x27; Committee, consisting of descendants of the founding Boehringer and von Baumbach families, holds ultimate oversight responsibility for strategic direction and major appointments. This committee ensures continuity and alignment with long-term generational planning, free from the quarterly pressures typical of publicly traded firms. Effective July 1, 2025, Hubertus von Baumbach assumed the role of Chairman of the Shareholders&#x27; Committee, succeeding Christian Boehringer, following von Baumbach&#x27;s prior tenure as Chairman of the Board of Managing Directors.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4eqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[40]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_6eqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[41]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">The Board of Managing Directors, comprising five members as of October 2025, handles day-to-day executive leadership and operational decisions across the company&#x27;s global activities. Shashank Deshpande serves as Chairman, concurrently leading the Human Pharma Business Unit; he joined the company in 2012 after executive roles at Sanofi and Cap Gemini, and was elevated to the board in 2022 before assuming the chairmanship in July 2025. Michael Schmelmer acts as Vice Chairman with responsibility for Group Functions, having joined in 2012 with engineering expertise from aerospace and industrial fields. Dr. Paola Casarosa oversees the Innovation Unit, bringing a PhD in molecular pharmacology and experience since 2004. Frank HÃ¼bler manages Finance, with an MSc in business administration and tenure since 2005. Dr. Armin Wiesler directs the Animal Health Business Unit, holding economics degrees and joining in 2008.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4fabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[42]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_6fabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[40]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8fabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[43]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">This structure facilitates data-informed, sustainable decision-making, as evidenced by the company&#x27;s emphasis on long-term investments like â‚¬4.1 billion annual R&amp;D spending, unhindered by external investor demands. Family control allows for agile responses to opportunities, such as strategic acquisitions, while maintaining risk aversion rooted in stewardship obligations; for instance, digital transformation initiatives prioritize foundational data governance to support evidence-based choices across units. The absence of codetermination boards or public disclosures enables confidential deliberations, contrasting with more transparent public peers, but aligns with the firm&#x27;s independence since 1885.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4fqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[33]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_6fqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[44]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8fqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[38]</sup></span>
<h2 id="business-segments" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Business Segments<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<h3 id="human-pharmaceuticals-division" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Human Pharmaceuticals Division<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">The Human Pharmaceuticals Division constitutes the core of Boehringer Ingelheim&#x27;s operations, concentrating on the discovery, development, and commercialization of innovative therapies to address unmet medical needs in humans. It encompasses a portfolio spanning multiple disease categories, with a strategic emphasis on conditions driven by complex pathophysiological mechanisms such as inflammation, fibrosis, and metabolic dysregulation. In 2024, the division generated net sales of â‚¬21,928 million, representing about 82% of the company&#x27;s total revenue of â‚¬26,796 million, underscoring its dominant contribution to overall performance.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4habav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[5]</sup> This segment benefits from the company&#x27;s integrated model, combining in-house R&amp;D with targeted partnerships to accelerate drug advancement.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8habav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[45]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Key therapeutic areas include cardiovascular and metabolic diseases, respiratory disorders, oncology, immunology, mental health, retinal diseases, and chronic kidney disease. Within cardiovascular-metabolic health, therapies target heart failure, type 2 diabetes, and associated comorbidities through mechanisms like SGLT2 inhibition to mitigate cardiorenal risks. Respiratory efforts focus on chronic obstructive pulmonary disease (COPD) and idiopathic pulmonary fibrosis (IPF), addressing progressive lung remodeling via antifibrotic and bronchodilatory agents. Oncology initiatives prioritize tumor microenvironment modulation, particularly in lung and gastrointestinal cancers, while immunology and mental health programs explore neuroinflammatory pathways. These areas align with epidemiological trends, such as rising incidences of cardiometabolic and neurodegenerative conditions in aging populations.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4hqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[46]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Prominent products driving revenue include Jardiance (empagliflozin), an SGLT2 inhibitor approved for reducing cardiovascular death and hospitalization in heart failure patients with reduced ejection fraction, as well as glycemic control in type 2 diabetes; it recorded â‚¬4.3 billion in sales for the first half of 2025. Ofev (nintedanib), a tyrosine kinase inhibitor that slows IPF progression by inhibiting fibrotic signaling, contributed â‚¬2.0 billion in the same period, with expanded indications for systemic sclerosis-associated interstitial lung disease. The division maintains a robust late-stage pipeline, with over 20 assets in clinical development as of mid-2025, including novel candidates for cardiometabolic, oncology, and mental health indications, supported by annual R&amp;D investments exceeding â‚¬5 billion group-wide, of which a substantial portion funds human pharma initiatives.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4iabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[47]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_6iabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[45]</sup> This pipeline reflects a commitment to causal interventions targeting disease drivers, evidenced by phase III advancements in areas like fibrosis and neuroinflammation.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_aiabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[5]</sup></span>
<h3 id="animal-health-division" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Animal Health Division<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">The Animal Health Division of Boehringer Ingelheim specializes in vaccines, parasiticides, and therapeutics for companion animals and livestock, emphasizing disease prevention and innovative solutions to support animal well-being and food security.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4jabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[48]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_6jabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[49]</sup> With over 3,000 employees in the United States alone, the division operates globally as part of the family-owned company, focusing on partnerships with veterinarians, producers, and health authorities to address infectious diseases and parasitic challenges.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_ajabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[49]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_cjabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[50]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">The division traces its origins to 1955, when Boehringer Ingelheim acquired Pfizer&#x27;s veterinary program, establishing a dedicated animal health operation amid post-war expansion in pharmaceuticals.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4jqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[51]</sup> Growth accelerated through strategic acquisitions, including the 2017 business swap with Sanofi that integrated Merial&#x27;s portfolio, elevating Boehringer Ingelheim to the second-largest animal health company worldwide with enhanced capabilities in vaccines and ectoparasiticides.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8jqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[19]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_ajqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[15]</sup> More recently, in September 2024, the division acquired Saiba Animal Health to bolster its research and development pipeline for novel pet therapeutics targeting chronic diseases.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_ejqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[52]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">For livestock, the division provides products such as the 3FLEX vaccine for bovine respiratory disease in cattle, Bovikalc calcium supplement for hypocalcemia prevention during calving, and Ubrolexin antibiotic for bacterial infections in poultry and swine.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4kabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[53]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_6kabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[54]</sup> In companion animals, offerings include Frontline Plus for flea and tick control in dogs and cats, IMRAB rabies vaccines for multiple species, and Vetmedin (pimobendan) chewable tablets for congestive heart failure in dogs.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_akabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[54]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_ckabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[55]</sup> These products, many derived from the Merial integration, prioritize efficacy and safety, with eight of the division&#x27;s top-selling items stemming from external collaborations.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_gkabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[56]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Through its Veterinary Public Health Center, the division collaborates with governments and NGOs on vaccine access and zoonotic disease control, investing in initiatives like the &quot;More Health&quot; program with â‚¬250 million allocated for human-animal health partnerships.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4kqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[50]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_6kqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[57]</sup> This approach underscores a commitment to causal links between animal health, public health, and sustainable agriculture, evidenced by targeted R&amp;D in areas like respiratory vaccines and antiparasitics.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_akqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[58]</sup></span>
<h2 id="research-and-development" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Research and Development<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<h3 id="rd-investment-and-strategy" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">R&amp;D Investment and Strategy<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Boehringer Ingelheim allocates a substantial portion of its revenue to research and development, reflecting its research-driven model as a family-owned enterprise unburdened by short-term shareholder demands. In 2024, the company invested â‚¬6.2 billion in R&amp;D, equivalent to 23.2% of its group net sales of â‚¬26.8 billion, marking an increase from 22.5% of net sales in 2023. Over the preceding five years, cumulative R&amp;D expenditures approximated â‚¬25 billion, underscoring a consistent commitment to innovation amid rising operational costs and pipeline advancement. This high reinvestment rateâ€”among the industry&#x27;s highestâ€”supports both human pharmaceuticals and animal health divisions, with approximately 91% directed toward human pharma in recent assessments, including significant outlays for clinical trials.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4mabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[59]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_6mabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[59]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8mabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[60]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">The company&#x27;s R&amp;D strategy emphasizes a mechanistic approach to disease, prioritizing deep biological insights to identify causal pathways and select optimal therapeutic modalities, such as small molecules, biologics, or cell therapies, tailored to unmet needs. This patient-centric framework builds on established expertise in areas like respiratory and cardiovascular diseases while expanding into high-potential domains through internal discovery and external partnerships. Key focus areas in human health include cardio-renal-metabolic diseases, oncology, respiratory conditions, immunology, central nervous system disorders, and retinal diseases, with pipeline efforts targeting mechanisms like fibrosis, inflammation, and tumor microenvironments. In animal health, R&amp;D parallels human efforts by addressing infectious diseases, oncology, and chronic conditions in livestock and companion animals, often leveraging shared platforms for efficiency.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4mqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[61]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_6mqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[62]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Strategic initiatives integrate open collaboration and venture investments to accelerate innovation, including alliances with biotech firms and academic institutions to access novel technologies like AI-driven drug design and gene editing. Boehringer Ingelheim plans â‚¬20 billion in investments from 2025 to 2030 across human and animal health, focusing on late-stage assets and manufacturing scalability to transition discoveries into marketable therapies. This approach mitigates risks inherent in pharmaceutical R&amp;Dâ€”such as high failure rates in clinical phasesâ€”by diversifying modalities and emphasizing evidence-based validation over speculative trends.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4nabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[63]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_6nabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup></span>
<h3 id="major-collaborations-and-innovations" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Major Collaborations and Innovations<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Boehringer Ingelheim has pursued extensive research collaborations to advance its pipeline in oncology, immunology, and respiratory diseases, partnering with academic institutions, biotech firms, and advocacy groups. In oncology, the company maintains long-term alliances with leading organizations to accelerate drug discovery and development.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4oabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[64]</sup> A notable expansion occurred in 2023 with BioMed X, establishing XSeed Labs in Ridgefield, Connecticut, to leverage biologics expertise for retinal drug delivery innovations, followed by a new U.S.-based team in 2024 focused on disease models for complex conditions.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8oabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[63]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_aoabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[65]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">In early 2024, Boehringer Ingelheim initiated five new R&amp;D partnerships, including one with Suzhou Ribo Life Science Co., Ltd., targeting RNA interference technologies for therapeutic applications.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4oqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[66]</sup> This momentum continued into 2025 with a collaboration alongside the Lung Cancer Research Foundation, committing $2.25 million to investigate HER2-mutated lung cancers and support treatment advancements.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8oqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[67]</sup> In May 2025, the company entered a strategic alliance with Tempus to utilize AI and real-world data for enhancing its cancer pipeline, building on prior joint efforts.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_coqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[68]</sup> Additionally, a partnership with Cue Biopharma advanced the immunotherapy candidate CUE-501, involving a $12 million upfront payment to explore T-cell engagement in solid tumors.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_goqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[69]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Key innovations from these efforts include antibody-drug conjugate (ADC) technologies, with a January 2025 agreement with Synaffix granting access to proprietary linker-payload platforms for multiple oncology targets, aiming to improve targeted cancer therapies.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4pabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[27]</sup> In animal health, Boehringer Ingelheim integrates human pharma insights into veterinary innovations, such as digital tools for data analytics and connectivity to enhance disease prevention in livestock and pets.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8pabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[70]</sup> The company supports this through a renewed R&amp;D strategy investing â‚¬11 billion over five years, emphasizing external partnerships to bolster internal capabilities in biologics and precision medicine.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_cpabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[71]</sup> These collaborations have contributed to pipeline progress, including potential launches in oncology by late 2025.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_gpabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[72]</sup></span>
<h3 id="clinical-pipeline-highlights" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Clinical Pipeline Highlights<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Boehringer Ingelheim maintains a robust clinical pipeline emphasizing oncology, respiratory, and cardiovascular-renal-metabolic diseases, with multiple candidates in phase 3 development as of July 2025. The company anticipates initiating over ten new phase II and III trials within the subsequent 12 to 18 months, building on empirical data from prior studies to address unmet needs in fibrosis, targeted cancers, and obesity-related conditions.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4qabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[45]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_6qabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[32]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">In oncology, zongertinib (BI 1810631), an irreversible HER2-selective tyrosine kinase inhibitor, advanced through phase 3 trials such as Beamion LUNG-2 and Beamion LUNG-3, evaluating its role in first-line and pretreated HER2-mutant non-small cell lung cancer (NSCLC). It received U.S. FDA accelerated approval under the brand HERNEXEOS in August 2025 for adults with unresectable or metastatic HER2-mutant NSCLC post-prior systemic therapy, supported by phase 2 data showing durable responses and primarily low-grade adverse events. Additional October 2025 results from early trials reported a 77% objective response rate in treatment-naÃ¯ve advanced HER2-mutant NSCLC patients.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4qqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[73]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_6qqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[74]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8qqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[75]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_aqqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[76]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Respiratory pipeline highlights include nerandomilast (BI 1015550), a PDE4B inhibitor targeting idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF). The phase 3 FIBRONEER- IPF and FIBRONEER-PPF trials, reported in May 2025, demonstrated statistically significant slowing of forced vital capacity decline versus placebo, with discontinuation rates comparable to placebo and no new safety signals beyond known PDE4 inhibitor effects.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4rabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[77]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_6rabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[78]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8rabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[79]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">In the cardiovascular-renal-metabolic area, survodutide (BI 456906), a GLP-1/glucagon receptor dual agonist co-developed with Zealand Pharma, progressed to phase 3 programs including SYNCHRONIZE for obesity with cardiovascular risk and trials for metabolic dysfunction-associated steatohepatitis (MASH) with fibrosis. Phase 2 data from August 2023 indicated up to 19% mean weight reduction in overweight or obese patients, prompting FDA Breakthrough Therapy designation for MASH in October 2024 and initiation of confirmatory trials.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4rqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[80]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_6rqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[81]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8rqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[82]</sup></span>

































<div class="border-border-l1 overflow-x-auto rounded-lg border my-6 w-full"><table node="[object Object]" class="w-full border-collapse text-sm"><thead node="[object Object]" class="border-border-l1 border-b bg-surface-l1"><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><th node="[object Object]" class="dark:text-fg-primary bg-gray-100 px-2 py-1 text-left align-top font-bold dark:bg-black"><span class="text-[1em] leading-7">Candidate</span></th><th node="[object Object]" class="dark:text-fg-primary bg-gray-100 px-2 py-1 text-left align-top font-bold dark:bg-black"><span class="text-[1em] leading-7">Therapeutic Area</span></th><th node="[object Object]" class="dark:text-fg-primary bg-gray-100 px-2 py-1 text-left align-top font-bold dark:bg-black"><span class="text-[1em] leading-7">Indication</span></th><th node="[object Object]" class="dark:text-fg-primary bg-gray-100 px-2 py-1 text-left align-top font-bold dark:bg-black"><span class="text-[1em] leading-7">Phase</span></th><th node="[object Object]" class="dark:text-fg-primary bg-gray-100 px-2 py-1 text-left align-top font-bold dark:bg-black"><span class="text-[1em] leading-7">Key Recent Milestone</span></th></tr></thead><tbody node="[object Object]" class="divide-border-l1 divide-y"><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Zongertinib (BI 1810631)</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Oncology</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">HER2-mutant NSCLC</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">3 (ongoing post-approval)</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Accelerated FDA approval August 2025; 77% ORR in naÃ¯ve patients October 2025</span><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_lcsabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[74]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_tcsabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[75]</sup></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Nerandomilast (BI 1015550)</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Respiratory</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">IPF/PPF</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">3</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Slowed FVC decline in FIBRONEER trials May 2025</span><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_lksabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[78]</sup></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Survodutide (BI 456906)</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Metabolic</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Obesity/MASH</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">3</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Breakthrough designation; up to 19% weight loss phase 2 August 2023</span><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_lssabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[81]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_tssabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[82]</sup></td></tr></tbody></table></div>
<h2 id="key-products" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Key Products<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<h3 id="established-human-pharma-products" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Established Human Pharma Products<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Boehringer Ingelheim&#x27;s established human pharmaceutical products encompass a range of therapies primarily targeting respiratory conditions, cardiovascular diseases, and anticoagulation needs, with many originating from decades of development in core therapeutic areas. These products, developed through internal R&amp;D and partnerships, have achieved widespread market adoption due to their efficacy in managing chronic conditions, contributing substantially to the company&#x27;s Human Pharma net sales, which reached â‚¬21.9 billion in 2024.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4tqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[47]</sup> Key examples include long-acting bronchodilators for chronic obstructive pulmonary disease (COPD) and angiotensin receptor blockers for hypertension, reflecting the firm&#x27;s historical emphasis on these domains since the mid-20th century.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8tqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[83]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">In respiratory therapeutics, Spiriva (tiotropium bromide), a once-daily inhaled long-acting muscarinic antagonist, serves as a cornerstone product for maintenance treatment of COPD, including chronic bronchitis and emphysema, as well as add-on therapy for severe asthma in patients aged 6 and older with a history of exacerbations. First approved by the FDA in 2004, Spiriva has been available in HandiHaler and Respimat formulations, demonstrating sustained clinical benefits in reducing exacerbations and improving lung function in multiple randomized controlled trials.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4uabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[84]</sup> Atrovent (ipratropium bromide), an anticholinergic bronchodilator introduced earlier in the 1970s in various markets, treats and prevents shortness of breath in COPD and supports acute asthma management as an adjunct to beta-agonists, with formulations including HFA inhalation aerosols for targeted delivery.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8uabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[85]</sup> Complementary combination products like Combivent Respimat (ipratropium bromide and salbutamol sulphate) address reversible bronchospasms in obstructive airway diseases requiring dual bronchodilation, enhancing symptom control in patients unresponsive to single agents.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_cuabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[83]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Cardiovascular offerings include Micardis (telmisartan), an angiotensin II receptor blocker approved by the FDA in 1998 for hypertension treatment, which reduces risks of cardiovascular events such as heart attack, stroke, or death in patients aged 55 and older with high risk factors. Clinical data from the ONTARGET trial confirmed its noninferiority to ramipril in preventing composite cardiovascular outcomes.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4uqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[86]</sup> Pradaxa (dabigatran etexilate), a direct oral anticoagulant approved in 2010, prevents strokes and systemic emboli in nonvalvular atrial fibrillation, reduces venous thromboembolism recurrence, and treats deep vein thrombosis or pulmonary embolism, offering a reversal agent (idarucizumab) for bleeding management, which differentiates it from warfarin in real-world evidence studies showing lower intracranial hemorrhage rates.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8uqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[87]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Other notable established products address niche needs, such as Ofev (nintedanib), a tyrosine kinase inhibitor approved in 2014 for idiopathic pulmonary fibrosis and later expanded to progressive fibrosing interstitial lung diseases, slowing forced vital capacity decline as evidenced by phase III INPULSIS trials.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4vabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[84]</sup> These products&#x27; longevity stems from robust patent protection, generic competition delays in some markets, and ongoing label expansions, though sales dynamics have shifted with newer entrants; for instance, respiratory products like Spiriva historically drove growth but now complement diabetes and fibrosis therapies in the portfolio.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8vabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[83]</sup></span>









































<div class="border-border-l1 overflow-x-auto rounded-lg border my-6 w-full"><table node="[object Object]" class="w-full border-collapse text-sm"><thead node="[object Object]" class="border-border-l1 border-b bg-surface-l1"><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><th node="[object Object]" class="dark:text-fg-primary bg-gray-100 px-2 py-1 text-left align-top font-bold dark:bg-black"><span class="text-[1em] leading-7">Product</span></th><th node="[object Object]" class="dark:text-fg-primary bg-gray-100 px-2 py-1 text-left align-top font-bold dark:bg-black"><span class="text-[1em] leading-7">Active Ingredient</span></th><th node="[object Object]" class="dark:text-fg-primary bg-gray-100 px-2 py-1 text-left align-top font-bold dark:bg-black"><span class="text-[1em] leading-7">Primary Indication</span></th><th node="[object Object]" class="dark:text-fg-primary bg-gray-100 px-2 py-1 text-left align-top font-bold dark:bg-black"><span class="text-[1em] leading-7">Key Approval Milestone</span></th></tr></thead><tbody node="[object Object]" class="divide-border-l1 divide-y"><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Spiriva</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Tiotropium bromide</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">COPD maintenance</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">FDA 2004</span><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_18cvqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[84]</sup></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Atrovent</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Ipratropium bromide</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">COPD, asthma adjunct</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Marketed since 1970s</span><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_18kvqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[85]</sup></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Micardis</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Telmisartan</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Hypertension</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">FDA 1998</span><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_18svqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[86]</sup></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Pradaxa</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Dabigatran etexilate</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Stroke prevention in AF</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">FDA 2010</span><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_194vqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[87]</sup></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Ofev</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Nintedanib</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Idiopathic pulmonary fibrosis</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">FDA 2014</span><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_19cvqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[84]</sup></td></tr></tbody></table></div>
<h3 id="prominent-animal-health-products" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Prominent Animal Health Products<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Boehringer Ingelheim&#x27;s Animal Health division features prominent parasiticides, vaccines, and therapeutics, with pet products driving substantial revenue growth due to high demand for flea, tick, and heartworm prevention.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_50qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[59]</sup> In 2024, the division&#x27;s net sales reached 4.7 billion euros, led by pet parasiticides and therapeutics.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_90qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[59]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">NexGard, an oral beef-flavored chewable containing afoxolaner, provides monthly protection against fleas, ticks, and mites in dogs by killing parasites before they lay eggs or transmit diseases like Lyme.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_51abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[88]</sup> It was the division&#x27;s top product in 2024, generating 1.35 billion euros in net sales.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_91abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[89]</sup> NexGard variants, such as NexGard PLUS (combining afoxolaner, moxidectin, and pyrantel) and NexGard COMBO for cats, extend coverage to heartworms, roundworms, hookworms, and tapeworms.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_d1abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[90]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_f1abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[91]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Other leading pet brands include Frontline, a topical solution for flea and tick control in dogs and cats, and Heartgard, an ivermectin-based chew for heartworm prevention in dogs.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_51qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[37]</sup> These core parasiticides, acquired via the 2017 Merial integration, form the backbone of the companion animal portfolio.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_91qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[37]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Metacam (meloxicam oral suspension or injection) is a non-steroidal anti-inflammatory drug used for postoperative pain, osteoarthritis, and inflammation in dogs, cats, horses, and livestock species like cattle and pigs, with precise dosing via graduated syringes for efficacy and safety.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_52abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[92]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">In livestock, vaccines such as Ingelvac CIRCOFLEX (for porcine circovirus type 2) and Bovi-Shield (for bovine viral diarrhea and respiratory diseases) support disease prevention in swine and cattle herds, contributing to ruminant and poultry segments.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_52qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[93]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_72qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[94]</sup> These products emphasize preventive strategies amid rising antimicrobial resistance concerns.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_b2qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[95]</sup></span>
<h2 id="operations-and-global-footprint" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Operations and Global Footprint<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<h3 id="manufacturing-and-research-sites" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Manufacturing and Research Sites<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">
Boehringer Ingelheim maintains an extensive global network of manufacturing and research facilities, spanning over 170 locations worldwide to support its operations in human pharmaceuticals and animal health. The company&#x27;s infrastructure emphasizes integrated research and production capabilities, with key hubs in Germany, the United States, and other regions, enabling efficient development and commercialization of therapies.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_74abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[96]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Major research and development sites include Biberach, Germany, which serves as the company&#x27;s largest R&amp;D center globally and houses specialized units for biologics development, including analytical development and bioprocess development; this site also features Europe&#x27;s largest biotechnology center and received a â‚¬350 million investment in 2023 for a new biopharmaceutical R&amp;D facility.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_54qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[97]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_74qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[98]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_94qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[99]</sup> In the United States, Ridgefield, Connecticut, functions as the U.S. headquarters and a primary R&amp;D site focused on human health innovation.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_d4qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[100]</sup> Athens, Georgia, hosts an expanded animal health R&amp;D facility, which became the company&#x27;s largest U.S. R&amp;D siteâ€”and third globallyâ€”following a $66.1 million investment and grand opening in October 2024, creating 63 new jobs and enhancing capabilities in vaccine and therapeutic development.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_h4qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[101]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_j4qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[102]</sup> Vienna, Austria, specializes in oncology research alongside biopharmaceutical development.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_n4qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[96]</sup></span>





































<div class="border-border-l1 overflow-x-auto rounded-lg border my-6 w-full"><table node="[object Object]" class="w-full border-collapse text-sm"><thead node="[object Object]" class="border-border-l1 border-b bg-surface-l1"><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><th node="[object Object]" class="dark:text-fg-primary bg-gray-100 px-2 py-1 text-left align-top font-bold dark:bg-black"><span class="text-[1em] leading-7">Site Location</span></th><th node="[object Object]" class="dark:text-fg-primary bg-gray-100 px-2 py-1 text-left align-top font-bold dark:bg-black"><span class="text-[1em] leading-7">Primary Functions</span></th></tr></thead><tbody node="[object Object]" class="divide-border-l1 divide-y"><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Ingelheim, Germany</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Headquarters; manufacturing of new active pharmaceutical ingredients and initial medication launches; upcoming Chemical Innovation Plant operational by 2026.</span><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_kd5abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[103]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_sd5abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[104]</sup></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Biberach, Germany</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Biopharmaceutical manufacturing with 240,000 L bioreactor capacity for fed-batch and perfusion processes; aseptic filling; production of therapeutic proteins and antibodies.</span><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_kl5abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[105]</sup></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Vienna, Austria</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Mammalian cell culture (135,000 L capacity) and microbial fermentation (12,000 L); recombinant proteins, vaccines, and plasmid DNA production for clinical and commercial supply.</span><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_kt5abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[105]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_st5abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[96]</sup></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Fremont, California, USA</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Mammalian cell culture manufacturing (up to 51,000 L capacity) for monoclonal antibodies and proteins; multi-product clinical and commercial supply.</span><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_l55abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[105]</sup></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Shanghai, China</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Single-use bioreactors (6,000 L total); aseptic filling for process optimization and regional supply.</span><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_ld5abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[105]</sup></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Sant Cugat del VallÃ¨s, Spain</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Pharmaceutical production, including aseptic cartridges and RESPIMAT inhaler packaging.</span><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_ll5abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[96]</sup></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Fornovo San Giovanni, Italy</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Production of active pharmaceutical ingredients for human pharmaceuticals and animal health products.</span><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_lt5abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[96]</sup></td></tr></tbody></table></div>
<span class="mb-4 block break-words text-[1em] leading-7">Additional manufacturing occurs at sites like St. Joseph, Missouri, dedicated to animal health production, with expansions announced in May 2024 to enhance global operations.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_55qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[106]</sup> These facilities collectively support Boehringer Ingelheim&#x27;s capacity for over 54,500 employees and its focus on biopharmaceutical and chemical manufacturing excellence.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_95qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[96]</sup></span>
<h3 id="workforce-and-operational-efficiency" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Workforce and Operational Efficiency<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Boehringer Ingelheim maintains a global workforce of approximately 54,500 employees as of 2024, supporting operations in over 130 markets.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_56qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[59]</sup> The majority are based in Europe, with over 10,200 at the Ingelheim headquarters in Germany handling production, research, development, and administration.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_96qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[107]</sup> In the United States, more than 9,000 employees contribute across various functions.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_d6qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup> Of these, an average of 11,563 were engaged in global research networks for Human Pharma and Animal Health divisions during 2024, reflecting a strategic emphasis on innovation-driven roles.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_h6qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[37]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Operational efficiency is pursued through digital transformation and process optimization. The company utilizes workforce management software to streamline scheduling, time tracking, and resource allocation across complex global sites, reducing administrative burdens and enhancing collaboration.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_57abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[108]</sup> In March 2025, Boehringer Ingelheim partnered with Cognizant to deploy a unified cloud platform, integrating data systems to expedite medicinal development workflows and improve overall operational throughput.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_97abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[109]</sup> Machine learning applications in biopharmaceutical manufacturing further support efficiency by enabling rapid identification of production variables, minimizing downtime and variability.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_d7abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[110]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Employee development initiatives bolster productivity, including structured leadership programs that emphasize self-awareness and emotional intelligence to drive engagement and performance outcomes.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_57qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[111]</sup> These efforts align with the family-owned structure&#x27;s long-term orientation, prioritizing sustainable growth over short-term metrics, as evidenced by steady workforce expansion alongside revenue of 26.8 billion euros in 2024.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_97qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[112]</sup></span>
<h2 id="financial-performance" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Financial Performance<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<h3 id="revenue-growth-and-key-metrics" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Revenue Growth and Key Metrics<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">In 2023, Boehringer Ingelheim achieved net sales of â‚¬25.6 billion, reflecting a currency-adjusted increase of 9.7% from 2022, driven primarily by strong performance in Human Pharma products such as Jardiance for type 2 diabetes and Ofev for idiopathic pulmonary fibrosis.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_59abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[4]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_79abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[113]</sup> Human Pharma net sales reached â‚¬20.8 billion that year, bolstered by a 14.2% rise in research-driven therapies.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_b9abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[114]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Net sales grew to â‚¬26.8 billion in 2024, a currency-adjusted gain of 6.1%, with Human Pharma accounting for â‚¬21.9 billion and Animal Health contributing â‚¬4.7 billion; overall growth was supported by expanded patient access and regional expansion in the Americas and Asia-Pacific.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_59qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[37]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_79qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[115]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_99qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[5]</sup> This marked a nominal increase of approximately 4.7% from 2023, amid currency headwinds in Europe.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_d9qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[116]</sup></span>



































<div class="border-border-l1 overflow-x-auto rounded-lg border my-6 w-full"><table node="[object Object]" class="w-full border-collapse text-sm"><thead node="[object Object]" class="border-border-l1 border-b bg-surface-l1"><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><th node="[object Object]" class="dark:text-fg-primary bg-gray-100 px-2 py-1 text-left align-top font-bold dark:bg-black"><span class="text-[1em] leading-7">Year</span></th><th node="[object Object]" class="dark:text-fg-primary bg-gray-100 px-2 py-1 text-left align-top font-bold dark:bg-black"><span class="text-[1em] leading-7">Net Sales (â‚¬ billion)</span></th><th node="[object Object]" class="dark:text-fg-primary bg-gray-100 px-2 py-1 text-left align-top font-bold dark:bg-black"><span class="text-[1em] leading-7">Currency-Adjusted Growth (%)</span></th><th node="[object Object]" class="dark:text-fg-primary bg-gray-100 px-2 py-1 text-left align-top font-bold dark:bg-black"><span class="text-[1em] leading-7">Key Driver</span></th></tr></thead><tbody node="[object Object]" class="divide-border-l1 divide-y"><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">2021</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">20.6</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">+5.0 (vs. 2020)</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Respiratory and cardiovascular portfolio expansion</span><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_18daabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[117]</sup></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">2022</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">~24.2</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">+6.0 (vs. 2021)</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Animal Health recovery post-COVID</span><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_18laabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[118]</sup></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">2023</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">25.6</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">+9.7</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Jardiance and Ofev demand</span><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_18taabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[4]</sup></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">2024</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">26.8</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">+6.1</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Broader therapeutic area gains</span><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_195aabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[115]</sup></td></tr></tbody></table></div>
<span class="mb-4 block break-words text-[1em] leading-7">The company&#x27;s revenue trajectory demonstrates resilience as a privately held entity, with consistent double-digit growth in prior years tapering to mid-single digits amid maturing markets and increased R&amp;D reinvestment, positioning it among the top 20 global pharmaceutical firms by sales.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_5aqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[119]</sup> In the first half of 2025, Human Pharma net sales reached â‚¬11.3 billion, up 5.7% year-over-year, signaling sustained momentum.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9aqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[47]</sup></span>
<h3 id="rd-and-capital-expenditures" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">R&amp;D and Capital Expenditures<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Boehringer Ingelheim allocates a substantial portion of its resources to research and development, emphasizing innovation in human pharmaceuticals and animal health. In 2024, the company reported R&amp;D expenditures of â‚¬6.2 billion, equivalent to 23.2% of group net sales, with the majorityâ€”â‚¬5.7 billionâ€”directed toward the human pharma division.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_5bqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[59]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_7bqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[37]</sup> This represented an increase from â‚¬5.8 billion in 2023, or 22.5% of net sales, continuing a trend of rising investments that outpaced sales growth in recent years.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_bbqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[120]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_dbqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[60]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Over the preceding five years through 2024, cumulative R&amp;D spending totaled approximately â‚¬25 billion, underscoring the firm&#x27;s long-term commitment to pipeline advancement amid a private ownership structure that avoids short-term shareholder pressures.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_5cabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[59]</sup> In the human pharma segment specifically, R&amp;D investment reached 25.1% of net sales in 2023, positioning the company among top industry spenders relative to revenue.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9cabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[113]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Capital expenditures complement these efforts by expanding manufacturing and research infrastructure. From 2019 to 2023, Boehringer Ingelheim invested â‚¬5.6 billion in capital projects, including â‚¬2.3 billion for production capacity enhancements to support growing demand for biologics and other therapies.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_5cqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[4]</sup> In 2022, the company pledged over â‚¬7 billion through 2025 for such initiatives, focusing on sites in Germany, the United States, and other key locations to bolster global operations and innovation capabilities.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9cqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[121]</sup> These investments prioritize efficiency and scalability, driven by the need to transition from chemical to biological manufacturing processes.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_dcqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[122]</sup></span>
<h2 id="legal-and-regulatory-challenges" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Legal and Regulatory Challenges<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<h3 id="patent-disputes-and-competition-issues" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Patent Disputes and Competition Issues<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">In 2024, Boehringer Ingelheim faced allegations of patent misuse in U.S. federal court, where plaintiffs claimed the company improperly listed device patents for its inhaler products, including Spiriva Respimat (tiotropium bromide) and Combivent Respimat (ipratropium bromide and albuterol), in the FDA&#x27;s Orange Book to delay generic competition.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_5eabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[123]</sup> The lawsuit, filed in the U.S. District Court for the District of Massachusetts, accused Boehringer of listing 19 patents covering the Respimat inhaler device despite their expiration or inapplicability to the drug formulation, thereby triggering 30-month stays on generic approvals under the Hatch-Waxman Act.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9eabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[124]</sup> These actions allegedly maintained monopoly pricing for COPD and asthma treatments, with plaintiffs seeking damages and injunctive relief to delist the patents.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_deabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[7]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">The U.S. Federal Trade Commission (FTC) supported such challenges by issuing warning letters in November 2023 to Boehringer and other manufacturers, asserting that listing patents solely for delivery devices without claiming the drug itself violated FDA regulations and antitrust principles, as it artificially extended exclusivity beyond the drug&#x27;s compound patent life.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_5eqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[125]</sup> Boehringer defended the listings as compliant with statutory requirements for patents covering methods of use or approved formulations, arguing they protect innovation in patient-friendly delivery systems essential for drug efficacy.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9eqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[126]</sup> Related multidistrict antitrust litigation consolidated cases alleging overcharges from delayed generic entry for Respimat products, with Boehringer opposing centralization and maintaining that device patents are legitimately tied to therapeutic delivery.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_deqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[126]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">In Europe, Boehringer encountered competition scrutiny for product hopping with Spiriva, transitioning from the HandiHaler dry powder inhaler to the Respimat soft mist version around 2014-2015, then withdrawing the original to block generic approvals. The Romanian Competition Authority fined Boehringer â‚¬25.81 million in January 2025 for abuse of dominance, finding the strategy deprived patients of cheaper alternatives and maintained supra-competitive prices without clinical justification for the switch.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_5fabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[127]</sup> Boehringer contested the decision, claiming the Respimat offered superior lung deposition and adherence benefits supported by clinical data, not mere lifecycle management.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9fabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[128]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Boehringer has also initiated and prevailed in defensive patent actions, such as securing preliminary injunctions against Zentiva in 2025 for imminent infringement of Ofev (nintedanib) patents in the Unified Patent Court, though the Court of Appeal later refined standards for &quot;imminent&quot; harm in pharmaceutical cases.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_5fqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[129]</sup> In Canada, the Federal Court upheld formulation and treatment patents for nintedanib in idiopathic pulmonary fibrosis, enjoining generic entry in August 2024.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9fqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[130]</sup> For Pradaxa (dabigatran etexilate), Boehringer resolved U.S. generic challenges through a 2014 comprehensive settlement allowing limited entry post-patent expiry and litigated patent term extensions with the FDA, securing additional exclusivity.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_dfqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[131]</sup> These outcomes reflect Boehringer&#x27;s strategy of robust IP enforcement amid generics pressure, though critics argue secondary patents on devices or formulations extend monopolies absent proportional innovation.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_hfqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[132]</sup></span>
<h3 id="product-liability-and-safety-litigation" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Product Liability and Safety Litigation<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Boehringer Ingelheim has faced significant product liability litigation primarily related to alleged safety defects in its pharmaceuticals, with the most prominent cases involving the anticoagulant Pradaxa (dabigatran etexilate) and the Parkinson&#x27;s disease treatment Mirapex (pramipexole). These suits have centered on claims of inadequate warnings about severe side effects, such as uncontrollable bleeding for Pradaxa and impulse control disorders for Mirapex, leading to multidistrict litigation (MDL) and substantial settlements.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_5gqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[133]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_7gqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[134]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Pradaxa, approved by the FDA in 2010 as an alternative to warfarin for stroke prevention in atrial fibrillation patients, drew over 4,000 lawsuits by 2014 alleging gastrointestinal and intracranial hemorrhages due to the drug&#x27;s irreversible anticoagulation effects and initial lack of a reversal agent. Plaintiffs claimed Boehringer Ingelheim failed to adequately warn of bleeding risks, particularly in elderly patients or those with renal impairment, resulting in deaths and severe injuries. In May 2014, the company announced a $650 million settlement resolving approximately 3,985 claims without admitting liability, covering cases in both federal MDL proceedings in the Southern District of Illinois and state courts.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_5habav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[133]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_7habav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[135]</sup> Additional settlements followed for remaining claims, though some individual suits persisted into the late 2010s, with ongoing investigations reported as late as 2025 for bleeding events.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_bhabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[136]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Mirapex litigation, consolidated in MDL No. 1836 in the District of Minnesota starting in 2007, involved claims that the dopamine agonist caused compulsive gambling, hypersexuality, and other behavioral disorders not sufficiently disclosed in labeling. Patients and families alleged failure to warn of these risks, leading to financial ruin and personal harm; one appellate case highlighted a plaintiff seeking recovery for $4 million in gambling losses. Courts often dismissed claims on statute of limitations grounds, ruling plaintiffs had notice of potential links by 2005 following FDA warnings and medical literature. Boehringer Ingelheim prevailed in key appeals, such as the Eighth Circuit&#x27;s 2019 affirmance limiting liability, though the company faced related antitrust scrutiny over patent extensions rather than direct safety verdicts.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_5hqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[137]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_7hqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[134]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9hqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[138]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Other safety-related suits include allegations involving inhalers like Spiriva, where plaintiffs claimed design defects exacerbated respiratory issues, but these have seen limited success with dismissals on preemption grounds under federal drug approval processes. In Zantac-related cancer claims, Boehringer Ingelheim secured defense verdicts in multiple Illinois trials through 2025, with juries rejecting causation links to alleged NDMA contamination in acid reducers. Recent filings, such as Keys v. Boehringer Ingelheim in Alameda County Superior Court (filed October 23, 2025), remain pending without resolved outcomes. Overall, while settlements have resolved bulk claims, Boehringer has contested liability emphasizing FDA-approved labeling and clinical data.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_5iabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[139]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_7iabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[140]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9iabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[141]</sup></span>
<h3 id="government-pricing-and-regulatory-conflicts" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Government Pricing and Regulatory Conflicts<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">In August 2023, Boehringer Ingelheim filed a lawsuit against the U.S. Department of Health and Human Services (HHS) challenging the Medicare Drug Price Negotiation Program established by the Inflation Reduction Act of 2022, which authorizes the Centers for Medicare &amp; Medicaid Services (CMS) to negotiate maximum fair prices for select high-cost drugs covered by Medicare Part D and Part B.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_5jabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[142]</sup> The company argued that the program violated the First Amendment by compelling speech during negotiations, the Fifth Amendment through due process and takings claims by effectively coercing price concessions without adequate opt-out mechanisms, and the Eighth Amendment by imposing excessive penalties for non-participation, such as a 75% excise tax on sales of non-negotiated drugs.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9jabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[143]</sup> In July 2024, the U.S. District Court for the District of Connecticut granted summary judgment to HHS, ruling that the program constituted permissible regulation of commerce rather than unconstitutional compulsion.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_djabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[144]</sup> The U.S. Court of Appeals for the Second Circuit affirmed this decision on August 7, 2025, holding that manufacturers retain meaningful choices, including withdrawal from Medicare, and that any burdens were rationally related to Congress&#x27;s goal of reducing federal spending.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_hjabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[143]</sup> Boehringer&#x27;s drug nintedanib (Ofev), used for idiopathic pulmonary fibrosis, was selected for negotiation in the program&#x27;s second cycle announced in 2025.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_ljabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[145]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Boehringer Ingelheim has also faced conflicts over the 340B Drug Pricing Program, a U.S. federal initiative requiring manufacturers to provide outpatient drugs at steep discounts to eligible safety-net providers. In 2022, the company expanded restrictions on 340B pricing for its products at contract pharmacies affiliated with certain disproportionate share hospitals and health centers, citing concerns over program diversion and duplicate discounts.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_5jqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[146]</sup> This policy prompted lawsuits from providers and criticism from HHS, which in October 2021 issued guidance affirming that manufacturers cannot impose such limits without violating statutory obligations.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9jqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[147]</sup> Boehringer sued HHS in federal court, alleging the agency&#x27;s contract pharmacy policy and related enforcement letters were arbitrary and capricious under the Administrative Procedure Act, seeking to vacate them and exemption from providing discounts to contract pharmacies.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_djqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[147]</sup> In March 2022, the 340B Health alliance referred Boehringer to HHS for penalties over alleged continued violations of 340B pricing requirements.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_hjqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[148]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Internationally, Boehringer Ingelheim encountered regulatory scrutiny for pricing-related anticompetitive conduct. In October 2023, the European Commission fined the company â‚¬2.2 million as part of a â‚¬13.4 million cartel settlement involving coordination on minimum sales prices for scopolamine butylbromide (SNBB), an active pharmaceutical ingredient used in Boehringer&#x27;s Buscopan antispasmodic drug, from 2007 to 2015.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_5kabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[149]</sup> The infringement decision followed an investigation into six firms fixing SNBB prices allocated to customers, including generic producers, thereby inflating input costs for downstream products.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9kabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[149]</sup> Separately, in January 2025, Romania&#x27;s Competition Council imposed a â‚¬25.81 million fine on Boehringer for product hopping with its Spiriva Respimat inhaler, a strategy deemed abusive that involved reformulating the tiotropium bromide product and withdrawing the original dry powder version in 2015 to delay generic entry and sustain monopoly pricing, violating EU and national competition rules.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_dkabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[127]</sup> These cases highlight tensions between pharmaceutical pricing strategies and antitrust enforcement aimed at preventing artificial price maintenance.</span></article><div id="references" class="min-w-0 scroll-mt-8 overflow-hidden"><div class="text-[16px]"><h2 id="references" node="[object Object]" class="mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden">References</h2></div><ol class="columns-1 gap-x-12 [counter-reset:item] md:columns-2"><li id="https://www.boehringer-ingelheim.com/us/about-us/who-we-are" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.boehringer-ingelheim.com/us/about-us/who-we-are" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.boehringer-ingelheim.com/us/about-us/who-we-are</a></span></div></li><li id="https://www.forbes.com/companies/boehringer-ingelheim/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.forbes.com/companies/boehringer-ingelheim/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.forbes.com/companies/boehringer-ingelheim/</a></span></div></li><li id="https://www.boehringer-ingelheim.com/us/about-us/who-we-are/history" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.boehringer-ingelheim.com/us/about-us/who-we-are/history" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.boehringer-ingelheim.com/us/about-us/who-we-are/history</a></span></div></li><li id="https://www.boehringer-ingelheim.com/us/media/boehringer-ingelheim-reports-strong-growth-2023-and-accelerates-late-stage-pipeline" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.boehringer-ingelheim.com/us/media/boehringer-ingelheim-reports-strong-growth-2023-and-accelerates-late-stage-pipeline" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.boehringer-ingelheim.com/us/media/boehringer-ingelheim-reports-strong-growth-2023-and-accelerates-late-stage-pipeline</a></span></div></li><li id="https://boehringer-ingelheim.com/annualreport/2024/facts-and-figures/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://boehringer-ingelheim.com/annualreport/2024/facts-and-figures/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://boehringer-ingelheim.com/annualreport/2024/facts-and-figures/</a></span></div></li><li id="https://www.justice.gov/archives/opa/pr/boehringer-ingelheim-pay-95-million-resolve-false-claims-act-allegations" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.justice.gov/archives/opa/pr/boehringer-ingelheim-pay-95-million-resolve-false-claims-act-allegations" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.justice.gov/archives/opa/pr/boehringer-ingelheim-pay-95-million-resolve-false-claims-act-allegations</a></span></div></li><li id="https://globalcompetitionreview.com/gcr-usa/article/boehringer-ingelheim-accused-of-orange-book-violations" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://globalcompetitionreview.com/gcr-usa/article/boehringer-ingelheim-accused-of-orange-book-violations" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://globalcompetitionreview.com/gcr-usa/article/boehringer-ingelheim-accused-of-orange-book-violations</a></span></div></li><li id="https://www.boehringer-ingelheim.com/about-us/who-we-are/history/1885-1948-innovative-beginnings" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.boehringer-ingelheim.com/about-us/who-we-are/history/1885-1948-innovative-beginnings" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.boehringer-ingelheim.com/about-us/who-we-are/history/1885-1948-innovative-beginnings</a></span></div></li><li id="https://www.boehringer-ingelheim.com/us/about-us/who-we-are/history/1885-1948-innovative-beginnings-boehringer-ingelheim-us" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.boehringer-ingelheim.com/us/about-us/who-we-are/history/1885-1948-innovative-beginnings-boehringer-ingelheim-us" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.boehringer-ingelheim.com/us/about-us/who-we-are/history/1885-1948-innovative-beginnings-boehringer-ingelheim-us</a></span></div></li><li id="https://pharmaphorum.com/views-and-analysis/a_history_of-_boehringer_ingelheim" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pharmaphorum.com/views-and-analysis/a_history_of-_boehringer_ingelheim" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pharmaphorum.com/views-and-analysis/a_history_of-_boehringer_ingelheim</a></span></div></li><li id="https://www.encyclopedia.com/books/politics-and-business-magazines/ch-boehringer-sohn" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.encyclopedia.com/books/politics-and-business-magazines/ch-boehringer-sohn" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.encyclopedia.com/books/politics-and-business-magazines/ch-boehringer-sohn</a></span></div></li><li id="https://sk.sagepub.com/ency/edvol/the-sage-encyclopedia-of-pharmacology-and-society/chpt/boehringer-ingelheim" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://sk.sagepub.com/ency/edvol/the-sage-encyclopedia-of-pharmacology-and-society/chpt/boehringer-ingelheim" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://sk.sagepub.com/ency/edvol/the-sage-encyclopedia-of-pharmacology-and-society/chpt/boehringer-ingelheim</a></span></div></li><li id="https://www.fundinguniverse.com/company-histories/c-h-boehringer-sohn-history/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.fundinguniverse.com/company-histories/c-h-boehringer-sohn-history/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.fundinguniverse.com/company-histories/c-h-boehringer-sohn-history/</a></span></div></li><li id="https://www.boehringer-ingelheim.com/about-us/who-we-are/history/1948-1990-going-global" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.boehringer-ingelheim.com/about-us/who-we-are/history/1948-1990-going-global" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.boehringer-ingelheim.com/about-us/who-we-are/history/1948-1990-going-global</a></span></div></li><li id="https://www.boehringer-ingelheim.com/about-us/who-we-are/history/1990-2025-value-through-innovation" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.boehringer-ingelheim.com/about-us/who-we-are/history/1990-2025-value-through-innovation" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.boehringer-ingelheim.com/about-us/who-we-are/history/1990-2025-value-through-innovation</a></span></div></li><li id="https://www.boehringer-ingelheim.com/in/about-us/who-we-are/history/1988-2015" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.boehringer-ingelheim.com/in/about-us/who-we-are/history/1988-2015" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.boehringer-ingelheim.com/in/about-us/who-we-are/history/1988-2015</a></span></div></li><li id="https://www.prnewswire.com/news-releases/boehringer-ingelheim-invests-more-than-350-million-in-2011-us-expansion-projects-133899483.html" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.prnewswire.com/news-releases/boehringer-ingelheim-invests-more-than-350-million-in-2011-us-expansion-projects-133899483.html" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.prnewswire.com/news-releases/boehringer-ingelheim-invests-more-than-350-million-in-2011-us-expansion-projects-133899483.html</a></span></div></li><li id="https://www.biospace.com/boehringer-ingelheim-reports-a-successful-financial-year-2015" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.biospace.com/boehringer-ingelheim-reports-a-successful-financial-year-2015" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.biospace.com/boehringer-ingelheim-reports-a-successful-financial-year-2015</a></span></div></li><li id="https://www.boehringer-ingelheim.com/us/media/press-releases/sanofi-and-boehringer-ingelheim-confirm-closing-business-swap-january-1st-2017" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.boehringer-ingelheim.com/us/media/press-releases/sanofi-and-boehringer-ingelheim-confirm-closing-business-swap-january-1st-2017" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.boehringer-ingelheim.com/us/media/press-releases/sanofi-and-boehringer-ingelheim-confirm-closing-business-swap-january-1st-2017</a></span></div></li><li id="https://www.boehringer-ingelheim.com/us/media/press-releases/vetmedica-inc-sell-vaccine-portfolio-boehringer-ingelheim-us" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.boehringer-ingelheim.com/us/media/press-releases/vetmedica-inc-sell-vaccine-portfolio-boehringer-ingelheim-us" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.boehringer-ingelheim.com/us/media/press-releases/vetmedica-inc-sell-vaccine-portfolio-boehringer-ingelheim-us</a></span></div></li><li id="https://firstwordpharma.com/story/4238116" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://firstwordpharma.com/story/4238116" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://firstwordpharma.com/story/4238116</a></span></div></li><li id="https://www.biospace.com/boehringer-ingelheim-expands-collaboration-with-sarah-cannon-research-institute-to-investigate-novel-immuno-oncology-combination-therapy" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.biospace.com/boehringer-ingelheim-expands-collaboration-with-sarah-cannon-research-institute-to-investigate-novel-immuno-oncology-combination-therapy" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.biospace.com/boehringer-ingelheim-expands-collaboration-with-sarah-cannon-research-institute-to-investigate-novel-immuno-oncology-combination-therapy</a></span></div></li><li id="https://www.prnewswire.com/news-releases/boehringer-ingelheim-boosts-immune-oncology-pipeline-through-collaboration-with-viratherapeutics-300335137.html" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.prnewswire.com/news-releases/boehringer-ingelheim-boosts-immune-oncology-pipeline-through-collaboration-with-viratherapeutics-300335137.html" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.prnewswire.com/news-releases/boehringer-ingelheim-boosts-immune-oncology-pipeline-through-collaboration-with-viratherapeutics-300335137.html</a></span></div></li><li id="https://www.drugdiscoverynews.com/boehringer-ingelheim-acquires-all-viratherapeutics-shares-12818" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.drugdiscoverynews.com/boehringer-ingelheim-acquires-all-viratherapeutics-shares-12818" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.drugdiscoverynews.com/boehringer-ingelheim-acquires-all-viratherapeutics-shares-12818</a></span></div></li><li id="https://www.boehringer-ingelheim.com/us/media/press-releases/boehringer-ingelheim-acquires-abexxa-biologics-further-expand-its-research-efforts-cancer-immunology" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.boehringer-ingelheim.com/us/media/press-releases/boehringer-ingelheim-acquires-abexxa-biologics-further-expand-its-research-efforts-cancer-immunology" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.boehringer-ingelheim.com/us/media/press-releases/boehringer-ingelheim-acquires-abexxa-biologics-further-expand-its-research-efforts-cancer-immunology</a></span></div></li><li id="https://tracxn.com/d/acquisitions/acquisitions-by-boehringer-ingelheim/__ooKdHxXtEcyDITzNJ6ncOXIosHFWVdjBkDWzzeDMuNQ" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://tracxn.com/d/acquisitions/acquisitions-by-boehringer-ingelheim/__ooKdHxXtEcyDITzNJ6ncOXIosHFWVdjBkDWzzeDMuNQ" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://tracxn.com/d/acquisitions/acquisitions-by-boehringer-ingelheim/__ooKdHxXtEcyDITzNJ6ncOXIosHFWVdjBkDWzzeDMuNQ</a></span></div></li><li id="https://www.boehringer-ingelheim.com/us/science-innovation/human-health-innovation/new-partnership-and-significant-pipeline-progress" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.boehringer-ingelheim.com/us/science-innovation/human-health-innovation/new-partnership-and-significant-pipeline-progress" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.boehringer-ingelheim.com/us/science-innovation/human-health-innovation/new-partnership-and-significant-pipeline-progress</a></span></div></li><li id="https://accenttx.com/news-events/boehringer-ingelheim-obtains-novel-preclinical-oncology-program-from-accent-therapeutics/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://accenttx.com/news-events/boehringer-ingelheim-obtains-novel-preclinical-oncology-program-from-accent-therapeutics/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://accenttx.com/news-events/boehringer-ingelheim-obtains-novel-preclinical-oncology-program-from-accent-therapeutics/</a></span></div></li><li id="https://www.tempus.com/news/tempus-enters-multi-year-strategic-collaboration-with-boehringer-ingelheim-to-advance-its-cancer-pipeline/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.tempus.com/news/tempus-enters-multi-year-strategic-collaboration-with-boehringer-ingelheim-to-advance-its-cancer-pipeline/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.tempus.com/news/tempus-enters-multi-year-strategic-collaboration-with-boehringer-ingelheim-to-advance-its-cancer-pipeline/</a></span></div></li><li id="https://www.boehringer-ingelheim.com/us/science-innovation/human-health-innovation/extended-release-eye-therapies-collaboration" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.boehringer-ingelheim.com/us/science-innovation/human-health-innovation/extended-release-eye-therapies-collaboration" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.boehringer-ingelheim.com/us/science-innovation/human-health-innovation/extended-release-eye-therapies-collaboration</a></span></div></li><li id="https://www.biospace.com/business/boehringer-ingelheim-bets-up-to-nearly-1b-in-adc-play-with-aimedbio-deal" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.biospace.com/business/boehringer-ingelheim-bets-up-to-nearly-1b-in-adc-play-with-aimedbio-deal" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.biospace.com/business/boehringer-ingelheim-bets-up-to-nearly-1b-in-adc-play-with-aimedbio-deal</a></span></div></li><li id="https://www.boehringer-ingelheim.com/us/media/press-releases/boehringer-ingelheim-reports-strong-h1-2025-growth-and-prepares-key-launches" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.boehringer-ingelheim.com/us/media/press-releases/boehringer-ingelheim-reports-strong-h1-2025-growth-and-prepares-key-launches" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.boehringer-ingelheim.com/us/media/press-releases/boehringer-ingelheim-reports-strong-h1-2025-growth-and-prepares-key-launches</a></span></div></li><li id="https://annualreport.boehringer-ingelheim.com/2022/downloads/2020/bi_fb_konzernlagebericht_2020_en.pdf" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://annualreport.boehringer-ingelheim.com/2022/downloads/2020/bi_fb_konzernlagebericht_2020_en.pdf" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://annualreport.boehringer-ingelheim.com/2022/downloads/2020/bi_fb_konzernlagebericht_2020_en.pdf</a></span></div></li><li id="https://www.beckershospitalreview.com/finance/2-of-the-worlds-richest-families-are-tied-to-healthcare/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.beckershospitalreview.com/finance/2-of-the-worlds-richest-families-are-tied-to-healthcare/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.beckershospitalreview.com/finance/2-of-the-worlds-richest-families-are-tied-to-healthcare/</a></span></div></li><li id="https://www.redcarpetlife.in/billionaires/profile/mathias-boehringer.html" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.redcarpetlife.in/billionaires/profile/mathias-boehringer.html" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.redcarpetlife.in/billionaires/profile/mathias-boehringer.html</a></span></div></li><li id="https://www.boehringer-ingelheim.com/us/about-us/who-we-are/leadership" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.boehringer-ingelheim.com/us/about-us/who-we-are/leadership" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.boehringer-ingelheim.com/us/about-us/who-we-are/leadership</a></span></div></li><li id="https://www.boehringer-ingelheim.com/annualreport/2024/files/downloads-and-archive/highlights-2024/BOE_Highlights_2024_EN.pdf" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.boehringer-ingelheim.com/annualreport/2024/files/downloads-and-archive/highlights-2024/BOE_Highlights_2024_EN.pdf" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.boehringer-ingelheim.com/annualreport/2024/files/downloads-and-archive/highlights-2024/BOE_Highlights_2024_EN.pdf</a></span></div></li><li id="https://www.boehringer-ingelheim.com/about-us/who-we-are/history/living-independence" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.boehringer-ingelheim.com/about-us/who-we-are/history/living-independence" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.boehringer-ingelheim.com/about-us/who-we-are/history/living-independence</a></span></div></li><li id="https://www.contractpharma.com/top-company-profile/boehringer-ingelheim/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.contractpharma.com/top-company-profile/boehringer-ingelheim/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.contractpharma.com/top-company-profile/boehringer-ingelheim/</a></span></div></li><li id="https://www.globenewswire.com/news-release/2025/04/17/3063157/0/en/Boehringer-Ingelheim-announces-succession-Chairmen-Shareholders-Committee-and-Board-of-Managing-Directors.html" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.globenewswire.com/news-release/2025/04/17/3063157/0/en/Boehringer-Ingelheim-announces-succession-Chairmen-Shareholders-Committee-and-Board-of-Managing-Directors.html" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.globenewswire.com/news-release/2025/04/17/3063157/0/en/Boehringer-Ingelheim-announces-succession-Chairmen-Shareholders-Committee-and-Board-of-Managing-Directors.html</a></span></div></li><li id="https://www.boehringer-ingelheim.com/about-us/who-we-are/leadership/succession-chairmen-shareholders-committee-and-board-managing-directors" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.boehringer-ingelheim.com/about-us/who-we-are/leadership/succession-chairmen-shareholders-committee-and-board-managing-directors" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.boehringer-ingelheim.com/about-us/who-we-are/leadership/succession-chairmen-shareholders-committee-and-board-managing-directors</a></span></div></li><li id="https://www.boehringer-ingelheim.com/about-us/who-we-are/leadership" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.boehringer-ingelheim.com/about-us/who-we-are/leadership" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.boehringer-ingelheim.com/about-us/who-we-are/leadership</a></span></div></li><li id="https://www.boehringer-ingelheim.com/about-us/who-we-are/leadership/boehringer-ingelheim-announces-appointments-board-managing-directors" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.boehringer-ingelheim.com/about-us/who-we-are/leadership/boehringer-ingelheim-announces-appointments-board-managing-directors" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.boehringer-ingelheim.com/about-us/who-we-are/leadership/boehringer-ingelheim-announces-appointments-board-managing-directors</a></span></div></li><li id="https://www.cio.com/article/4043753/boehringer-ingelheim-a-digital-journey-with-a-focus-on-data.html" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.cio.com/article/4043753/boehringer-ingelheim-a-digital-journey-with-a-focus-on-data.html" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.cio.com/article/4043753/boehringer-ingelheim-a-digital-journey-with-a-focus-on-data.html</a></span></div></li><li id="https://www.boehringer-ingelheim.com/science-innovation/human-health-innovation/clinical-pipeline" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.boehringer-ingelheim.com/science-innovation/human-health-innovation/clinical-pipeline" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.boehringer-ingelheim.com/science-innovation/human-health-innovation/clinical-pipeline</a></span></div></li><li id="https://www.boehringer-ingelheim.com/us/human-health" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.boehringer-ingelheim.com/us/human-health" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.boehringer-ingelheim.com/us/human-health</a></span></div></li><li id="https://www.boehringer-ingelheim.com/about-us/who-we-are/boehringer-ingelheim-half-year-results-2025" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.boehringer-ingelheim.com/about-us/who-we-are/boehringer-ingelheim-half-year-results-2025" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.boehringer-ingelheim.com/about-us/who-we-are/boehringer-ingelheim-half-year-results-2025</a></span></div></li><li id="https://www.boehringer-ingelheim.com/us/animal-health" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.boehringer-ingelheim.com/us/animal-health" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.boehringer-ingelheim.com/us/animal-health</a></span></div></li><li id="https://bi-animalhealth.com/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://bi-animalhealth.com/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://bi-animalhealth.com/</a></span></div></li><li id="https://www.boehringer-ingelheim.com/us/animal-health/veterinary-public-health" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.boehringer-ingelheim.com/us/animal-health/veterinary-public-health" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.boehringer-ingelheim.com/us/animal-health/veterinary-public-health</a></span></div></li><li id="https://www.boehringer-ingelheim.com/in/animal-health/our-history" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.boehringer-ingelheim.com/in/animal-health/our-history" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.boehringer-ingelheim.com/in/animal-health/our-history</a></span></div></li><li id="https://www.boehringer-ingelheim.com/science-innovation/animal-health-innovation/boehringer-ingelheim-acquires-saiba-animal-health-adding-innovative-technology-platform-its-pet" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.boehringer-ingelheim.com/science-innovation/animal-health-innovation/boehringer-ingelheim-acquires-saiba-animal-health-adding-innovative-technology-platform-its-pet" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.boehringer-ingelheim.com/science-innovation/animal-health-innovation/boehringer-ingelheim-acquires-saiba-animal-health-adding-innovative-technology-platform-its-pet</a></span></div></li><li id="https://www.boehringer-ingelheim.com/us/animal-health/products" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.boehringer-ingelheim.com/us/animal-health/products" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.boehringer-ingelheim.com/us/animal-health/products</a></span></div></li><li id="https://www.boehringer-ingelheim.com/in/animal-health/products" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.boehringer-ingelheim.com/in/animal-health/products" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.boehringer-ingelheim.com/in/animal-health/products</a></span></div></li><li id="https://www.boehringer-ingelheim.com/products" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.boehringer-ingelheim.com/products" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.boehringer-ingelheim.com/products</a></span></div></li><li id="https://www.boehringer-ingelheim.com/partnering/animal-health-partnering/perspectives/building-successful-partnerships-animal-health" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.boehringer-ingelheim.com/partnering/animal-health-partnering/perspectives/building-successful-partnerships-animal-health" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.boehringer-ingelheim.com/partnering/animal-health-partnering/perspectives/building-successful-partnerships-animal-health</a></span></div></li><li id="https://www.boehringer-ingelheim.com/about-us/sustainable-development/more-health/more-health-overview" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.boehringer-ingelheim.com/about-us/sustainable-development/more-health/more-health-overview" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.boehringer-ingelheim.com/about-us/sustainable-development/more-health/more-health-overview</a></span></div></li><li id="https://www.boehringer-ingelheim.com/us/partnering/animal-health-partnering" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.boehringer-ingelheim.com/us/partnering/animal-health-partnering" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.boehringer-ingelheim.com/us/partnering/animal-health-partnering</a></span></div></li><li id="https://www.boehringer-ingelheim.com/about-us/who-we-are/2024-results-research-and-development-investment-rise" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.boehringer-ingelheim.com/about-us/who-we-are/2024-results-research-and-development-investment-rise" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.boehringer-ingelheim.com/about-us/who-we-are/2024-results-research-and-development-investment-rise</a></span></div></li><li id="https://annualreport.boehringer-ingelheim.com/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://annualreport.boehringer-ingelheim.com/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://annualreport.boehringer-ingelheim.com/</a></span></div></li><li id="https://www.boehringer-ingelheim.com/science-innovation/human-health-innovation/our-innovation-strategy" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.boehringer-ingelheim.com/science-innovation/human-health-innovation/our-innovation-strategy" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.boehringer-ingelheim.com/science-innovation/human-health-innovation/our-innovation-strategy</a></span></div></li><li id="https://www.boehringer-ingelheim.com/about-us/sustainable-development/more-health/advancing-health-our-impactful-rd-investments" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.boehringer-ingelheim.com/about-us/sustainable-development/more-health/advancing-health-our-impactful-rd-investments" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.boehringer-ingelheim.com/about-us/sustainable-development/more-health/advancing-health-our-impactful-rd-investments</a></span></div></li><li id="https://www.boehringer-ingelheim.com/us/science-innovation/human-health-innovation/science-focus/advancing-biomedical-innovation-through-open-collaboration" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.boehringer-ingelheim.com/us/science-innovation/human-health-innovation/science-focus/advancing-biomedical-innovation-through-open-collaboration" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.boehringer-ingelheim.com/us/science-innovation/human-health-innovation/science-focus/advancing-biomedical-innovation-through-open-collaboration</a></span></div></li><li id="https://www.boehringer-ingelheim.com/research-collaborations" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.boehringer-ingelheim.com/research-collaborations" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.boehringer-ingelheim.com/research-collaborations</a></span></div></li><li id="https://bmedx.com/news-events/press-releases/new-xseed-labs-research-team-starts-activity-in-the-u-s-in-collaboration-with-boehringer-ingelheim-011574/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://bmedx.com/news-events/press-releases/new-xseed-labs-research-team-starts-activity-in-the-u-s-in-collaboration-with-boehringer-ingelheim-011574/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://bmedx.com/news-events/press-releases/new-xseed-labs-research-team-starts-activity-in-the-u-s-in-collaboration-with-boehringer-ingelheim-011574/</a></span></div></li><li id="https://www.boehringer-ingelheim.com/science-innovation/human-health-innovation/kicking-2024-five-new-rd-partnerships" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.boehringer-ingelheim.com/science-innovation/human-health-innovation/kicking-2024-five-new-rd-partnerships" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.boehringer-ingelheim.com/science-innovation/human-health-innovation/kicking-2024-five-new-rd-partnerships</a></span></div></li><li id="https://www.lungcancerresearchfoundation.org/lcrf-bi-research/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.lungcancerresearchfoundation.org/lcrf-bi-research/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.lungcancerresearchfoundation.org/lcrf-bi-research/</a></span></div></li><li id="https://www.tempus.com/news/tempus-enters-multi-year-strategic-collaboration-with-boehringer-ingelheim-to-advance-its-cancer-pipeline/?srsltid=AfmBOopfPOhnboHerN3khDHryfC_BqqwtHLh2og_qKYiFpMUDc8uSL2C" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.tempus.com/news/tempus-enters-multi-year-strategic-collaboration-with-boehringer-ingelheim-to-advance-its-cancer-pipeline/?srsltid=AfmBOopfPOhnboHerN3khDHryfC_BqqwtHLh2og_qKYiFpMUDc8uSL2C" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.tempus.com/news/tempus-enters-multi-year-strategic-collaboration-with-boehringer-ingelheim-to-advance-its-cancer-pipeline/?srsltid=AfmBOopfPOhnboHerN3khDHryfC_BqqwtHLh2og_qKYiFpMUDc8uSL2C</a></span></div></li><li id="https://www.quiverquant.com/news/Cue%2BBiopharma%2BReports%2BStrategic%2BCollaboration%2Bwith%2BBoehringer%2BIngelheim%2Band%2BFinancial%2BResults%2Bfor%2BQ1%2B2025" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.quiverquant.com/news/Cue%2BBiopharma%2BReports%2BStrategic%2BCollaboration%2Bwith%2BBoehringer%2BIngelheim%2Band%2BFinancial%2BResults%2Bfor%2BQ1%2B2025" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.quiverquant.com/news/Cue%2BBiopharma%2BReports%2BStrategic%2BCollaboration%2Bwith%2BBoehringer%2BIngelheim%2Band%2BFinancial%2BResults%2Bfor%2BQ1%2B2025</a></span></div></li><li id="https://www.boehringer-ingelheim.com/partnering/animal-health-partnering/perspectives/translating-human-pharma-science-animal-health-innovation" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.boehringer-ingelheim.com/partnering/animal-health-partnering/perspectives/translating-human-pharma-science-animal-health-innovation" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.boehringer-ingelheim.com/partnering/animal-health-partnering/perspectives/translating-human-pharma-science-animal-health-innovation</a></span></div></li><li id="https://firstwordpharma.com/story/3240666" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://firstwordpharma.com/story/3240666" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://firstwordpharma.com/story/3240666</a></span></div></li><li id="https://www.fiercepharma.com/pharma/asco-boehringer-ingelheim-make-name-oncology-two-upcoming-launches" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.fiercepharma.com/pharma/asco-boehringer-ingelheim-make-name-oncology-two-upcoming-launches" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.fiercepharma.com/pharma/asco-boehringer-ingelheim-make-name-oncology-two-upcoming-launches</a></span></div></li><li id="https://www.boehringer-ingelheim.com/science-innovation/human-health-innovation/clinical-pipeline/zongertinib-bi-1810631-her2-tyrosine-kinase-inhibitor-tki-0" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.boehringer-ingelheim.com/science-innovation/human-health-innovation/clinical-pipeline/zongertinib-bi-1810631-her2-tyrosine-kinase-inhibitor-tki-0" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.boehringer-ingelheim.com/science-innovation/human-health-innovation/clinical-pipeline/zongertinib-bi-1810631-her2-tyrosine-kinase-inhibitor-tki-0</a></span></div></li><li id="https://www.boehringer-ingelheim.com/us/media/press-releases/hernexeos-zongertinib-tablets-gains-accelerated-approval" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.boehringer-ingelheim.com/us/media/press-releases/hernexeos-zongertinib-tablets-gains-accelerated-approval" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.boehringer-ingelheim.com/us/media/press-releases/hernexeos-zongertinib-tablets-gains-accelerated-approval</a></span></div></li><li id="https://www.boehringer-ingelheim.com/human-health/cancer/lung-cancer/zongertinib-77-percent-response-rate-advanced-her2-mutant-nsclc" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.boehringer-ingelheim.com/human-health/cancer/lung-cancer/zongertinib-77-percent-response-rate-advanced-her2-mutant-nsclc" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.boehringer-ingelheim.com/human-health/cancer/lung-cancer/zongertinib-77-percent-response-rate-advanced-her2-mutant-nsclc</a></span></div></li><li id="https://www.nejm.org/doi/full/10.1056/NEJMoa2503704" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.nejm.org/doi/full/10.1056/NEJMoa2503704" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.nejm.org/doi/full/10.1056/NEJMoa2503704</a></span></div></li><li id="https://www.boehringer-ingelheim.com/science-innovation/human-health-innovation/clinical-pipeline/nerandomilast-bi-1015550-pde4b-inhibitor" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.boehringer-ingelheim.com/science-innovation/human-health-innovation/clinical-pipeline/nerandomilast-bi-1015550-pde4b-inhibitor" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.boehringer-ingelheim.com/science-innovation/human-health-innovation/clinical-pipeline/nerandomilast-bi-1015550-pde4b-inhibitor</a></span></div></li><li id="https://www.boehringer-ingelheim.com/human-health/lung-diseases/pulmonary-fibrosis/phase-3-trials-nerandomilast-slowed-lung-function-decline-ipf-and-ppf" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.boehringer-ingelheim.com/human-health/lung-diseases/pulmonary-fibrosis/phase-3-trials-nerandomilast-slowed-lung-function-decline-ipf-and-ppf" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.boehringer-ingelheim.com/human-health/lung-diseases/pulmonary-fibrosis/phase-3-trials-nerandomilast-slowed-lung-function-decline-ipf-and-ppf</a></span></div></li><li id="https://www.nejm.org/doi/full/10.1056/NEJMoa2414108" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.nejm.org/doi/full/10.1056/NEJMoa2414108" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.nejm.org/doi/full/10.1056/NEJMoa2414108</a></span></div></li><li id="https://www.boehringer-ingelheim.com/science-innovation/human-health-innovation/clinical-pipeline/survodutide-bi-456906-glp1-gcgr-agonist" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.boehringer-ingelheim.com/science-innovation/human-health-innovation/clinical-pipeline/survodutide-bi-456906-glp1-gcgr-agonist" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.boehringer-ingelheim.com/science-innovation/human-health-innovation/clinical-pipeline/survodutide-bi-456906-glp1-gcgr-agonist</a></span></div></li><li id="https://www.boehringer-ingelheim.com/human-health/metabolic-diseases/survodutide-us-fda-breakthrough-therapy-phase-3-trials-mash" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.boehringer-ingelheim.com/human-health/metabolic-diseases/survodutide-us-fda-breakthrough-therapy-phase-3-trials-mash" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.boehringer-ingelheim.com/human-health/metabolic-diseases/survodutide-us-fda-breakthrough-therapy-phase-3-trials-mash</a></span></div></li><li id="https://www.boehringer-ingelheim.com/human-health/metabolic-diseases/survodutide-phase-iii-study-weight-loss" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.boehringer-ingelheim.com/human-health/metabolic-diseases/survodutide-phase-iii-study-weight-loss" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.boehringer-ingelheim.com/human-health/metabolic-diseases/survodutide-phase-iii-study-weight-loss</a></span></div></li><li id="https://annualreport.boehringer-ingelheim.com/2022/downloads/2020/bi_fb_produktportfolio_2020_en.pdf" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://annualreport.boehringer-ingelheim.com/2022/downloads/2020/bi_fb_produktportfolio_2020_en.pdf" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://annualreport.boehringer-ingelheim.com/2022/downloads/2020/bi_fb_produktportfolio_2020_en.pdf</a></span></div></li><li id="https://pro.boehringer-ingelheim.com/products" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pro.boehringer-ingelheim.com/products" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pro.boehringer-ingelheim.com/products</a></span></div></li><li id="https://www.boehringer-ingelheim.com/us/human-health/products" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.boehringer-ingelheim.com/us/human-health/products" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.boehringer-ingelheim.com/us/human-health/products</a></span></div></li><li id="https://www.boehringer-ingelheim.com/human-health/products/micardis" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.boehringer-ingelheim.com/human-health/products/micardis" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.boehringer-ingelheim.com/human-health/products/micardis</a></span></div></li><li id="https://www.boehringer-ingelheim.com/human-health/products/pradaxa" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.boehringer-ingelheim.com/human-health/products/pradaxa" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.boehringer-ingelheim.com/human-health/products/pradaxa</a></span></div></li><li id="https://www.boehringer-ingelheim.com/animal-health/products/nexgard" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.boehringer-ingelheim.com/animal-health/products/nexgard" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.boehringer-ingelheim.com/animal-health/products/nexgard</a></span></div></li><li id="https://www.statista.com/statistics/831366/boehringer-ingelheims-revenues-by-top-animal-health-products/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.statista.com/statistics/831366/boehringer-ingelheims-revenues-by-top-animal-health-products/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.statista.com/statistics/831366/boehringer-ingelheims-revenues-by-top-animal-health-products/</a></span></div></li><li id="https://bi-animalhealth.com/pets/canine/products/parasiticides/nexgard-plus" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://bi-animalhealth.com/pets/canine/products/parasiticides/nexgard-plus" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://bi-animalhealth.com/pets/canine/products/parasiticides/nexgard-plus</a></span></div></li><li id="https://www.prnewswire.com/news-releases/boehringer-ingelheim-introduces-nexgard-combo-esafoxolaner-eprinomectin-and-praziquantel-topical-solution-the-first-and-only-feline-broad-spectrum-parasite-protection-that-treats-tapeworms-301805098.html" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.prnewswire.com/news-releases/boehringer-ingelheim-introduces-nexgard-combo-esafoxolaner-eprinomectin-and-praziquantel-topical-solution-the-first-and-only-feline-broad-spectrum-parasite-protection-that-treats-tapeworms-301805098.html" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.prnewswire.com/news-releases/boehringer-ingelheim-introduces-nexgard-combo-esafoxolaner-eprinomectin-and-praziquantel-topical-solution-the-first-and-only-feline-broad-spectrum-parasite-protection-that-treats-tapeworms-301805098.html</a></span></div></li><li id="https://www.allivet.com/product/metacam-15-mg-ml-oral-suspension/16000.html" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.allivet.com/product/metacam-15-mg-ml-oral-suspension/16000.html" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.allivet.com/product/metacam-15-mg-ml-oral-suspension/16000.html</a></span></div></li><li id="https://bi-animalhealth.com/cattle/products" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://bi-animalhealth.com/cattle/products" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://bi-animalhealth.com/cattle/products</a></span></div></li><li id="https://www.boehringer-ingelheim.com/us/media/press-releases/boehringer-launches-swine-vaccine-advanced-protection-against-pcv2" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.boehringer-ingelheim.com/us/media/press-releases/boehringer-launches-swine-vaccine-advanced-protection-against-pcv2" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.boehringer-ingelheim.com/us/media/press-releases/boehringer-launches-swine-vaccine-advanced-protection-against-pcv2</a></span></div></li><li id="https://www.boehringer-ingelheim.com/us/animal-health/livestock" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.boehringer-ingelheim.com/us/animal-health/livestock" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.boehringer-ingelheim.com/us/animal-health/livestock</a></span></div></li><li id="https://www.boehringer-ingelheim.com/us/about-us/where-find-us" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.boehringer-ingelheim.com/us/about-us/where-find-us" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.boehringer-ingelheim.com/us/about-us/where-find-us</a></span></div></li><li id="https://www.boehringer-ingelheim.com/about-us/where-find-us/biberach" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.boehringer-ingelheim.com/about-us/where-find-us/biberach" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.boehringer-ingelheim.com/about-us/where-find-us/biberach</a></span></div></li><li id="https://www.boehringer-ingelheim.com/science-innovation/human-health-innovation/science-stories/biologicals-development-center" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.boehringer-ingelheim.com/science-innovation/human-health-innovation/science-stories/biologicals-development-center" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.boehringer-ingelheim.com/science-innovation/human-health-innovation/science-stories/biologicals-development-center</a></span></div></li><li id="https://www.europeanpharmaceuticalreview.com/news/181845/boehringer-ingelheim-invests-e350m-in-new-biotech-rd-facility/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.europeanpharmaceuticalreview.com/news/181845/boehringer-ingelheim-invests-e350m-in-new-biotech-rd-facility/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.europeanpharmaceuticalreview.com/news/181845/boehringer-ingelheim-invests-e350m-in-new-biotech-rd-facility/</a></span></div></li><li id="https://www.boehringer-ingelheim.com/us/science-innovation/human-health-innovation/science-focus/ridgefield-research-and-innovation" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.boehringer-ingelheim.com/us/science-innovation/human-health-innovation/science-focus/ridgefield-research-and-innovation" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.boehringer-ingelheim.com/us/science-innovation/human-health-innovation/science-focus/ridgefield-research-and-innovation</a></span></div></li><li id="https://www.prnewswire.com/news-releases/boehringer-ingelheim-expands-research-and-development-in-athens-georgia-302286462.html" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.prnewswire.com/news-releases/boehringer-ingelheim-expands-research-and-development-in-athens-georgia-302286462.html" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.prnewswire.com/news-releases/boehringer-ingelheim-expands-research-and-development-in-athens-georgia-302286462.html</a></span></div></li><li id="https://www.dvm360.com/view/boehringer-ingelheim-announces-research-and-development-facility-expansion" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.dvm360.com/view/boehringer-ingelheim-announces-research-and-development-facility-expansion" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.dvm360.com/view/boehringer-ingelheim-announces-research-and-development-facility-expansion</a></span></div></li><li id="https://www.boehringer-ingelheim.com/us/about-us/where-find-us/ingelheim" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.boehringer-ingelheim.com/us/about-us/where-find-us/ingelheim" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.boehringer-ingelheim.com/us/about-us/where-find-us/ingelheim</a></span></div></li><li id="https://www.pharmaceutical-technology.com/projects/boehringers-chemical-innovation-plant-ingelheim-germany/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.pharmaceutical-technology.com/projects/boehringers-chemical-innovation-plant-ingelheim-germany/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.pharmaceutical-technology.com/projects/boehringers-chemical-innovation-plant-ingelheim-germany/</a></span></div></li><li id="https://www.boehringer-ingelheim.com/partnering/boehringer-ingelheim-bioxcellence/our-global-network" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.boehringer-ingelheim.com/partnering/boehringer-ingelheim-bioxcellence/our-global-network" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.boehringer-ingelheim.com/partnering/boehringer-ingelheim-bioxcellence/our-global-network</a></span></div></li><li id="https://choosesaintjoseph.com/boehringer-ingelheim-expands-in-st-joseph/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://choosesaintjoseph.com/boehringer-ingelheim-expands-in-st-joseph/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://choosesaintjoseph.com/boehringer-ingelheim-expands-in-st-joseph/</a></span></div></li><li id="https://www.boehringer-ingelheim.com/about-us/where-find-us/ingelheim" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.boehringer-ingelheim.com/about-us/where-find-us/ingelheim" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.boehringer-ingelheim.com/about-us/where-find-us/ingelheim</a></span></div></li><li id="https://workforcesoftware.com/blog/boehringer-ingelheim-global-workforce-management-technology/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://workforcesoftware.com/blog/boehringer-ingelheim-global-workforce-management-technology/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://workforcesoftware.com/blog/boehringer-ingelheim-global-workforce-management-technology/</a></span></div></li><li id="https://news.cognizant.com/2025-03-11-Boehringer-Ingelheim-and-Cognizant-announce-the-launch-of-a-unified-cloud-platform-to-bring-innovative-therapies-to-patients-faster" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://news.cognizant.com/2025-03-11-Boehringer-Ingelheim-and-Cognizant-announce-the-launch-of-a-unified-cloud-platform-to-bring-innovative-therapies-to-patients-faster" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://news.cognizant.com/2025-03-11-Boehringer-Ingelheim-and-Cognizant-announce-the-launch-of-a-unified-cloud-platform-to-bring-innovative-therapies-to-patients-faster</a></span></div></li><li id="https://www.boehringer-ingelheim.com/partnering/boehringer-ingelheim-bioxcellence/newsroom/biopharma-machine-learning-bioxcellence" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.boehringer-ingelheim.com/partnering/boehringer-ingelheim-bioxcellence/newsroom/biopharma-machine-learning-bioxcellence" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.boehringer-ingelheim.com/partnering/boehringer-ingelheim-bioxcellence/newsroom/biopharma-machine-learning-bioxcellence</a></span></div></li><li id="https://www.forbes.com/sites/kevinkruse/2020/10/05/how-boehringer-ingelheim-develops-leaders-who-drive-employee-engagement-and-high-performance/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.forbes.com/sites/kevinkruse/2020/10/05/how-boehringer-ingelheim-develops-leaders-who-drive-employee-engagement-and-high-performance/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.forbes.com/sites/kevinkruse/2020/10/05/how-boehringer-ingelheim-develops-leaders-who-drive-employee-engagement-and-high-performance/</a></span></div></li><li id="https://www.reuters.com/business/healthcare-pharmaceuticals/boehringer-ingelheim-2024-sales-up-forex-adj-61-2025-04-02/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.reuters.com/business/healthcare-pharmaceuticals/boehringer-ingelheim-2024-sales-up-forex-adj-61-2025-04-02/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.reuters.com/business/healthcare-pharmaceuticals/boehringer-ingelheim-2024-sales-up-forex-adj-61-2025-04-02/</a></span></div></li><li id="https://annualreport.boehringer-ingelheim.com/2023/download/BOE_AR23_Highlights_2023_EN_safe.pdf" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://annualreport.boehringer-ingelheim.com/2023/download/BOE_AR23_Highlights_2023_EN_safe.pdf" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://annualreport.boehringer-ingelheim.com/2023/download/BOE_AR23_Highlights_2023_EN_safe.pdf</a></span></div></li><li id="https://www.pharmaceutical-technology.com/news/jardiance-and-ofev-propel-boehringers-human-pharma-sales/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.pharmaceutical-technology.com/news/jardiance-and-ofev-propel-boehringers-human-pharma-sales/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.pharmaceutical-technology.com/news/jardiance-and-ofev-propel-boehringers-human-pharma-sales/</a></span></div></li><li id="https://www.thepharmaletter.com/boehringer-reports-6-percent-sales-growth-for-2024" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.thepharmaletter.com/boehringer-reports-6-percent-sales-growth-for-2024" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.thepharmaletter.com/boehringer-reports-6-percent-sales-growth-for-2024</a></span></div></li><li id="https://www.fiercepharma.com/special-reports/top-20-pharma-companies-2024-revenue" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.fiercepharma.com/special-reports/top-20-pharma-companies-2024-revenue" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.fiercepharma.com/special-reports/top-20-pharma-companies-2024-revenue</a></span></div></li><li id="https://annualreport.boehringer-ingelheim.com/2021/downloads/en/BOE_AR21_Financial-Report_EN.pdf" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://annualreport.boehringer-ingelheim.com/2021/downloads/en/BOE_AR21_Financial-Report_EN.pdf" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://annualreport.boehringer-ingelheim.com/2021/downloads/en/BOE_AR21_Financial-Report_EN.pdf</a></span></div></li><li id="https://www.pharmalive.com/boehringer-ingelheim-an-independent-course/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.pharmalive.com/boehringer-ingelheim-an-independent-course/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.pharmalive.com/boehringer-ingelheim-an-independent-course/</a></span></div></li><li id="https://www.fiercepharma.com/pharma/top-20-pharma-companies-2023-revenue" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.fiercepharma.com/pharma/top-20-pharma-companies-2023-revenue" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.fiercepharma.com/pharma/top-20-pharma-companies-2023-revenue</a></span></div></li><li id="https://financialpost.com/globe-newswire/boehringer-ingelheim-reports-strong-growth-in-2023-and-accelerates-late-stage-pipeline" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://financialpost.com/globe-newswire/boehringer-ingelheim-reports-strong-growth-in-2023-and-accelerates-late-stage-pipeline" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://financialpost.com/globe-newswire/boehringer-ingelheim-reports-strong-growth-in-2023-and-accelerates-late-stage-pipeline</a></span></div></li><li id="https://www.fiercepharma.com/pharma/boehringer-ingelheim-spend-eu7-billion-capital-improvements-through-2025" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.fiercepharma.com/pharma/boehringer-ingelheim-spend-eu7-billion-capital-improvements-through-2025" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.fiercepharma.com/pharma/boehringer-ingelheim-spend-eu7-billion-capital-improvements-through-2025</a></span></div></li><li id="https://www.boehringer-ingelheim.com/building-blocks-our-future" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.boehringer-ingelheim.com/building-blocks-our-future" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.boehringer-ingelheim.com/building-blocks-our-future</a></span></div></li><li id="https://www.reuters.com/legal/litigation/lawsuit-claims-boehringer-misused-us-patents-delay-asthma-drug-rivals-2024-03-07/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.reuters.com/legal/litigation/lawsuit-claims-boehringer-misused-us-patents-delay-asthma-drug-rivals-2024-03-07/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.reuters.com/legal/litigation/lawsuit-claims-boehringer-misused-us-patents-delay-asthma-drug-rivals-2024-03-07/</a></span></div></li><li id="https://www.law.com/ctlawtribune/2024/04/30/boehringer-ingelheim-accused-of-using-expired-patents-to-control-market/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.law.com/ctlawtribune/2024/04/30/boehringer-ingelheim-accused-of-using-expired-patents-to-control-market/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.law.com/ctlawtribune/2024/04/30/boehringer-ingelheim-accused-of-using-expired-patents-to-control-market/</a></span></div></li><li id="https://www.ftc.gov/system/files/ftc_gov/pdf/boehringer-ingelheim-orange-book.pdf" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.ftc.gov/system/files/ftc_gov/pdf/boehringer-ingelheim-orange-book.pdf" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.ftc.gov/system/files/ftc_gov/pdf/boehringer-ingelheim-orange-book.pdf</a></span></div></li><li id="https://www.govinfo.gov/content/pkg/USCOURTS-jpml-1_25-F-03154/pdf/USCOURTS-jpml-1_25-F-03154-0.pdf" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.govinfo.gov/content/pkg/USCOURTS-jpml-1_25-F-03154/pdf/USCOURTS-jpml-1_25-F-03154-0.pdf" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.govinfo.gov/content/pkg/USCOURTS-jpml-1_25-F-03154/pdf/USCOURTS-jpml-1_25-F-03154-0.pdf</a></span></div></li><li id="https://www.vbb.com/insights/romanian-competition-authority-fines-boehringer-ingelheim-on-account-of-product-hopping" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.vbb.com/insights/romanian-competition-authority-fines-boehringer-ingelheim-on-account-of-product-hopping" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.vbb.com/insights/romanian-competition-authority-fines-boehringer-ingelheim-on-account-of-product-hopping</a></span></div></li><li id="https://www.concurrences.com/en/bulletin/news-issues/january-2025/the-romanian-competition-authority-fines-a-pharmaceutical-company-for-abusing" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.concurrences.com/en/bulletin/news-issues/january-2025/the-romanian-competition-authority-fines-a-pharmaceutical-company-for-abusing" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.concurrences.com/en/bulletin/news-issues/january-2025/the-romanian-competition-authority-fines-a-pharmaceutical-company-for-abusing</a></span></div></li><li id="https://www.juve-patent.com/cases/court-of-appeal-grants-final-victory-to-boehringer-in-pi-case-against-zentiva/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.juve-patent.com/cases/court-of-appeal-grants-final-victory-to-boehringer-in-pi-case-against-zentiva/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.juve-patent.com/cases/court-of-appeal-grants-final-victory-to-boehringer-in-pi-case-against-zentiva/</a></span></div></li><li id="https://www.pharmainbrief.com/2024/08/federal-court-addresses-treatment-and-formulation-patent-claims-in-pmnoc-case/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.pharmainbrief.com/2024/08/federal-court-addresses-treatment-and-formulation-patent-claims-in-pmnoc-case/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.pharmainbrief.com/2024/08/federal-court-addresses-treatment-and-formulation-patent-claims-in-pmnoc-case/</a></span></div></li><li id="https://www.prnewswire.com/news-releases/boehringer-ingelheim-announces-comprehensive-settlement-of-us-pradaxa-dabigatran-etexilate-mesylate-litigation-260907991.html" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.prnewswire.com/news-releases/boehringer-ingelheim-announces-comprehensive-settlement-of-us-pradaxa-dabigatran-etexilate-mesylate-litigation-260907991.html" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.prnewswire.com/news-releases/boehringer-ingelheim-announces-comprehensive-settlement-of-us-pradaxa-dabigatran-etexilate-mesylate-litigation-260907991.html</a></span></div></li><li id="https://www.thefdalawblog.com/2015/10/cross-motions-for-summary-judgment-filed-in-pradaxa-patent-term-extension-dispute/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.thefdalawblog.com/2015/10/cross-motions-for-summary-judgment-filed-in-pradaxa-patent-term-extension-dispute/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.thefdalawblog.com/2015/10/cross-motions-for-summary-judgment-filed-in-pradaxa-patent-term-extension-dispute/</a></span></div></li><li id="https://www.boehringer-ingelheim.com/us/media/press-releases/boehringer-ingelheim-announces-comprehensive-settlement-us-pradaxa-dabigatran-etexilate-mesylate" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.boehringer-ingelheim.com/us/media/press-releases/boehringer-ingelheim-announces-comprehensive-settlement-us-pradaxa-dabigatran-etexilate-mesylate" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.boehringer-ingelheim.com/us/media/press-releases/boehringer-ingelheim-announces-comprehensive-settlement-us-pradaxa-dabigatran-etexilate-mesylate</a></span></div></li><li id="https://www.govinfo.gov/app/details/USCOURTS-mnd-0_07-md-01836" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.govinfo.gov/app/details/USCOURTS-mnd-0_07-md-01836" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.govinfo.gov/app/details/USCOURTS-mnd-0_07-md-01836</a></span></div></li><li id="https://violationtracker.goodjobsfirst.org/parent/boehringer-ingelheim" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://violationtracker.goodjobsfirst.org/parent/boehringer-ingelheim" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://violationtracker.goodjobsfirst.org/parent/boehringer-ingelheim</a></span></div></li><li id="https://www.boehringer-ingelheim.com/pradaxa-us-litigation-settlement" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.boehringer-ingelheim.com/pradaxa-us-litigation-settlement" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.boehringer-ingelheim.com/pradaxa-us-litigation-settlement</a></span></div></li><li id="https://law.justia.com/cases/federal/appellate-courts/ca8/17-2204/17-2204-2019-01-10.html" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://law.justia.com/cases/federal/appellate-courts/ca8/17-2204/17-2204-2019-01-10.html" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://law.justia.com/cases/federal/appellate-courts/ca8/17-2204/17-2204-2019-01-10.html</a></span></div></li><li id="https://law.justia.com/cases/federal/appellate-courts/ca8/10-3129/103129p-2011-07-28.html" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://law.justia.com/cases/federal/appellate-courts/ca8/10-3129/103129p-2011-07-28.html" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://law.justia.com/cases/federal/appellate-courts/ca8/10-3129/103129p-2011-07-28.html</a></span></div></li><li id="https://law.justia.com/cases/federal/appellate-courts/ca2/20-3643/20-3643-2021-08-06.html" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://law.justia.com/cases/federal/appellate-courts/ca2/20-3643/20-3643-2021-08-06.html" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://law.justia.com/cases/federal/appellate-courts/ca2/20-3643/20-3643-2021-08-06.html</a></span></div></li><li id="https://www.kslaw.com/news-and-insights/king-spalding-secures-another-victory-for-boehringer-ingelheim-in-zantac-related-retrial" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.kslaw.com/news-and-insights/king-spalding-secures-another-victory-for-boehringer-ingelheim-in-zantac-related-retrial" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.kslaw.com/news-and-insights/king-spalding-secures-another-victory-for-boehringer-ingelheim-in-zantac-related-retrial</a></span></div></li><li id="https://www.law.com/radar/card/ca-alamedacounty-613455-keys-v-boehringer-ingelheim-pharmaceuticals-inc" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.law.com/radar/card/ca-alamedacounty-613455-keys-v-boehringer-ingelheim-pharmaceuticals-inc" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.law.com/radar/card/ca-alamedacounty-613455-keys-v-boehringer-ingelheim-pharmaceuticals-inc</a></span></div></li><li id="https://www.reuters.com/legal/boehringer-latest-sue-us-over-drug-price-negotiation-plan-2023-08-21/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.reuters.com/legal/boehringer-latest-sue-us-over-drug-price-negotiation-plan-2023-08-21/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.reuters.com/legal/boehringer-latest-sue-us-over-drug-price-negotiation-plan-2023-08-21/</a></span></div></li><li id="https://law.justia.com/cases/federal/appellate-courts/ca2/24-2092/24-2092-2025-08-07.html" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://law.justia.com/cases/federal/appellate-courts/ca2/24-2092/24-2092-2025-08-07.html" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://law.justia.com/cases/federal/appellate-courts/ca2/24-2092/24-2092-2025-08-07.html</a></span></div></li><li id="https://www.statnews.com/2024/07/05/boehringer-ingelheim-loses-medicare-drug-price-negotiation-case/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.statnews.com/2024/07/05/boehringer-ingelheim-loses-medicare-drug-price-negotiation-case/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.statnews.com/2024/07/05/boehringer-ingelheim-loses-medicare-drug-price-negotiation-case/</a></span></div></li><li id="https://www.cms.gov/newsroom/fact-sheets/cms-announces-manufacturer-participation-second-cycle-medicare-drug-price-negotiation" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.cms.gov/newsroom/fact-sheets/cms-announces-manufacturer-participation-second-cycle-medicare-drug-price-negotiation" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.cms.gov/newsroom/fact-sheets/cms-announces-manufacturer-participation-second-cycle-medicare-drug-price-negotiation</a></span></div></li><li id="https://340breport.com/boehringer-ingelheim-expands-its-340b-drug-pricing-restrictions/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://340breport.com/boehringer-ingelheim-expands-its-340b-drug-pricing-restrictions/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://340breport.com/boehringer-ingelheim-expands-its-340b-drug-pricing-restrictions/</a></span></div></li><li id="https://rwc340b.org/boehringer-ingelheim-is-latest-manufacturer-to-file-a-lawsuit-against-hhs-on-contract-pharmacy-program/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://rwc340b.org/boehringer-ingelheim-is-latest-manufacturer-to-file-a-lawsuit-against-hhs-on-contract-pharmacy-program/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://rwc340b.org/boehringer-ingelheim-is-latest-manufacturer-to-file-a-lawsuit-against-hhs-on-contract-pharmacy-program/</a></span></div></li><li id="https://www.340bhealth.org/newsroom/boehringer-ingelheim-referred-for-penalties-for-continued-violations-of-federal-law-on-340b-pricing/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.340bhealth.org/newsroom/boehringer-ingelheim-referred-for-penalties-for-continued-violations-of-federal-law-on-340b-pricing/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.340bhealth.org/newsroom/boehringer-ingelheim-referred-for-penalties-for-continued-violations-of-federal-law-on-340b-pricing/</a></span></div></li><li id="https://ec.europa.eu/commission/presscorner/detail/es/ip_23_5104" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://ec.europa.eu/commission/presscorner/detail/es/ip_23_5104" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://ec.europa.eu/commission/presscorner/detail/es/ip_23_5104</a></span></div></li></ol></div></div></div><div class="hidden min-[1400px]:block"></div></div></div><!--$--><!--/$--><div role="region" aria-label="Notifications (F8)" tabindex="-1" style="pointer-events:none"><ol tabindex="-1" class="pointer-events-none fixed top-0 z-[100] flex max-h-screen w-full flex-col-reverse p-4 max-sm:left-0 sm:bottom-0 sm:right-0 sm:top-auto sm:max-w-[420px] sm:flex-col pl-16 pr-2 pt-16 sm:px-4"></ol></div><script type="application/json" id="server-client-data-experimentation">{"status":"uninitialized"}</script><script src="/_next/static/chunks/webpack-e121ed42680f327e.js" nonce="MDFkNTc1MWYtZjA5OC00YWU2LWJmZGQtOTJjODZlMmExY2I0" id="_R_" async=""></script><script nonce="MDFkNTc1MWYtZjA5OC00YWU2LWJmZGQtOTJjODZlMmExY2I0">(self.__next_f=self.__next_f||[]).push([0])</script><script nonce="MDFkNTc1MWYtZjA5OC00YWU2LWJmZGQtOTJjODZlMmExY2I0">self.__next_f.push([1,"1:\"$Sreact.fragment\"\n3:I[91363,[],\"\"]\n4:I[23775,[],\"\"]\n5:I[57654,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"7618\",\"static/chunks/7618-43536a8fb0dd3bfe.js\",\"3699\",\"static/chunks/app/page/%5Bslug%5D/layout-55a344716dd57c44.js\"],\"PageHeaderProvider\"]\n6:I[17618,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"7618\",\"static/chunks/7618-43536a8fb0dd3bfe.js\",\"3699\",\"static/chunks/app/page/%5Bslug%5D/layout-55a344716dd57c44.js\"],\"HeaderContent\"]\n7:I[25529,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"7720\",\"static/chunks/7720-3a1e7e411adba2d3.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"7618\",\"static/chunks/7618-43536a8fb0dd3bfe.js\",\"6751\",\"static/chunks/app/page/%5Bslug%5D/not-found-69a3edc7db5749d6.js\"],\"default\"]\n9:I[6666,[],\"OutletBoundary\"]\nb:I[80415,[],\"AsyncMetadataOutlet\"]\nd:I[6666,[],\"ViewportBoundary\"]\nf:I[6666,[],\"MetadataBoundary\"]\n10:\"$Sreact.suspense\"\n12:I[95909,[\"4219\",\"static/chunks/app/global-error-4d07d20223cd4b4c.js\"],\"default\"]\n"])</script><script nonce="MDFkNTc1MWYtZjA5OC00YWU2LWJmZGQtOTJjODZlMmExY2I0">self.__next_f.push([1,"13:I[51498,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"ConstantsProvider\"]\n"])</script><script nonce="MDFkNTc1MWYtZjA5OC00YWU2LWJmZGQtOTJjODZlMmExY2I0">self.__next_f.push([1,"14:I[91073,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"default\"]\n"])</script><script nonce="MDFkNTc1MWYtZjA5OC00YWU2LWJmZGQtOTJjODZlMmExY2I0">self.__next_f.push([1,"15:I[38642,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"default\"]\n"])</script><script nonce="MDFkNTc1MWYtZjA5OC00YWU2LWJmZGQtOTJjODZlMmExY2I0">self.__next_f.push([1,"16:I[99648,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"4684\",\"static/chunks/24cf1b50-159cca90b09285e0.js\",\"1829\",\"static/chunks/9ffa21ba-c069766d809bd4c7.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"7720\",\"static/chunks/7720-3a1e7e411adba2d3.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"600\",\"static/chunks/600-9a9fcafaaa6c1c4c.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"5448\",\"static/chunks/5448-2a3cfd853d899c9a.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"8\",\"static/chunks/8-8ca70ca619d8e099.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"6304\",\"static/chunks/app/page/%5Bslug%5D/page-540a27b6839afde5.js\"],\"default\"]\n"])</script><script nonce="MDFkNTc1MWYtZjA5OC00YWU2LWJmZGQtOTJjODZlMmExY2I0">self.__next_f.push([1,"17:I[78825,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"default\"]\n"])</script><script nonce="MDFkNTc1MWYtZjA5OC00YWU2LWJmZGQtOTJjODZlMmExY2I0">self.__next_f.push([1,"18:I[8550,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"MixpanelProvider\"]\n"])</script><script nonce="MDFkNTc1MWYtZjA5OC00YWU2LWJmZGQtOTJjODZlMmExY2I0">self.__next_f.push([1,"19:I[12290,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"MobileTocProvider\"]\n"])</script><script nonce="MDFkNTc1MWYtZjA5OC00YWU2LWJmZGQtOTJjODZlMmExY2I0">self.__next_f.push([1,"1a:I[53947,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"NuqsAdapter\"]\n"])</script><script nonce="MDFkNTc1MWYtZjA5OC00YWU2LWJmZGQtOTJjODZlMmExY2I0">self.__next_f.push([1,"1b:I[91873,[\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"8039\",\"static/chunks/app/error-4a29e9399afba038.js\"],\"default\"]\n1c:I[5091,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"7720\",\"static/chunks/7720-3a1e7e411adba2d3.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"7618\",\"static/chunks/7618-43536a8fb0dd3bfe.js\",\"4345\",\"static/chunks/app/not-found-dd95690acf732f18.js\"],\"default\"]\n"])</script><script nonce="MDFkNTc1MWYtZjA5OC00YWU2LWJmZGQtOTJjODZlMmExY2I0">self.__next_f.push([1,"1d:I[16091,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"default\"]\n"])</script><script nonce="MDFkNTc1MWYtZjA5OC00YWU2LWJmZGQtOTJjODZlMmExY2I0">self.__next_f.push([1,":HL[\"/_next/static/media/1f2316909698f815.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"MDFkNTc1MWYtZjA5OC00YWU2LWJmZGQtOTJjODZlMmExY2I0\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/3d4419af2cf8609b.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"MDFkNTc1MWYtZjA5OC00YWU2LWJmZGQtOTJjODZlMmExY2I0\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/4dec29efcaeb336c.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"MDFkNTc1MWYtZjA5OC00YWU2LWJmZGQtOTJjODZlMmExY2I0\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/74452ea3ef0f9101.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"MDFkNTc1MWYtZjA5OC00YWU2LWJmZGQtOTJjODZlMmExY2I0\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/904ef0a86fe32a00.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"MDFkNTc1MWYtZjA5OC00YWU2LWJmZGQtOTJjODZlMmExY2I0\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/d886a03bcda7ad8f.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"MDFkNTc1MWYtZjA5OC00YWU2LWJmZGQtOTJjODZlMmExY2I0\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/e1447589d6f59c4b.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"MDFkNTc1MWYtZjA5OC00YWU2LWJmZGQtOTJjODZlMmExY2I0\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/f5a90156f8995c8c.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"MDFkNTc1MWYtZjA5OC00YWU2LWJmZGQtOTJjODZlMmExY2I0\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/css/62c4caba71dfda84.css\",\"style\",{\"nonce\":\"MDFkNTc1MWYtZjA5OC00YWU2LWJmZGQtOTJjODZlMmExY2I0\"}]\n:HL[\"/_next/static/css/eb3d87f98fe1565f.css\",\"style\",{\"nonce\":\"MDFkNTc1MWYtZjA5OC00YWU2LWJmZGQtOTJjODZlMmExY2I0\"}]\n:HL[\"/_next/static/css/1b5e561215938d4d.css\",\"style\",{\"nonce\":\"MDFkNTc1MWYtZjA5OC00YWU2LWJmZGQtOTJjODZlMmExY2I0\"}]\n:HL[\"/_next/static/css/0227d069a630d414.css\",\"style\",{\"nonce\":\"MDFkNTc1MWYtZjA5OC00YWU2LWJmZGQtOTJjODZlMmExY2I0\"}]\n:HL[\"/_next/static/css/f87fff2ab93d05a7.css\",\"style\",{\"nonce\":\"MDFkNTc1MWYtZjA5OC00YWU2LWJmZGQtOTJjODZlMmExY2I0\"}]\n"])</script><script nonce="MDFkNTc1MWYtZjA5OC00YWU2LWJmZGQtOTJjODZlMmExY2I0">self.__next_f.push([1,"0:{\"P\":null,\"b\":\"BpM29AX4fmgcUxZ_6t0le\",\"p\":\"\",\"c\":[\"\",\"page\",\"Boehringer_Ingelheim\"],\"i\":false,\"f\":[[[\"\",{\"children\":[\"page\",{\"children\":[[\"slug\",\"Boehringer_Ingelheim\",\"d\"],{\"children\":[\"__PAGE__\",{}]}]}]},\"$undefined\",\"$undefined\",true],[\"\",[\"$\",\"$1\",\"c\",{\"children\":[[[\"$\",\"link\",\"0\",{\"rel\":\"stylesheet\",\"href\":\"/_next/static/css/62c4caba71dfda84.css\",\"precedence\":\"next\",\"crossOrigin\":\"$undefined\",\"nonce\":\"MDFkNTc1MWYtZjA5OC00YWU2LWJmZGQtOTJjODZlMmExY2I0\"}],[\"$\",\"link\",\"1\",{\"rel\":\"stylesheet\",\"href\":\"/_next/static/css/eb3d87f98fe1565f.css\",\"precedence\":\"next\",\"crossOrigin\":\"$undefined\",\"nonce\":\"MDFkNTc1MWYtZjA5OC00YWU2LWJmZGQtOTJjODZlMmExY2I0\"}],[\"$\",\"link\",\"2\",{\"rel\":\"stylesheet\",\"href\":\"/_next/static/css/1b5e561215938d4d.css\",\"precedence\":\"next\",\"crossOrigin\":\"$undefined\",\"nonce\":\"MDFkNTc1MWYtZjA5OC00YWU2LWJmZGQtOTJjODZlMmExY2I0\"}],[\"$\",\"link\",\"3\",{\"rel\":\"stylesheet\",\"href\":\"/_next/static/css/0227d069a630d414.css\",\"precedence\":\"next\",\"crossOrigin\":\"$undefined\",\"nonce\":\"MDFkNTc1MWYtZjA5OC00YWU2LWJmZGQtOTJjODZlMmExY2I0\"}]],\"$L2\"]}],{\"children\":[\"page\",[\"$\",\"$1\",\"c\",{\"children\":[null,[\"$\",\"$L3\",null,{\"parallelRouterKey\":\"children\",\"error\":\"$undefined\",\"errorStyles\":\"$undefined\",\"errorScripts\":\"$undefined\",\"template\":[\"$\",\"$L4\",null,{}],\"templateStyles\":\"$undefined\",\"templateScripts\":\"$undefined\",\"notFound\":\"$undefined\",\"forbidden\":\"$undefined\",\"unauthorized\":\"$undefined\"}]]}],{\"children\":[[\"slug\",\"Boehringer_Ingelheim\",\"d\"],[\"$\",\"$1\",\"c\",{\"children\":[null,[\"$\",\"$L5\",null,{\"children\":[[\"$\",\"$L6\",null,{\"maxWidth\":\"full\",\"mobileOptions\":{\"right\":{\"showFixedIssues\":true,\"showThemeSwitcher\":true,\"showSearch\":true,\"showTableOfContents\":true}}}],[\"$\",\"$L3\",null,{\"parallelRouterKey\":\"children\",\"error\":\"$undefined\",\"errorStyles\":\"$undefined\",\"errorScripts\":\"$undefined\",\"template\":[\"$\",\"$L4\",null,{}],\"templateStyles\":\"$undefined\",\"templateScripts\":\"$undefined\",\"notFound\":[[\"$\",\"$L7\",null,{}],[]],\"forbidden\":\"$undefined\",\"unauthorized\":\"$undefined\"}]]}]]}],{\"children\":[\"__PAGE__\",[\"$\",\"$1\",\"c\",{\"children\":[\"$L8\",[[\"$\",\"link\",\"0\",{\"rel\":\"stylesheet\",\"href\":\"/_next/static/css/f87fff2ab93d05a7.css\",\"precedence\":\"next\",\"crossOrigin\":\"$undefined\",\"nonce\":\"MDFkNTc1MWYtZjA5OC00YWU2LWJmZGQtOTJjODZlMmExY2I0\"}]],[\"$\",\"$L9\",null,{\"children\":[\"$La\",[\"$\",\"$Lb\",null,{\"promise\":\"$@c\"}]]}]]}],{},null,false]},null,false]},null,false]},null,false],[\"$\",\"$1\",\"h\",{\"children\":[null,[[\"$\",\"$Ld\",null,{\"children\":\"$Le\"}],[\"$\",\"meta\",null,{\"name\":\"next-size-adjust\",\"content\":\"\"}]],[\"$\",\"$Lf\",null,{\"children\":[\"$\",\"div\",null,{\"hidden\":true,\"children\":[\"$\",\"$10\",null,{\"fallback\":null,\"children\":\"$L11\"}]}]}]]}],false]],\"m\":\"$undefined\",\"G\":[\"$12\",[]],\"s\":false,\"S\":false}\n"])</script><script nonce="MDFkNTc1MWYtZjA5OC00YWU2LWJmZGQtOTJjODZlMmExY2I0">self.__next_f.push([1,"2:[\"$\",\"html\",null,{\"lang\":\"en\",\"className\":\"bg-surface-base antialiased\",\"suppressHydrationWarning\":true,\"children\":[[\"$\",\"head\",null,{\"children\":[[\"$\",\"title\",null,{\"children\":\"Grokipedia\"}],[\"$\",\"meta\",null,{\"name\":\"description\",\"content\":\"Grokipedia is an open source, comprehensive collection of all knowledge.\"}],[\"$\",\"link\",null,{\"rel\":\"icon\",\"type\":\"image/x-icon\",\"href\":\"/favicon.ico\",\"sizes\":\"48x48\"}],[\"$\",\"link\",null,{\"rel\":\"icon\",\"href\":\"/images/icon-dark.png\",\"media\":\"(prefers-color-scheme: light)\",\"type\":\"image/png\"}],[\"$\",\"link\",null,{\"rel\":\"icon\",\"href\":\"/images/icon-light.png\",\"media\":\"(prefers-color-scheme: dark)\",\"type\":\"image/png\"}],[\"$\",\"link\",null,{\"rel\":\"apple-touch-icon\",\"href\":\"/icon-192x192.png\"}],[\"$\",\"link\",null,{\"rel\":\"manifest\",\"href\":\"/manifest.webmanifest\"}],[\"$\",\"meta\",null,{\"name\":\"robots\",\"content\":\"index, follow\"}],[\"$\",\"meta\",null,{\"name\":\"googlebot\",\"content\":\"index, follow, max-snippet:-1\"}],[\"$\",\"meta\",null,{\"property\":\"og:title\",\"content\":\"Grokipedia\"}],[\"$\",\"meta\",null,{\"property\":\"og:description\",\"content\":\"Grokipedia is an open source, comprehensive collection of all knowledge.\"}],[\"$\",\"meta\",null,{\"property\":\"og:url\",\"content\":\"https://grokipedia.com\"}],[\"$\",\"meta\",null,{\"property\":\"og:site_name\",\"content\":\"Grokipedia\"}],[\"$\",\"meta\",null,{\"property\":\"og:locale\",\"content\":\"en_US\"}],[\"$\",\"meta\",null,{\"property\":\"og:type\",\"content\":\"website\"}],[\"$\",\"meta\",null,{\"property\":\"og:image\",\"content\":\"https://grokipedia.com/icon-512x512.png\"}],[\"$\",\"meta\",null,{\"property\":\"og:image:width\",\"content\":\"512\"}],[\"$\",\"meta\",null,{\"property\":\"og:image:height\",\"content\":\"512\"}],[\"$\",\"meta\",null,{\"property\":\"og:image:alt\",\"content\":\"Grokipedia\"}],[\"$\",\"meta\",null,{\"name\":\"twitter:card\",\"content\":\"summary\"}],[\"$\",\"meta\",null,{\"name\":\"twitter:creator\",\"content\":\"@Grokipedia\"}],[\"$\",\"meta\",null,{\"name\":\"twitter:title\",\"content\":\"Grokipedia\"}],[\"$\",\"meta\",null,{\"name\":\"twitter:description\",\"content\":\"Grokipedia is an open source, comprehensive collection of all knowledge.\"}],[\"$\",\"meta\",null,{\"name\":\"twitter:image\",\"content\":\"https://grokipedia.com/icon-512x512.png\"}]]}],[\"$\",\"body\",null,{\"className\":\"flex h-[100svh] w-full flex-col __variable_13c637 __variable_8a0ba0 __variable_779740 __variable_2484fd __variable_525cc3 __variable_13486b\",\"children\":[[\"$\",\"$L13\",null,{\"children\":[\"$\",\"$L14\",null,{\"children\":[\"$\",\"$L15\",null,{\"defaultTheme\":\"dark\",\"nonce\":\"MDFkNTc1MWYtZjA5OC00YWU2LWJmZGQtOTJjODZlMmExY2I0\",\"children\":[\"$\",\"$L16\",null,{\"children\":[\"$\",\"$L17\",null,{\"children\":[\"$\",\"$L18\",null,{\"children\":[\"$\",\"$L19\",null,{\"children\":[\"$\",\"$L1a\",null,{\"children\":[[\"$\",\"$L3\",null,{\"parallelRouterKey\":\"children\",\"error\":\"$1b\",\"errorStyles\":[],\"errorScripts\":[],\"template\":[\"$\",\"$L4\",null,{}],\"templateStyles\":\"$undefined\",\"templateScripts\":\"$undefined\",\"notFound\":[[\"$\",\"$L1c\",null,{}],[]],\"forbidden\":\"$undefined\",\"unauthorized\":\"$undefined\"}],[\"$\",\"$L1d\",null,{}]]}]}]}]}]}]}]}]}],[\"$\",\"script\",null,{\"type\":\"application/json\",\"id\":\"server-client-data-experimentation\",\"children\":\"{\\\"status\\\":\\\"uninitialized\\\"}\"}]]}]]}]\n"])</script><script nonce="MDFkNTc1MWYtZjA5OC00YWU2LWJmZGQtOTJjODZlMmExY2I0">self.__next_f.push([1,"e:[[\"$\",\"meta\",\"0\",{\"charSet\":\"utf-8\"}],[\"$\",\"meta\",\"1\",{\"name\":\"viewport\",\"content\":\"width=device-width, initial-scale=1, interactive-widget=resizes-content\"}]]\na:null\n"])</script><script nonce="MDFkNTc1MWYtZjA5OC00YWU2LWJmZGQtOTJjODZlMmExY2I0">self.__next_f.push([1,"1e:I[42712,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"4684\",\"static/chunks/24cf1b50-159cca90b09285e0.js\",\"1829\",\"static/chunks/9ffa21ba-c069766d809bd4c7.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"7720\",\"static/chunks/7720-3a1e7e411adba2d3.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"600\",\"static/chunks/600-9a9fcafaaa6c1c4c.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"5448\",\"static/chunks/5448-2a3cfd853d899c9a.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"8\",\"static/chunks/8-8ca70ca619d8e099.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"6304\",\"static/chunks/app/page/%5Bslug%5D/page-540a27b6839afde5.js\"],\"HydrationBoundary\"]\n"])</script><script nonce="MDFkNTc1MWYtZjA5OC00YWU2LWJmZGQtOTJjODZlMmExY2I0">self.__next_f.push([1,"21:I[6367,[],\"IconMark\"]\n1f:T12eb6,"])</script><script nonce="MDFkNTc1MWYtZjA5OC00YWU2LWJmZGQtOTJjODZlMmExY2I0">self.__next_f.push([1,"# Boehringer Ingelheim\n\n![Boehringer Ingelheim headquarters](./_assets_/Ingelheim_site%252C_of_Boehringer_Ingelheim.jpg)  \nBoehringer Ingelheim is a privately held, research-driven biopharmaceutical company headquartered in Ingelheim am Rhein, Germany.[](https://www.boehringer-ingelheim.com/us/about-us/who-we-are)[](https://www.forbes.com/companies/boehringer-ingelheim/) Founded in 1885 by Albert Boehringer initially as a chemicals manufacturer producing tartaric acid and baking powder, it has grown into a global enterprise focused on developing innovative therapies for human and animal health.[](https://www.boehringer-ingelheim.com/us/about-us/who-we-are/history) The company's independence from public markets allows a long-term perspective on research and development, with annual R\u0026D investments exceeding â‚¬5 billion.[](https://www.boehringer-ingelheim.com/us/media/boehringer-ingelheim-reports-strong-growth-2023-and-accelerates-late-stage-pipeline) In 2023, Boehringer Ingelheim achieved net sales of â‚¬25.6 billion (USD 27.7 billion), driven by growth in key products like Jardiance in human pharmaceuticals and strong performance in animal health, while employing over 53,000 people across more than 130 countries.[](https://www.boehringer-ingelheim.com/us/media/boehringer-ingelheim-reports-strong-growth-2023-and-accelerates-late-stage-pipeline)[](https://boehringer-ingelheim.com/annualreport/2024/facts-and-figures/)  \n\nThe firm has faced various legal challenges typical of the pharmaceutical industry, including settlements for off-label promotion of drugs like Aggrenox and antitrust allegations related to patent listings, though these have not fundamentally altered its operational focus on innovation.[](https://www.justice.gov/archives/opa/pr/boehringer-ingelheim-pay-95-million-resolve-false-claims-act-allegations)[](https://globalcompetitionreview.com/gcr-usa/article/boehringer-ingelheim-accused-of-orange-book-violations)\n\n## History\n\n### Founding and Early Years (1885â€“1945)\n\n![Albert Boehringer](./_assets_/AlbertB.jpg)\nIn 1885, Albert Boehringer (1861â€“1939), a pharmacist trained in Heidelberg and Munich, acquired a small tartar refining factory in the Rhine-Hessian village of Nieder-Ingelheim, Germany, for 7,000 marks.[](https://www.boehringer-ingelheim.com/about-us/who-we-are/history/1885-1948-innovative-beginnings) On July 31, the enterprise was registered in the commercial register as C.H. Boehringer Sohn, honoring his grandfather, with initial operations commencing August 1 employing 28 workers to produce tartaric acid salts for pharmaceutical and food applications, including baking powder and carbonated beverages.[](https://www.boehringer-ingelheim.com/us/about-us/who-we-are/history/1885-1948-innovative-beginnings-boehringer-ingelheim-us) The factory's location near the Rhine facilitated raw material imports like wine lees, essential for tartaric acid extraction.[](https://pharmaphorum.com/views-and-analysis/a_history_of-_boehringer_ingelheim)\n\nBy 1893, the company was renamed C.H. Boehringer Sohn to reflect its chemical focus, and production expanded to include lactic acid alongside tartaric derivatives, capitalizing on rising demand from the burgeoning food industry.[](https://www.boehringer-ingelheim.com/about-us/who-we-are/history/1885-1948-innovative-beginnings) In 1895, Boehringer secured its first patent for Boeson, a baking powder utilizing lactic acid, marking an early commercial innovation that boosted revenue and established the firm's reputation in applied chemistry.[](https://www.boehringer-ingelheim.com/about-us/who-we-are/history/1885-1948-innovative-beginnings) The late 1890s saw initial forays into pharmaceuticals, with research into active substances like morphine and codeine from opium, leveraging the company's expertise in organic acids to isolate alkaloids for medical use.[](https://www.encyclopedia.com/books/politics-and-business-magazines/ch-boehringer-sohn)\n\nWorld War I disrupted operations in 1914, requiring Albert Boehringer to oversee a medical supply entity for the German war economy while his nephew Robert assumed daily management; production shifted toward wartime needs, yet research persisted.[](https://www.encyclopedia.com/books/politics-and-business-magazines/ch-boehringer-sohn) Post-war recovery in the 1920s involved rebuilding and international expansion, with subsidiaries established in Austria and Italy by the 1930s.[](https://www.boehringer-ingelheim.com/about-us/who-we-are/history/1885-1948-innovative-beginnings) Albert Boehringer's death in 1939 preceded World War II's outbreak, during which numerous employees were conscripted into the Wehrmacht and facilities adapted for war-relevant chemicals and pharmaceuticals, though core R\u0026D continued uninterrupted despite Allied bombings.[](https://www.boehringer-ingelheim.com/about-us/who-we-are/history/1885-1948-innovative-beginnings) By 1945, the company had weathered two global conflicts, maintaining family ownership and a foundation in chemical-pharmaceutical manufacturing.[](https://sk.sagepub.com/ency/edvol/the-sage-encyclopedia-of-pharmacology-and-society/chpt/boehringer-ingelheim)\n\n![Poster for Boeson baking powder, the first patented Boehringer Ingelheim product](./_assets_/Poster_for_Boeson_baking_powder%252C_the_first_patented_Boehringer_Ingelheim_product.jpg)\n\n### Post-War Reconstruction and Expansion (1946â€“1999)\n\nFollowing the end of World War II, Boehringer Ingelheim resumed operations at its Ingelheim plant on May 28, 1945, after closure on March 16 amid Allied occupation, establishing a procurement department to secure raw materials amid shortages.[](https://www.boehringer-ingelheim.com/us/about-us/who-we-are/history/1885-1948-innovative-beginnings-boehringer-ingelheim-us)[](https://www.fundinguniverse.com/company-histories/c-h-boehringer-sohn-history/) In 1946, the company re-established Dr. Karl Thomae GmbH in Biberach an der Riss with 70 employees, launching the analgesic Thomapyrin, and founded CELA Landwirtschaftliche Chemikalien GmbH for pesticide production.[](https://www.boehringer-ingelheim.com/us/about-us/who-we-are/history/1885-1948-innovative-beginnings-boehringer-ingelheim-us) By 1948, Germany's monetary reform facilitated economic recovery, enabling the establishment of the first foreign subsidiary, Bender \u0026 Co. GmbH in Vienna, and Olivin for cosmetic sales; the company was removed from Allied war reparations lists in June 1949.[](https://www.boehringer-ingelheim.com/about-us/who-we-are/history/1948-1990-going-global)[](https://www.fundinguniverse.com/company-histories/c-h-boehringer-sohn-history/)\n\nInternational expansion accelerated in the 1950s, with subsidiaries founded in Spain (1953), Italy (1955), Brazil (1956), Argentina (1957), and Canada (1958), followed by Japan and the UK (1961), Mexico (1962), France (1968), and the US (1971, initially in New York and later Ridgefield, Connecticut).[](https://www.boehringer-ingelheim.com/about-us/who-we-are/history/1948-1990-going-global)[](https://www.fundinguniverse.com/company-histories/c-h-boehringer-sohn-history/) Employee numbers quadrupled from pre-war levels by 1955, coinciding with the launch of the Animal Health division through a collaboration with Pfizer to market Terramycin.[](https://www.boehringer-ingelheim.com/about-us/who-we-are/history/1948-1990-going-global) Key product introductions included Buscopan for gastrointestinal disorders (1951), Persantin for coronary heart disease (1959), Bisolvon as a respiratory expectorant (1963), Atrovent for respiratory diseases (1975), Asasantin for thromboses (1977), Mexitil and Mucosolvan (1979), Actilyse as the first thrombolytic (1987), and Alveofact for neonatal respiratory distress (1989).[](https://www.boehringer-ingelheim.com/about-us/who-we-are/history/1948-1990-going-global)\n\nLeadership transitioned with Dr. Wilhelm Boehringer and Hubertus Liebrecht joining the board in 1967; Liebrecht became chairman in 1971 following Wilhelm's death in 1975, guiding the firm through global growth while maintaining family ownership.[](https://www.boehringer-ingelheim.com/about-us/who-we-are/history/1948-1990-going-global) Structural changes included forming C. H. Boehringer Sohn as the German holding in 1981 and Boehringer Ingelheim International GmbH for overseas operations; the Boehringer Ingelheim Fonds was established in 1983 to support biomedical research.[](https://www.boehringer-ingelheim.com/about-us/who-we-are/history/1948-1990-going-global) The 1985 centenary marked 22,000 employees and DM 4.5 billion in sales, with R\u0026D staff exceeding 3,000 and annual investment reaching DM 500 million by then.[](https://www.boehringer-ingelheim.com/about-us/who-we-are/history/1948-1990-going-global)[](https://www.fundinguniverse.com/company-histories/c-h-boehringer-sohn-history/)\n\nIn the 1990s, focus shifted to unified management, designating Biberach as the research center and Ingelheim for production (1993), alongside the \"Value through Innovation\" mission (1994).[](https://www.boehringer-ingelheim.com/about-us/who-we-are/history/1990-2025-value-through-innovation) Product advancements included Combivent for chronic obstructive pulmonary disease (1995), Viramune for reducing HIV mother-to-child transmission, Alna/Flomax for benign prostatic hyperplasia, and Mobec as an antirheumatic (all 1996), and Micardis for hypertension (1999).[](https://www.boehringer-ingelheim.com/about-us/who-we-are/history/1990-2025-value-through-innovation) Sales reached DM 9.94 billion (approximately $5.07 billion) in 1999, bolstered by the acquisition of Ben Venue Laboratories in Bedford, Ohio, and a new organizational structure under Boehringer Ingelheim Pharma KG.[](https://www.fundinguniverse.com/company-histories/c-h-boehringer-sohn-history/)[](https://www.boehringer-ingelheim.com/about-us/who-we-are/history/1990-2025-value-through-innovation)\n\n### Globalization and Key Acquisitions (2000â€“2015)\n\nIn the early 2000s, Boehringer Ingelheim advanced its globalization through substantial infrastructure investments in Germany, serving as hubs for international operations. The Boehringer Ingelheim Center was inaugurated in 2000 as the new global headquarters in Ingelheim, centralizing administrative, research, and corporate functions to support worldwide activities.[](https://www.boehringer-ingelheim.com/about-us/who-we-are/history/1990-2025-value-through-innovation) In 2002, a new active ingredient plant opened in Ingelheim to bolster pharmaceutical production capacity amid growing global demand. By 2003, the company allocated over â‚¬255 million to expand biopharmaceutical facilities in Biberach, culminating in the inauguration of the G 104 production site for biologics.[](https://www.boehringer-ingelheim.com/about-us/who-we-are/history/1990-2025-value-through-innovation)\n\nA pivotal acquisition occurred in 2004 when Boehringer Ingelheim purchased STEAG microparts GmbH, a German micro-technology specialist, renaming it Boehringer Ingelheim microParts GmbH and basing it in Dortmund to manufacture components for the RespimatÂ® soft inhaler device.[](https://www.boehringer-ingelheim.com/about-us/who-we-are/history/1990-2025-value-through-innovation) This move enhanced production capabilities for respiratory therapeutics, a core area of international expansion. Subsequent investments in Dortmund followed, including â‚¬70 million in 2007 for an atomization factory to increase RespimatÂ® output and â‚¬100 million in 2014 to elevate annual production to 44 million units, reflecting sustained commitment to scaling global supply chains.[](https://www.boehringer-ingelheim.com/in/about-us/who-we-are/history/1988-2015)\n\nFurther globalization efforts included U.S. expansion via the acquisition of Amgen's biomanufacturing facility in Fremont, California, around 2010, which supported biologics production and added over 300,000 square feet of capacity; this underpinned more than $350 million in 2011 U.S. projects for research and manufacturing.[](https://www.prnewswire.com/news-releases/boehringer-ingelheim-invests-more-than-350-million-in-2011-us-expansion-projects-133899483.html) In 2009, a â‚¬64 million investment led to the inauguration of the PUROS production site in Ingelheim for innovative anticoagulants, generating 60 new positions.[](https://www.boehringer-ingelheim.com/in/about-us/who-we-are/history/1988-2015) By 2012, the company opened the European Research Center for animal vaccines in Hanover, focusing on farm animal diseases to strengthen its veterinary division's global reach. These initiatives drove net sales to â‚¬14.8 billion by 2015, with currency-adjusted growth of 4.1%, fueled by international markets and therapeutic advancements.[](https://www.biospace.com/boehringer-ingelheim-reports-a-successful-financial-year-2015)\n\n### Strategic Partnerships and Recent Developments (2016â€“present)\n\nIn 2017, Boehringer Ingelheim completed a significant asset swap with Sanofi, acquiring the French company's animal health subsidiary Merial for an effective value of approximately â‚¬12 billion while transferring its consumer healthcare business to Sanofi.[](https://www.boehringer-ingelheim.com/us/media/press-releases/sanofi-and-boehringer-ingelheim-confirm-closing-business-swap-january-1st-2017) This transaction, initially agreed in June 2016, bolstered Boehringer Ingelheim's animal health portfolio with established products such as NexGardÂ® for flea and tick control and FrontlineÂ® for parasite prevention, establishing Lyon, France, as a major hub for the division.[](https://www.boehringer-ingelheim.com/about-us/who-we-are/history/1990-2025-value-through-innovation) The deal required regulatory divestitures, including the sale of certain vaccine assets to Elanco in October 2016 to address antitrust concerns.[](https://www.boehringer-ingelheim.com/us/media/press-releases/vetmedica-inc-sell-vaccine-portfolio-boehringer-ingelheim-us)\n\nThe company pursued immuno-oncology advancements through targeted collaborations, launching a strategic partnership with Sarah Cannon Research Institute in September 2016 to develop novel therapies, which expanded in October 2017 to investigate combination treatments for lung and other cancers.[](https://firstwordpharma.com/story/4238116) [](https://www.biospace.com/boehringer-ingelheim-expands-collaboration-with-sarah-cannon-research-institute-to-investigate-novel-immuno-oncology-combination-therapy) Concurrently, Boehringer Ingelheim initiated a long-term collaboration with ViraTherapeutics in 2017 to engineer oncolytic viruses for tumor-targeted immune activation, culminating in the full acquisition of the Austrian biotech firm to integrate its VSV-GP platform into the oncology pipeline.[](https://www.prnewswire.com/news-releases/boehringer-ingelheim-boosts-immune-oncology-pipeline-through-collaboration-with-viratherapeutics-300335137.html) [](https://www.drugdiscoverynews.com/boehringer-ingelheim-acquires-all-viratherapeutics-shares-12818)\n\nAcquisitions accelerated in the 2020s to enhance capabilities in oncology and immunology. In December 2020, Boehringer Ingelheim acquired Swiss firm NBE-Therapeutics for its tumor-targeted immune cell engager technology and German biotech Labor Dr. Merk \u0026 Kollegen for dermatology expertise.[](https://www.boehringer-ingelheim.com/about-us/who-we-are/history/1990-2025-value-through-innovation) This was followed by the September 2021 purchase of Abexxa Biologics to advance cancer immunology research via novel protein targets.[](https://www.boehringer-ingelheim.com/us/media/press-releases/boehringer-ingelheim-acquires-abexxa-biologics-further-expand-its-research-efforts-cancer-immunology) In July 2025, the company acquired Saiba Animal Health, a Zurich-based developer of pet vaccines and therapeutics, to expand its veterinary offerings.[](https://tracxn.com/d/acquisitions/acquisitions-by-boehringer-ingelheim/__ooKdHxXtEcyDITzNJ6ncOXIosHFWVdjBkDWzzeDMuNQ)\n\nRecent developments emphasize high-potential modalities like antibody-drug conjugates (ADCs) and extended-release therapies. In January 2025, Boehringer Ingelheim partnered with Synaffix for ADC technology access across multiple oncology targets, alongside deals with Sosei Heptares (now Nxera Pharma) and the Broad Institute for mental health drug discovery.[](https://www.boehringer-ingelheim.com/us/science-innovation/human-health-innovation/new-partnership-and-significant-pipeline-progress) August 2025 saw the acquisition of a preclinical oncology program from Accent Therapeutics targeting epigenetic regulation.[](https://accenttx.com/news-events/boehringer-ingelheim-obtains-novel-preclinical-oncology-program-from-accent-therapeutics/) In May 2025, a multi-year collaboration with Tempus leveraged AI and multimodal data to advance the cancer pipeline.[](https://www.tempus.com/news/tempus-enters-multi-year-strategic-collaboration-with-boehringer-ingelheim-to-advance-its-cancer-pipeline/) July 2025 brought a potential $1 billion deal with Re-Vana Therapeutics for extended-release ocular implants to minimize injection frequency in eye diseases.[](https://www.boehringer-ingelheim.com/us/science-innovation/human-health-innovation/extended-release-eye-therapies-collaboration) October 2025 featured a licensing agreement with AimedBio for an ADC asset, with milestones up to $991 million, continuing the focus on precision oncology.[](https://www.biospace.com/business/boehringer-ingelheim-bets-up-to-nearly-1b-in-adc-play-with-aimedbio-deal) These initiatives supported 6.3% sales growth in the first half of 2025, driven by human pharmaceuticals and animal health.[](https://www.boehringer-ingelheim.com/us/media/press-releases/boehringer-ingelheim-reports-strong-h1-2025-growth-and-prepares-key-launches)\n\n## Ownership and Governance\n\n### Family-Owned Structure\n\nBoehringer Ingelheim is structured as a privately held *Kommanditgesellschaft* (KG), a form of German limited partnership that vests controlling interest in family partners while allowing for professional management and limited liability for other stakeholders. This legal form, under which the company operates as C.H. Boehringer Sohn AG \u0026 Co. KG, has preserved full family ownership since its founding in 1885 by Albert Boehringer, avoiding public listing and external shareholder influence.[](https://annualreport.boehringer-ingelheim.com/2022/downloads/2020/bi_fb_konzernlagebericht_2020_en.pdf)[](https://www.fundinguniverse.com/company-histories/c-h-boehringer-sohn-history/)\n\nOwnership is distributed among descendants of the founding Boehringer family and interconnected families, including the von Baumbach lineage through historical marriages and inheritance, with the fourth generation now holding stakes. Key figures such as Chairman and CEO Hubertus von Baumbach, a great-grandson of the founder, exemplify family involvement in oversight, though day-to-day operations are delegated to a professional Board of Managing Directors.[](https://www.beckershospitalreview.com/finance/2-of-the-worlds-richest-families-are-tied-to-healthcare/)[](https://www.redcarpetlife.in/billionaires/profile/mathias-boehringer.html)[](https://www.boehringer-ingelheim.com/us/about-us/who-we-are/leadership)\n\nThis family-controlled model prioritizes long-term strategic independence, enabling sustained investments in research and developmentâ€”totaling approximately â‚¬5.95 billion in 2023â€”without quarterly profit pressures typical of publicly traded peers. The structure supports a unified governance approach, where family shareholders influence major decisions via supervisory bodies, fostering continuity across generations while maintaining operational autonomy.[](https://www.boehringer-ingelheim.com/annualreport/2024/files/downloads-and-archive/highlights-2024/BOE_Highlights_2024_EN.pdf)[](https://www.boehringer-ingelheim.com/about-us/who-we-are/history/living-independence)[](https://www.contractpharma.com/top-company-profile/boehringer-ingelheim/)\n\n### Leadership and Decision-Making\n\nBoehringer Ingelheim operates under a family-owned governance model where the Shareholders' Committee, consisting of descendants of the founding Boehringer and von Baumbach families, holds ultimate oversight responsibility for strategic direction and major appointments. This committee ensures continuity and alignment with long-term generational planning, free from the quarterly pressures typical of publicly traded firms. Effective July 1, 2025, Hubertus von Baumbach assumed the role of Chairman of the Shareholders' Committee, succeeding Christian Boehringer, following von Baumbach's prior tenure as Chairman of the Board of Managing Directors.[](https://www.globenewswire.com/news-release/2025/04/17/3063157/0/en/Boehringer-Ingelheim-announces-succession-Chairmen-Shareholders-Committee-and-Board-of-Managing-Directors.html)[](https://www.boehringer-ingelheim.com/about-us/who-we-are/leadership/succession-chairmen-shareholders-committee-and-board-managing-directors)\n\nThe Board of Managing Directors, comprising five members as of October 2025, handles day-to-day executive leadership and operational decisions across the company's global activities. Shashank Deshpande serves as Chairman, concurrently leading the Human Pharma Business Unit; he joined the company in 2012 after executive roles at Sanofi and Cap Gemini, and was elevated to the board in 2022 before assuming the chairmanship in July 2025. Michael Schmelmer acts as Vice Chairman with responsibility for Group Functions, having joined in 2012 with engineering expertise from aerospace and industrial fields. Dr. Paola Casarosa oversees the Innovation Unit, bringing a PhD in molecular pharmacology and experience since 2004. Frank HÃ¼bler manages Finance, with an MSc in business administration and tenure since 2005. Dr. Armin Wiesler directs the Animal Health Business Unit, holding economics degrees and joining in 2008.[](https://www.boehringer-ingelheim.com/about-us/who-we-are/leadership)[](https://www.globenewswire.com/news-release/2025/04/17/3063157/0/en/Boehringer-Ingelheim-announces-succession-Chairmen-Shareholders-Committee-and-Board-of-Managing-Directors.html)[](https://www.boehringer-ingelheim.com/about-us/who-we-are/leadership/boehringer-ingelheim-announces-appointments-board-managing-directors)\n\nThis structure facilitates data-informed, sustainable decision-making, as evidenced by the company's emphasis on long-term investments like â‚¬4.1 billion annual R\u0026D spending, unhindered by external investor demands. Family control allows for agile responses to opportunities, such as strategic acquisitions, while maintaining risk aversion rooted in stewardship obligations; for instance, digital transformation initiatives prioritize foundational data governance to support evidence-based choices across units. The absence of codetermination boards or public disclosures enables confidential deliberations, contrasting with more transparent public peers, but aligns with the firm's independence since 1885.[](https://annualreport.boehringer-ingelheim.com/2022/downloads/2020/bi_fb_konzernlagebericht_2020_en.pdf)[](https://www.cio.com/article/4043753/boehringer-ingelheim-a-digital-journey-with-a-focus-on-data.html)[](https://www.boehringer-ingelheim.com/about-us/who-we-are/history/living-independence)\n\n## Business Segments\n\n### Human Pharmaceuticals Division\n\nThe Human Pharmaceuticals Division constitutes the core of Boehringer Ingelheim's operations, concentrating on the discovery, development, and commercialization of innovative therapies to address unmet medical needs in humans. It encompasses a portfolio spanning multiple disease categories, with a strategic emphasis on conditions driven by complex pathophysiological mechanisms such as inflammation, fibrosis, and metabolic dysregulation. In 2024, the division generated net sales of â‚¬21,928 million, representing about 82% of the company's total revenue of â‚¬26,796 million, underscoring its dominant contribution to overall performance.[](https://boehringer-ingelheim.com/annualreport/2024/facts-and-figures/) This segment benefits from the company's integrated model, combining in-house R\u0026D with targeted partnerships to accelerate drug advancement.[](https://www.boehringer-ingelheim.com/science-innovation/human-health-innovation/clinical-pipeline)\n\nKey therapeutic areas include cardiovascular and metabolic diseases, respiratory disorders, oncology, immunology, mental health, retinal diseases, and chronic kidney disease. Within cardiovascular-metabolic health, therapies target heart failure, type 2 diabetes, and associated comorbidities through mechanisms like SGLT2 inhibition to mitigate cardiorenal risks. Respiratory efforts focus on chronic obstructive pulmonary disease (COPD) and idiopathic pulmonary fibrosis (IPF), addressing progressive lung remodeling via antifibrotic and bronchodilatory agents. Oncology initiatives prioritize tumor microenvironment modulation, particularly in lung and gastrointestinal cancers, while immunology and mental health programs explore neuroinflammatory pathways. These areas align with epidemiological trends, such as rising incidences of cardiometabolic and neurodegenerative conditions in aging populations.[](https://www.boehringer-ingelheim.com/us/human-health)\n\nProminent products driving revenue include Jardiance (empagliflozin), an SGLT2 inhibitor approved for reducing cardiovascular death and hospitalization in heart failure patients with reduced ejection fraction, as well as glycemic control in type 2 diabetes; it recorded â‚¬4.3 billion in sales for the first half of 2025. Ofev (nintedanib), a tyrosine kinase inhibitor that slows IPF progression by inhibiting fibrotic signaling, contributed â‚¬2.0 billion in the same period, with expanded indications for systemic sclerosis-associated interstitial lung disease. The division maintains a robust late-stage pipeline, with over 20 assets in clinical development as of mid-2025, including novel candidates for cardiometabolic, oncology, and mental health indications, supported by annual R\u0026D investments exceeding â‚¬5 billion group-wide, of which a substantial portion funds human pharma initiatives.[](https://www.boehringer-ingelheim.com/about-us/who-we-are/boehringer-ingelheim-half-year-results-2025)[](https://www.boehringer-ingelheim.com/science-innovation/human-health-innovation/clinical-pipeline) This pipeline reflects a commitment to causal interventions targeting disease drivers, evidenced by phase III advancements in areas like fibrosis and neuroinflammation.[](https://boehringer-ingelheim.com/annualreport/2024/facts-and-figures/)\n\n### Animal Health Division\n\nThe Animal Health Division of Boehringer Ingelheim specializes in vaccines, parasiticides, and therapeutics for companion animals and livestock, emphasizing disease prevention and innovative solutions to support animal well-being and food security.[](https://www.boehringer-ingelheim.com/us/animal-health)[](https://bi-animalhealth.com/) With over 3,000 employees in the United States alone, the division operates globally as part of the family-owned company, focusing on partnerships with veterinarians, producers, and health authorities to address infectious diseases and parasitic challenges.[](https://bi-animalhealth.com/)[](https://www.boehringer-ingelheim.com/us/animal-health/veterinary-public-health)\n\nThe division traces its origins to 1955, when Boehringer Ingelheim acquired Pfizer's veterinary program, establishing a dedicated animal health operation amid post-war expansion in pharmaceuticals.[](https://www.boehringer-ingelheim.com/in/animal-health/our-history) Growth accelerated through strategic acquisitions, including the 2017 business swap with Sanofi that integrated Merial's portfolio, elevating Boehringer Ingelheim to the second-largest animal health company worldwide with enhanced capabilities in vaccines and ectoparasiticides.[](https://www.boehringer-ingelheim.com/us/media/press-releases/sanofi-and-boehringer-ingelheim-confirm-closing-business-swap-january-1st-2017)[](https://www.boehringer-ingelheim.com/about-us/who-we-are/history/1990-2025-value-through-innovation) More recently, in September 2024, the division acquired Saiba Animal Health to bolster its research and development pipeline for novel pet therapeutics targeting chronic diseases.[](https://www.boehringer-ingelheim.com/science-innovation/animal-health-innovation/boehringer-ingelheim-acquires-saiba-animal-health-adding-innovative-technology-platform-its-pet)\n\nFor livestock, the division provides products such as the 3FLEX vaccine for bovine respiratory disease in cattle, Bovikalc calcium supplement for hypocalcemia prevention during calving, and Ubrolexin antibiotic for bacterial infections in poultry and swine.[](https://www.boehringer-ingelheim.com/us/animal-health/products)[](https://www.boehringer-ingelheim.com/in/animal-health/products) In companion animals, offerings include Frontline Plus for flea and tick control in dogs and cats, IMRAB rabies vaccines for multiple species, and Vetmedin (pimobendan) chewable tablets for congestive heart failure in dogs.[](https://www.boehringer-ingelheim.com/in/animal-health/products)[](https://www.boehringer-ingelheim.com/products) These products, many derived from the Merial integration, prioritize efficacy and safety, with eight of the division's top-selling items stemming from external collaborations.[](https://www.boehringer-ingelheim.com/partnering/animal-health-partnering/perspectives/building-successful-partnerships-animal-health)\n\nThrough its Veterinary Public Health Center, the division collaborates with governments and NGOs on vaccine access and zoonotic disease control, investing in initiatives like the \"More Health\" program with â‚¬250 million allocated for human-animal health partnerships.[](https://www.boehringer-ingelheim.com/us/animal-health/veterinary-public-health)[](https://www.boehringer-ingelheim.com/about-us/sustainable-development/more-health/more-health-overview) This approach underscores a commitment to causal links between animal health, public health, and sustainable agriculture, evidenced by targeted R\u0026D in areas like respiratory vaccines and antiparasitics.[](https://www.boehringer-ingelheim.com/us/partnering/animal-health-partnering)\n\n## Research and Development\n\n### R\u0026D Investment and Strategy\n\nBoehringer Ingelheim allocates a substantial portion of its revenue to research and development, reflecting its research-driven model as a family-owned enterprise unburdened by short-term shareholder demands. In 2024, the company invested â‚¬6.2 billion in R\u0026D, equivalent to 23.2% of its group net sales of â‚¬26.8 billion, marking an increase from 22.5% of net sales in 2023. Over the preceding five years, cumulative R\u0026D expenditures approximated â‚¬25 billion, underscoring a consistent commitment to innovation amid rising operational costs and pipeline advancement. This high reinvestment rateâ€”among the industry's highestâ€”supports both human pharmaceuticals and animal health divisions, with approximately 91% directed toward human pharma in recent assessments, including significant outlays for clinical trials.[](https://www.boehringer-ingelheim.com/about-us/who-we-are/2024-results-research-and-development-investment-rise)[](https://www.boehringer-ingelheim.com/about-us/who-we-are/2024-results-research-and-development-investment-rise)[](https://annualreport.boehringer-ingelheim.com/)\n\nThe company's R\u0026D strategy emphasizes a mechanistic approach to disease, prioritizing deep biological insights to identify causal pathways and select optimal therapeutic modalities, such as small molecules, biologics, or cell therapies, tailored to unmet needs. This patient-centric framework builds on established expertise in areas like respiratory and cardiovascular diseases while expanding into high-potential domains through internal discovery and external partnerships. Key focus areas in human health include cardio-renal-metabolic diseases, oncology, respiratory conditions, immunology, central nervous system disorders, and retinal diseases, with pipeline efforts targeting mechanisms like fibrosis, inflammation, and tumor microenvironments. In animal health, R\u0026D parallels human efforts by addressing infectious diseases, oncology, and chronic conditions in livestock and companion animals, often leveraging shared platforms for efficiency.[](https://www.boehringer-ingelheim.com/science-innovation/human-health-innovation/our-innovation-strategy)[](https://www.boehringer-ingelheim.com/about-us/sustainable-development/more-health/advancing-health-our-impactful-rd-investments)\n\nStrategic initiatives integrate open collaboration and venture investments to accelerate innovation, including alliances with biotech firms and academic institutions to access novel technologies like AI-driven drug design and gene editing. Boehringer Ingelheim plans â‚¬20 billion in investments from 2025 to 2030 across human and animal health, focusing on late-stage assets and manufacturing scalability to transition discoveries into marketable therapies. This approach mitigates risks inherent in pharmaceutical R\u0026Dâ€”such as high failure rates in clinical phasesâ€”by diversifying modalities and emphasizing evidence-based validation over speculative trends.[](https://www.boehringer-ingelheim.com/us/science-innovation/human-health-innovation/science-focus/advancing-biomedical-innovation-through-open-collaboration)[](https://www.boehringer-ingelheim.com/us/about-us/who-we-are)\n\n### Major Collaborations and Innovations\n\nBoehringer Ingelheim has pursued extensive research collaborations to advance its pipeline in oncology, immunology, and respiratory diseases, partnering with academic institutions, biotech firms, and advocacy groups. In oncology, the company maintains long-term alliances with leading organizations to accelerate drug discovery and development.[](https://www.boehringer-ingelheim.com/research-collaborations) A notable expansion occurred in 2023 with BioMed X, establishing XSeed Labs in Ridgefield, Connecticut, to leverage biologics expertise for retinal drug delivery innovations, followed by a new U.S.-based team in 2024 focused on disease models for complex conditions.[](https://www.boehringer-ingelheim.com/us/science-innovation/human-health-innovation/science-focus/advancing-biomedical-innovation-through-open-collaboration)[](https://bmedx.com/news-events/press-releases/new-xseed-labs-research-team-starts-activity-in-the-u-s-in-collaboration-with-boehringer-ingelheim-011574/)\n\nIn early 2024, Boehringer Ingelheim initiated five new R\u0026D partnerships, including one with Suzhou Ribo Life Science Co., Ltd., targeting RNA interference technologies for therapeutic applications.[](https://www.boehringer-ingelheim.com/science-innovation/human-health-innovation/kicking-2024-five-new-rd-partnerships) This momentum continued into 2025 with a collaboration alongside the Lung Cancer Research Foundation, committing $2.25 million to investigate HER2-mutated lung cancers and support treatment advancements.[](https://www.lungcancerresearchfoundation.org/lcrf-bi-research/) In May 2025, the company entered a strategic alliance with Tempus to utilize AI and real-world data for enhancing its cancer pipeline, building on prior joint efforts.[](https://www.tempus.com/news/tempus-enters-multi-year-strategic-collaboration-with-boehringer-ingelheim-to-advance-its-cancer-pipeline/?srsltid=AfmBOopfPOhnboHerN3khDHryfC_BqqwtHLh2og_qKYiFpMUDc8uSL2C) Additionally, a partnership with Cue Biopharma advanced the immunotherapy candidate CUE-501, involving a $12 million upfront payment to explore T-cell engagement in solid tumors.[](https://www.quiverquant.com/news/Cue%2BBiopharma%2BReports%2BStrategic%2BCollaboration%2Bwith%2BBoehringer%2BIngelheim%2Band%2BFinancial%2BResults%2Bfor%2BQ1%2B2025)\n\nKey innovations from these efforts include antibody-drug conjugate (ADC) technologies, with a January 2025 agreement with Synaffix granting access to proprietary linker-payload platforms for multiple oncology targets, aiming to improve targeted cancer therapies.[](https://www.boehringer-ingelheim.com/us/science-innovation/human-health-innovation/new-partnership-and-significant-pipeline-progress) In animal health, Boehringer Ingelheim integrates human pharma insights into veterinary innovations, such as digital tools for data analytics and connectivity to enhance disease prevention in livestock and pets.[](https://www.boehringer-ingelheim.com/partnering/animal-health-partnering/perspectives/translating-human-pharma-science-animal-health-innovation) The company supports this through a renewed R\u0026D strategy investing â‚¬11 billion over five years, emphasizing external partnerships to bolster internal capabilities in biologics and precision medicine.[](https://firstwordpharma.com/story/3240666) These collaborations have contributed to pipeline progress, including potential launches in oncology by late 2025.[](https://www.fiercepharma.com/pharma/asco-boehringer-ingelheim-make-name-oncology-two-upcoming-launches)\n\n### Clinical Pipeline Highlights\n\nBoehringer Ingelheim maintains a robust clinical pipeline emphasizing oncology, respiratory, and cardiovascular-renal-metabolic diseases, with multiple candidates in phase 3 development as of July 2025. The company anticipates initiating over ten new phase II and III trials within the subsequent 12 to 18 months, building on empirical data from prior studies to address unmet needs in fibrosis, targeted cancers, and obesity-related conditions.[](https://www.boehringer-ingelheim.com/science-innovation/human-health-innovation/clinical-pipeline)[](https://www.boehringer-ingelheim.com/us/media/press-releases/boehringer-ingelheim-reports-strong-h1-2025-growth-and-prepares-key-launches)\n\nIn oncology, zongertinib (BI 1810631), an irreversible HER2-selective tyrosine kinase inhibitor, advanced through phase 3 trials such as Beamion LUNG-2 and Beamion LUNG-3, evaluating its role in first-line and pretreated HER2-mutant non-small cell lung cancer (NSCLC). It received U.S. FDA accelerated approval under the brand HERNEXEOS in August 2025 for adults with unresectable or metastatic HER2-mutant NSCLC post-prior systemic therapy, supported by phase 2 data showing durable responses and primarily low-grade adverse events. Additional October 2025 results from early trials reported a 77% objective response rate in treatment-naÃ¯ve advanced HER2-mutant NSCLC patients.[](https://www.boehringer-ingelheim.com/science-innovation/human-health-innovation/clinical-pipeline/zongertinib-bi-1810631-her2-tyrosine-kinase-inhibitor-tki-0)[](https://www.boehringer-ingelheim.com/us/media/press-releases/hernexeos-zongertinib-tablets-gains-accelerated-approval)[](https://www.boehringer-ingelheim.com/human-health/cancer/lung-cancer/zongertinib-77-percent-response-rate-advanced-her2-mutant-nsclc)[](https://www.nejm.org/doi/full/10.1056/NEJMoa2503704)\n\nRespiratory pipeline highlights include nerandomilast (BI 1015550), a PDE4B inhibitor targeting idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF). The phase 3 FIBRONEER- IPF and FIBRONEER-PPF trials, reported in May 2025, demonstrated statistically significant slowing of forced vital capacity decline versus placebo, with discontinuation rates comparable to placebo and no new safety signals beyond known PDE4 inhibitor effects.[](https://www.boehringer-ingelheim.com/science-innovation/human-health-innovation/clinical-pipeline/nerandomilast-bi-1015550-pde4b-inhibitor)[](https://www.boehringer-ingelheim.com/human-health/lung-diseases/pulmonary-fibrosis/phase-3-trials-nerandomilast-slowed-lung-function-decline-ipf-and-ppf)[](https://www.nejm.org/doi/full/10.1056/NEJMoa2414108)\n\nIn the cardiovascular-renal-metabolic area, survodutide (BI 456906), a GLP-1/glucagon receptor dual agonist co-developed with Zealand Pharma, progressed to phase 3 programs including SYNCHRONIZE for obesity with cardiovascular risk and trials for metabolic dysfunction-associated steatohepatitis (MASH) with fibrosis. Phase 2 data from August 2023 indicated up to 19% mean weight reduction in overweight or obese patients, prompting FDA Breakthrough Therapy designation for MASH in October 2024 and initiation of confirmatory trials.[](https://www.boehringer-ingelheim.com/science-innovation/human-health-innovation/clinical-pipeline/survodutide-bi-456906-glp1-gcgr-agonist)[](https://www.boehringer-ingelheim.com/human-health/metabolic-diseases/survodutide-us-fda-breakthrough-therapy-phase-3-trials-mash)[](https://www.boehringer-ingelheim.com/human-health/metabolic-diseases/survodutide-phase-iii-study-weight-loss)\n\n| Candidate | Therapeutic Area | Indication | Phase | Key Recent Milestone |\n|-----------|------------------|------------|-------|----------------------|\n| Zongertinib (BI 1810631) | Oncology | HER2-mutant NSCLC | 3 (ongoing post-approval) | Accelerated FDA approval August 2025; 77% ORR in naÃ¯ve patients October 2025[](https://www.boehringer-ingelheim.com/us/media/press-releases/hernexeos-zongertinib-tablets-gains-accelerated-approval)[](https://www.boehringer-ingelheim.com/human-health/cancer/lung-cancer/zongertinib-77-percent-response-rate-advanced-her2-mutant-nsclc) |\n| Nerandomilast (BI 1015550) | Respiratory | IPF/PPF | 3 | Slowed FVC decline in FIBRONEER trials May 2025[](https://www.boehringer-ingelheim.com/human-health/lung-diseases/pulmonary-fibrosis/phase-3-trials-nerandomilast-slowed-lung-function-decline-ipf-and-ppf) |\n| Survodutide (BI 456906) | Metabolic | Obesity/MASH | 3 | Breakthrough designation; up to 19% weight loss phase 2 August 2023[](https://www.boehringer-ingelheim.com/human-health/metabolic-diseases/survodutide-us-fda-breakthrough-therapy-phase-3-trials-mash)[](https://www.boehringer-ingelheim.com/human-health/metabolic-diseases/survodutide-phase-iii-study-weight-loss) |\n\n## Key Products\n\n### Established Human Pharma Products\n\nBoehringer Ingelheim's established human pharmaceutical products encompass a range of therapies primarily targeting respiratory conditions, cardiovascular diseases, and anticoagulation needs, with many originating from decades of development in core therapeutic areas. These products, developed through internal R\u0026D and partnerships, have achieved widespread market adoption due to their efficacy in managing chronic conditions, contributing substantially to the company's Human Pharma net sales, which reached â‚¬21.9 billion in 2024.[](https://www.boehringer-ingelheim.com/about-us/who-we-are/boehringer-ingelheim-half-year-results-2025) Key examples include long-acting bronchodilators for chronic obstructive pulmonary disease (COPD) and angiotensin receptor blockers for hypertension, reflecting the firm's historical emphasis on these domains since the mid-20th century.[](https://annualreport.boehringer-ingelheim.com/2022/downloads/2020/bi_fb_produktportfolio_2020_en.pdf)\n\nIn respiratory therapeutics, Spiriva (tiotropium bromide), a once-daily inhaled long-acting muscarinic antagonist, serves as a cornerstone product for maintenance treatment of COPD, including chronic bronchitis and emphysema, as well as add-on therapy for severe asthma in patients aged 6 and older with a history of exacerbations. First approved by the FDA in 2004, Spiriva has been available in HandiHaler and Respimat formulations, demonstrating sustained clinical benefits in reducing exacerbations and improving lung function in multiple randomized controlled trials.[](https://pro.boehringer-ingelheim.com/products) Atrovent (ipratropium bromide), an anticholinergic bronchodilator introduced earlier in the 1970s in various markets, treats and prevents shortness of breath in COPD and supports acute asthma management as an adjunct to beta-agonists, with formulations including HFA inhalation aerosols for targeted delivery.[](https://www.boehringer-ingelheim.com/us/human-health/products) Complementary combination products like Combivent Respimat (ipratropium bromide and salbutamol sulphate) address reversible bronchospasms in obstructive airway diseases requiring dual bronchodilation, enhancing symptom control in patients unresponsive to single agents.[](https://annualreport.boehringer-ingelheim.com/2022/downloads/2020/bi_fb_produktportfolio_2020_en.pdf)\n\nCardiovascular offerings include Micardis (telmisartan), an angiotensin II receptor blocker approved by the FDA in 1998 for hypertension treatment, which reduces risks of cardiovascular events such as heart attack, stroke, or death in patients aged 55 and older with high risk factors. Clinical data from the ONTARGET trial confirmed its noninferiority to ramipril in preventing composite cardiovascular outcomes.[](https://www.boehringer-ingelheim.com/human-health/products/micardis) Pradaxa (dabigatran etexilate), a direct oral anticoagulant approved in 2010, prevents strokes and systemic emboli in nonvalvular atrial fibrillation, reduces venous thromboembolism recurrence, and treats deep vein thrombosis or pulmonary embolism, offering a reversal agent (idarucizumab) for bleeding management, which differentiates it from warfarin in real-world evidence studies showing lower intracranial hemorrhage rates.[](https://www.boehringer-ingelheim.com/human-health/products/pradaxa)\n\nOther notable established products address niche needs, such as Ofev (nintedanib), a tyrosine kinase inhibitor approved in 2014 for idiopathic pulmonary fibrosis and later expanded to progressive fibrosing interstitial lung diseases, slowing forced vital capacity decline as evidenced by phase III INPULSIS trials.[](https://pro.boehringer-ingelheim.com/products) These products' longevity stems from robust patent protection, generic competition delays in some markets, and ongoing label expansions, though sales dynamics have shifted with newer entrants; for instance, respiratory products like Spiriva historically drove growth but now complement diabetes and fibrosis therapies in the portfolio.[](https://annualreport.boehringer-ingelheim.com/2022/downloads/2020/bi_fb_produktportfolio_2020_en.pdf)\n\n| Product | Active Ingredient | Primary Indication | Key Approval Milestone |\n|---------|-------------------|--------------------|------------------------|\n| Spiriva | Tiotropium bromide | COPD maintenance | FDA 2004[](https://pro.boehringer-ingelheim.com/products) |\n| Atrovent | Ipratropium bromide | COPD, asthma adjunct | Marketed since 1970s[](https://www.boehringer-ingelheim.com/us/human-health/products) |\n| Micardis | Telmisartan | Hypertension | FDA 1998[](https://www.boehringer-ingelheim.com/human-health/products/micardis) |\n| Pradaxa | Dabigatran etexilate | Stroke prevention in AF | FDA 2010[](https://www.boehringer-ingelheim.com/human-health/products/pradaxa) |\n| Ofev | Nintedanib | Idiopathic pulmonary fibrosis | FDA 2014[](https://pro.boehringer-ingelheim.com/products) |\n\n### Prominent Animal Health Products\n\nBoehringer Ingelheim's Animal Health division features prominent parasiticides, vaccines, and therapeutics, with pet products driving substantial revenue growth due to high demand for flea, tick, and heartworm prevention.[](https://www.boehringer-ingelheim.com/about-us/who-we-are/2024-results-research-and-development-investment-rise) In 2024, the division's net sales reached 4.7 billion euros, led by pet parasiticides and therapeutics.[](https://www.boehringer-ingelheim.com/about-us/who-we-are/2024-results-research-and-development-investment-rise)\n\nNexGard, an oral beef-flavored chewable containing afoxolaner, provides monthly protection against fleas, ticks, and mites in dogs by killing parasites before they lay eggs or transmit diseases like Lyme.[](https://www.boehringer-ingelheim.com/animal-health/products/nexgard) It was the division's top product in 2024, generating 1.35 billion euros in net sales.[](https://www.statista.com/statistics/831366/boehringer-ingelheims-revenues-by-top-animal-health-products/) NexGard variants, such as NexGard PLUS (combining afoxolaner, moxidectin, and pyrantel) and NexGard COMBO for cats, extend coverage to heartworms, roundworms, hookworms, and tapeworms.[](https://bi-animalhealth.com/pets/canine/products/parasiticides/nexgard-plus)[](https://www.prnewswire.com/news-releases/boehringer-ingelheim-introduces-nexgard-combo-esafoxolaner-eprinomectin-and-praziquantel-topical-solution-the-first-and-only-feline-broad-spectrum-parasite-protection-that-treats-tapeworms-301805098.html)\n\nOther leading pet brands include Frontline, a topical solution for flea and tick control in dogs and cats, and Heartgard, an ivermectin-based chew for heartworm prevention in dogs.[](https://www.boehringer-ingelheim.com/annualreport/2024/files/downloads-and-archive/highlights-2024/BOE_Highlights_2024_EN.pdf) These core parasiticides, acquired via the 2017 Merial integration, form the backbone of the companion animal portfolio.[](https://www.boehringer-ingelheim.com/annualreport/2024/files/downloads-and-archive/highlights-2024/BOE_Highlights_2024_EN.pdf)\n\nMetacam (meloxicam oral suspension or injection) is a non-steroidal anti-inflammatory drug used for postoperative pain, osteoarthritis, and inflammation in dogs, cats, horses, and livestock species like cattle and pigs, with precise dosing via graduated syringes for efficacy and safety.[](https://www.allivet.com/product/metacam-15-mg-ml-oral-suspension/16000.html)\n\nIn livestock, vaccines such as Ingelvac CIRCOFLEX (for porcine circovirus type 2) and Bovi-Shield (for bovine viral diarrhea and respiratory diseases) support disease prevention in swine and cattle herds, contributing to ruminant and poultry segments.[](https://bi-animalhealth.com/cattle/products)[](https://www.boehringer-ingelheim.com/us/media/press-releases/boehringer-launches-swine-vaccine-advanced-protection-against-pcv2) These products emphasize preventive strategies amid rising antimicrobial resistance concerns.[](https://www.boehringer-ingelheim.com/us/animal-health/livestock)\n\n## Operations and Global Footprint\n\n### Manufacturing and Research Sites\n\n![Ingelheim site of Boehringer Ingelheim](./_assets_/Ingelheim_site%252C_of_Boehringer_Ingelheim.jpg)\nBoehringer Ingelheim maintains an extensive global network of manufacturing and research facilities, spanning over 170 locations worldwide to support its operations in human pharmaceuticals and animal health. The company's infrastructure emphasizes integrated research and production capabilities, with key hubs in Germany, the United States, and other regions, enabling efficient development and commercialization of therapies.[](https://www.boehringer-ingelheim.com/us/about-us/where-find-us)\n\nMajor research and development sites include Biberach, Germany, which serves as the company's largest R\u0026D center globally and houses specialized units for biologics development, including analytical development and bioprocess development; this site also features Europe's largest biotechnology center and received a â‚¬350 million investment in 2023 for a new biopharmaceutical R\u0026D facility.[](https://www.boehringer-ingelheim.com/about-us/where-find-us/biberach)[](https://www.boehringer-ingelheim.com/science-innovation/human-health-innovation/science-stories/biologicals-development-center)[](https://www.europeanpharmaceuticalreview.com/news/181845/boehringer-ingelheim-invests-e350m-in-new-biotech-rd-facility/) In the United States, Ridgefield, Connecticut, functions as the U.S. headquarters and a primary R\u0026D site focused on human health innovation.[](https://www.boehringer-ingelheim.com/us/science-innovation/human-health-innovation/science-focus/ridgefield-research-and-innovation) Athens, Georgia, hosts an expanded animal health R\u0026D facility, which became the company's largest U.S. R\u0026D siteâ€”and third globallyâ€”following a $66.1 million investment and grand opening in October 2024, creating 63 new jobs and enhancing capabilities in vaccine and therapeutic development.[](https://www.prnewswire.com/news-releases/boehringer-ingelheim-expands-research-and-development-in-athens-georgia-302286462.html)[](https://www.dvm360.com/view/boehringer-ingelheim-announces-research-and-development-facility-expansion) Vienna, Austria, specializes in oncology research alongside biopharmaceutical development.[](https://www.boehringer-ingelheim.com/us/about-us/where-find-us)\n\n| Site Location | Primary Functions |\n|---------------|-------------------|\n| Ingelheim, Germany | Headquarters; manufacturing of new active pharmaceutical ingredients and initial medication launches; upcoming Chemical Innovation Plant operational by 2026.[](https://www.boehringer-ingelheim.com/us/about-us/where-find-us/ingelheim)[](https://www.pharmaceutical-technology.com/projects/boehringers-chemical-innovation-plant-ingelheim-germany/) |\n| Biberach, Germany | Biopharmaceutical manufacturing with 240,000 L bioreactor capacity for fed-batch and perfusion processes; aseptic filling; production of therapeutic proteins and antibodies.[](https://www.boehringer-ingelheim.com/partnering/boehringer-ingelheim-bioxcellence/our-global-network) |\n| Vienna, Austria | Mammalian cell culture (135,000 L capacity) and microbial fermentation (12,000 L); recombinant proteins, vaccines, and plasmid DNA production for clinical and commercial supply.[](https://www.boehringer-ingelheim.com/partnering/boehringer-ingelheim-bioxcellence/our-global-network)[](https://www.boehringer-ingelheim.com/us/about-us/where-find-us) |\n| Fremont, California, USA | Mammalian cell culture manufacturing (up to 51,000 L capacity) for monoclonal antibodies and proteins; multi-product clinical and commercial supply.[](https://www.boehringer-ingelheim.com/partnering/boehringer-ingelheim-bioxcellence/our-global-network) |\n| Shanghai, China | Single-use bioreactors (6,000 L total); aseptic filling for process optimization and regional supply.[](https://www.boehringer-ingelheim.com/partnering/boehringer-ingelheim-bioxcellence/our-global-network) |\n| Sant Cugat del VallÃ¨s, Spain | Pharmaceutical production, including aseptic cartridges and RESPIMAT inhaler packaging.[](https://www.boehringer-ingelheim.com/us/about-us/where-find-us) |\n| Fornovo San Giovanni, Italy | Production of active pharmaceutical ingredients for human pharmaceuticals and animal health products.[](https://www.boehringer-ingelheim.com/us/about-us/where-find-us) |\n\nAdditional manufacturing occurs at sites like St. Joseph, Missouri, dedicated to animal health production, with expansions announced in May 2024 to enhance global operations.[](https://choosesaintjoseph.com/boehringer-ingelheim-expands-in-st-joseph/) These facilities collectively support Boehringer Ingelheim's capacity for over 54,500 employees and its focus on biopharmaceutical and chemical manufacturing excellence.[](https://www.boehringer-ingelheim.com/us/about-us/where-find-us)\n\n### Workforce and Operational Efficiency\n\nBoehringer Ingelheim maintains a global workforce of approximately 54,500 employees as of 2024, supporting operations in over 130 markets.[](https://www.boehringer-ingelheim.com/about-us/who-we-are/2024-results-research-and-development-investment-rise) The majority are based in Europe, with over 10,200 at the Ingelheim headquarters in Germany handling production, research, development, and administration.[](https://www.boehringer-ingelheim.com/about-us/where-find-us/ingelheim) In the United States, more than 9,000 employees contribute across various functions.[](https://www.boehringer-ingelheim.com/us/about-us/who-we-are) Of these, an average of 11,563 were engaged in global research networks for Human Pharma and Animal Health divisions during 2024, reflecting a strategic emphasis on innovation-driven roles.[](https://www.boehringer-ingelheim.com/annualreport/2024/files/downloads-and-archive/highlights-2024/BOE_Highlights_2024_EN.pdf)\n\nOperational efficiency is pursued through digital transformation and process optimization. The company utilizes workforce management software to streamline scheduling, time tracking, and resource allocation across complex global sites, reducing administrative burdens and enhancing collaboration.[](https://workforcesoftware.com/blog/boehringer-ingelheim-global-workforce-management-technology/) In March 2025, Boehringer Ingelheim partnered with Cognizant to deploy a unified cloud platform, integrating data systems to expedite medicinal development workflows and improve overall operational throughput.[](https://news.cognizant.com/2025-03-11-Boehringer-Ingelheim-and-Cognizant-announce-the-launch-of-a-unified-cloud-platform-to-bring-innovative-therapies-to-patients-faster) Machine learning applications in biopharmaceutical manufacturing further support efficiency by enabling rapid identification of production variables, minimizing downtime and variability.[](https://www.boehringer-ingelheim.com/partnering/boehringer-ingelheim-bioxcellence/newsroom/biopharma-machine-learning-bioxcellence)\n\nEmployee development initiatives bolster productivity, including structured leadership programs that emphasize self-awareness and emotional intelligence to drive engagement and performance outcomes.[](https://www.forbes.com/sites/kevinkruse/2020/10/05/how-boehringer-ingelheim-develops-leaders-who-drive-employee-engagement-and-high-performance/) These efforts align with the family-owned structure's long-term orientation, prioritizing sustainable growth over short-term metrics, as evidenced by steady workforce expansion alongside revenue of 26.8 billion euros in 2024.[](https://www.reuters.com/business/healthcare-pharmaceuticals/boehringer-ingelheim-2024-sales-up-forex-adj-61-2025-04-02/)\n\n## Financial Performance\n\n### Revenue Growth and Key Metrics\n\nIn 2023, Boehringer Ingelheim achieved net sales of â‚¬25.6 billion, reflecting a currency-adjusted increase of 9.7% from 2022, driven primarily by strong performance in Human Pharma products such as Jardiance for type 2 diabetes and Ofev for idiopathic pulmonary fibrosis.[](https://www.boehringer-ingelheim.com/us/media/boehringer-ingelheim-reports-strong-growth-2023-and-accelerates-late-stage-pipeline)[](https://annualreport.boehringer-ingelheim.com/2023/download/BOE_AR23_Highlights_2023_EN_safe.pdf) Human Pharma net sales reached â‚¬20.8 billion that year, bolstered by a 14.2% rise in research-driven therapies.[](https://www.pharmaceutical-technology.com/news/jardiance-and-ofev-propel-boehringers-human-pharma-sales/)\n\nNet sales grew to â‚¬26.8 billion in 2024, a currency-adjusted gain of 6.1%, with Human Pharma accounting for â‚¬21.9 billion and Animal Health contributing â‚¬4.7 billion; overall growth was supported by expanded patient access and regional expansion in the Americas and Asia-Pacific.[](https://www.boehringer-ingelheim.com/annualreport/2024/files/downloads-and-archive/highlights-2024/BOE_Highlights_2024_EN.pdf)[](https://www.thepharmaletter.com/boehringer-reports-6-percent-sales-growth-for-2024)[](https://boehringer-ingelheim.com/annualreport/2024/facts-and-figures/) This marked a nominal increase of approximately 4.7% from 2023, amid currency headwinds in Europe.[](https://www.fiercepharma.com/special-reports/top-20-pharma-companies-2024-revenue)\n\n| Year | Net Sales (â‚¬ billion) | Currency-Adjusted Growth (%) | Key Driver |\n|------|-----------------------|------------------------------|------------|\n| 2021 | 20.6                 | +5.0 (vs. 2020)             | Respiratory and cardiovascular portfolio expansion[](https://annualreport.boehringer-ingelheim.com/2021/downloads/en/BOE_AR21_Financial-Report_EN.pdf) |\n| 2022 | ~24.2                | +6.0 (vs. 2021)             | Animal Health recovery post-COVID[](https://www.pharmalive.com/boehringer-ingelheim-an-independent-course/) |\n| 2023 | 25.6                 | +9.7                        | Jardiance and Ofev demand[](https://www.boehringer-ingelheim.com/us/media/boehringer-ingelheim-reports-strong-growth-2023-and-accelerates-late-stage-pipeline) |\n| 2024 | 26.8                 | +6.1                        | Broader therapeutic area gains[](https://www.thepharmaletter.com/boehringer-reports-6-percent-sales-growth-for-2024) |\n\nThe company's revenue trajectory demonstrates resilience as a privately held entity, with consistent double-digit growth in prior years tapering to mid-single digits amid maturing markets and increased R\u0026D reinvestment, positioning it among the top 20 global pharmaceutical firms by sales.[](https://www.fiercepharma.com/pharma/top-20-pharma-companies-2023-revenue) In the first half of 2025, Human Pharma net sales reached â‚¬11.3 billion, up 5.7% year-over-year, signaling sustained momentum.[](https://www.boehringer-ingelheim.com/about-us/who-we-are/boehringer-ingelheim-half-year-results-2025)\n\n### R\u0026D and Capital Expenditures\n\nBoehringer Ingelheim allocates a substantial portion of its resources to research and development, emphasizing innovation in human pharmaceuticals and animal health. In 2024, the company reported R\u0026D expenditures of â‚¬6.2 billion, equivalent to 23.2% of group net sales, with the majorityâ€”â‚¬5.7 billionâ€”directed toward the human pharma division.[](https://www.boehringer-ingelheim.com/about-us/who-we-are/2024-results-research-and-development-investment-rise)[](https://www.boehringer-ingelheim.com/annualreport/2024/files/downloads-and-archive/highlights-2024/BOE_Highlights_2024_EN.pdf) This represented an increase from â‚¬5.8 billion in 2023, or 22.5% of net sales, continuing a trend of rising investments that outpaced sales growth in recent years.[](https://financialpost.com/globe-newswire/boehringer-ingelheim-reports-strong-growth-in-2023-and-accelerates-late-stage-pipeline)[](https://annualreport.boehringer-ingelheim.com/)\n\nOver the preceding five years through 2024, cumulative R\u0026D spending totaled approximately â‚¬25 billion, underscoring the firm's long-term commitment to pipeline advancement amid a private ownership structure that avoids short-term shareholder pressures.[](https://www.boehringer-ingelheim.com/about-us/who-we-are/2024-results-research-and-development-investment-rise) In the human pharma segment specifically, R\u0026D investment reached 25.1% of net sales in 2023, positioning the company among top industry spenders relative to revenue.[](https://annualreport.boehringer-ingelheim.com/2023/download/BOE_AR23_Highlights_2023_EN_safe.pdf)\n\nCapital expenditures complement these efforts by expanding manufacturing and research infrastructure. From 2019 to 2023, Boehringer Ingelheim invested â‚¬5.6 billion in capital projects, including â‚¬2.3 billion for production capacity enhancements to support growing demand for biologics and other therapies.[](https://www.boehringer-ingelheim.com/us/media/boehringer-ingelheim-reports-strong-growth-2023-and-accelerates-late-stage-pipeline) In 2022, the company pledged over â‚¬7 billion through 2025 for such initiatives, focusing on sites in Germany, the United States, and other key locations to bolster global operations and innovation capabilities.[](https://www.fiercepharma.com/pharma/boehringer-ingelheim-spend-eu7-billion-capital-improvements-through-2025) These investments prioritize efficiency and scalability, driven by the need to transition from chemical to biological manufacturing processes.[](https://www.boehringer-ingelheim.com/building-blocks-our-future)\n\n## Legal and Regulatory Challenges\n\n### Patent Disputes and Competition Issues\n\nIn 2024, Boehringer Ingelheim faced allegations of patent misuse in U.S. federal court, where plaintiffs claimed the company improperly listed device patents for its inhaler products, including Spiriva Respimat (tiotropium bromide) and Combivent Respimat (ipratropium bromide and albuterol), in the FDA's Orange Book to delay generic competition.[](https://www.reuters.com/legal/litigation/lawsuit-claims-boehringer-misused-us-patents-delay-asthma-drug-rivals-2024-03-07/) The lawsuit, filed in the U.S. District Court for the District of Massachusetts, accused Boehringer of listing 19 patents covering the Respimat inhaler device despite their expiration or inapplicability to the drug formulation, thereby triggering 30-month stays on generic approvals under the Hatch-Waxman Act.[](https://www.law.com/ctlawtribune/2024/04/30/boehringer-ingelheim-accused-of-using-expired-patents-to-control-market/) These actions allegedly maintained monopoly pricing for COPD and asthma treatments, with plaintiffs seeking damages and injunctive relief to delist the patents.[](https://globalcompetitionreview.com/gcr-usa/article/boehringer-ingelheim-accused-of-orange-book-violations)\n\nThe U.S. Federal Trade Commission (FTC) supported such challenges by issuing warning letters in November 2023 to Boehringer and other manufacturers, asserting that listing patents solely for delivery devices without claiming the drug itself violated FDA regulations and antitrust principles, as it artificially extended exclusivity beyond the drug's compound patent life.[](https://www.ftc.gov/system/files/ftc_gov/pdf/boehringer-ingelheim-orange-book.pdf) Boehringer defended the listings as compliant with statutory requirements for patents covering methods of use or approved formulations, arguing they protect innovation in patient-friendly delivery systems essential for drug efficacy.[](https://www.govinfo.gov/content/pkg/USCOURTS-jpml-1_25-F-03154/pdf/USCOURTS-jpml-1_25-F-03154-0.pdf) Related multidistrict antitrust litigation consolidated cases alleging overcharges from delayed generic entry for Respimat products, with Boehringer opposing centralization and maintaining that device patents are legitimately tied to therapeutic delivery.[](https://www.govinfo.gov/content/pkg/USCOURTS-jpml-1_25-F-03154/pdf/USCOURTS-jpml-1_25-F-03154-0.pdf)\n\nIn Europe, Boehringer encountered competition scrutiny for product hopping with Spiriva, transitioning from the HandiHaler dry powder inhaler to the Respimat soft mist version around 2014-2015, then withdrawing the original to block generic approvals. The Romanian Competition Authority fined Boehringer â‚¬25.81 million in January 2025 for abuse of dominance, finding the strategy deprived patients of cheaper alternatives and maintained supra-competitive prices without clinical justification for the switch.[](https://www.vbb.com/insights/romanian-competition-authority-fines-boehringer-ingelheim-on-account-of-product-hopping) Boehringer contested the decision, claiming the Respimat offered superior lung deposition and adherence benefits supported by clinical data, not mere lifecycle management.[](https://www.concurrences.com/en/bulletin/news-issues/january-2025/the-romanian-competition-authority-fines-a-pharmaceutical-company-for-abusing)\n\nBoehringer has also initiated and prevailed in defensive patent actions, such as securing preliminary injunctions against Zentiva in 2025 for imminent infringement of Ofev (nintedanib) patents in the Unified Patent Court, though the Court of Appeal later refined standards for \"imminent\" harm in pharmaceutical cases.[](https://www.juve-patent.com/cases/court-of-appeal-grants-final-victory-to-boehringer-in-pi-case-against-zentiva/) In Canada, the Federal Court upheld formulation and treatment patents for nintedanib in idiopathic pulmonary fibrosis, enjoining generic entry in August 2024.[](https://www.pharmainbrief.com/2024/08/federal-court-addresses-treatment-and-formulation-patent-claims-in-pmnoc-case/) For Pradaxa (dabigatran etexilate), Boehringer resolved U.S. generic challenges through a 2014 comprehensive settlement allowing limited entry post-patent expiry and litigated patent term extensions with the FDA, securing additional exclusivity.[](https://www.prnewswire.com/news-releases/boehringer-ingelheim-announces-comprehensive-settlement-of-us-pradaxa-dabigatran-etexilate-mesylate-litigation-260907991.html) These outcomes reflect Boehringer's strategy of robust IP enforcement amid generics pressure, though critics argue secondary patents on devices or formulations extend monopolies absent proportional innovation.[](https://www.thefdalawblog.com/2015/10/cross-motions-for-summary-judgment-filed-in-pradaxa-patent-term-extension-dispute/)\n\n### Product Liability and Safety Litigation\n\nBoehringer Ingelheim has faced significant product liability litigation primarily related to alleged safety defects in its pharmaceuticals, with the most prominent cases involving the anticoagulant Pradaxa (dabigatran etexilate) and the Parkinson's disease treatment Mirapex (pramipexole). These suits have centered on claims of inadequate warnings about severe side effects, such as uncontrollable bleeding for Pradaxa and impulse control disorders for Mirapex, leading to multidistrict litigation (MDL) and substantial settlements.[](https://www.boehringer-ingelheim.com/us/media/press-releases/boehringer-ingelheim-announces-comprehensive-settlement-us-pradaxa-dabigatran-etexilate-mesylate)[](https://www.govinfo.gov/app/details/USCOURTS-mnd-0_07-md-01836)\n\nPradaxa, approved by the FDA in 2010 as an alternative to warfarin for stroke prevention in atrial fibrillation patients, drew over 4,000 lawsuits by 2014 alleging gastrointestinal and intracranial hemorrhages due to the drug's irreversible anticoagulation effects and initial lack of a reversal agent. Plaintiffs claimed Boehringer Ingelheim failed to adequately warn of bleeding risks, particularly in elderly patients or those with renal impairment, resulting in deaths and severe injuries. In May 2014, the company announced a $650 million settlement resolving approximately 3,985 claims without admitting liability, covering cases in both federal MDL proceedings in the Southern District of Illinois and state courts.[](https://www.boehringer-ingelheim.com/us/media/press-releases/boehringer-ingelheim-announces-comprehensive-settlement-us-pradaxa-dabigatran-etexilate-mesylate)[](https://violationtracker.goodjobsfirst.org/parent/boehringer-ingelheim) Additional settlements followed for remaining claims, though some individual suits persisted into the late 2010s, with ongoing investigations reported as late as 2025 for bleeding events.[](https://www.boehringer-ingelheim.com/pradaxa-us-litigation-settlement)\n\nMirapex litigation, consolidated in MDL No. 1836 in the District of Minnesota starting in 2007, involved claims that the dopamine agonist caused compulsive gambling, hypersexuality, and other behavioral disorders not sufficiently disclosed in labeling. Patients and families alleged failure to warn of these risks, leading to financial ruin and personal harm; one appellate case highlighted a plaintiff seeking recovery for $4 million in gambling losses. Courts often dismissed claims on statute of limitations grounds, ruling plaintiffs had notice of potential links by 2005 following FDA warnings and medical literature. Boehringer Ingelheim prevailed in key appeals, such as the Eighth Circuit's 2019 affirmance limiting liability, though the company faced related antitrust scrutiny over patent extensions rather than direct safety verdicts.[](https://law.justia.com/cases/federal/appellate-courts/ca8/17-2204/17-2204-2019-01-10.html)[](https://www.govinfo.gov/app/details/USCOURTS-mnd-0_07-md-01836)[](https://law.justia.com/cases/federal/appellate-courts/ca8/10-3129/103129p-2011-07-28.html)\n\nOther safety-related suits include allegations involving inhalers like Spiriva, where plaintiffs claimed design defects exacerbated respiratory issues, but these have seen limited success with dismissals on preemption grounds under federal drug approval processes. In Zantac-related cancer claims, Boehringer Ingelheim secured defense verdicts in multiple Illinois trials through 2025, with juries rejecting causation links to alleged NDMA contamination in acid reducers. Recent filings, such as Keys v. Boehringer Ingelheim in Alameda County Superior Court (filed October 23, 2025), remain pending without resolved outcomes. Overall, while settlements have resolved bulk claims, Boehringer has contested liability emphasizing FDA-approved labeling and clinical data.[](https://law.justia.com/cases/federal/appellate-courts/ca2/20-3643/20-3643-2021-08-06.html)[](https://www.kslaw.com/news-and-insights/king-spalding-secures-another-victory-for-boehringer-ingelheim-in-zantac-related-retrial)[](https://www.law.com/radar/card/ca-alamedacounty-613455-keys-v-boehringer-ingelheim-pharmaceuticals-inc)\n\n### Government Pricing and Regulatory Conflicts\n\nIn August 2023, Boehringer Ingelheim filed a lawsuit against the U.S. Department of Health and Human Services (HHS) challenging the Medicare Drug Price Negotiation Program established by the Inflation Reduction Act of 2022, which authorizes the Centers for Medicare \u0026 Medicaid Services (CMS) to negotiate maximum fair prices for select high-cost drugs covered by Medicare Part D and Part B.[](https://www.reuters.com/legal/boehringer-latest-sue-us-over-drug-price-negotiation-plan-2023-08-21/) The company argued that the program violated the First Amendment by compelling speech during negotiations, the Fifth Amendment through due process and takings claims by effectively coercing price concessions without adequate opt-out mechanisms, and the Eighth Amendment by imposing excessive penalties for non-participation, such as a 75% excise tax on sales of non-negotiated drugs.[](https://law.justia.com/cases/federal/appellate-courts/ca2/24-2092/24-2092-2025-08-07.html) In July 2024, the U.S. District Court for the District of Connecticut granted summary judgment to HHS, ruling that the program constituted permissible regulation of commerce rather than unconstitutional compulsion.[](https://www.statnews.com/2024/07/05/boehringer-ingelheim-loses-medicare-drug-price-negotiation-case/) The U.S. Court of Appeals for the Second Circuit affirmed this decision on August 7, 2025, holding that manufacturers retain meaningful choices, including withdrawal from Medicare, and that any burdens were rationally related to Congress's goal of reducing federal spending.[](https://law.justia.com/cases/federal/appellate-courts/ca2/24-2092/24-2092-2025-08-07.html) Boehringer's drug nintedanib (Ofev), used for idiopathic pulmonary fibrosis, was selected for negotiation in the program's second cycle announced in 2025.[](https://www.cms.gov/newsroom/fact-sheets/cms-announces-manufacturer-participation-second-cycle-medicare-drug-price-negotiation)\n\nBoehringer Ingelheim has also faced conflicts over the 340B Drug Pricing Program, a U.S. federal initiative requiring manufacturers to provide outpatient drugs at steep discounts to eligible safety-net providers. In 2022, the company expanded restrictions on 340B pricing for its products at contract pharmacies affiliated with certain disproportionate share hospitals and health centers, citing concerns over program diversion and duplicate discounts.[](https://340breport.com/boehringer-ingelheim-expands-its-340b-drug-pricing-restrictions/) This policy prompted lawsuits from providers and criticism from HHS, which in October 2021 issued guidance affirming that manufacturers cannot impose such limits without violating statutory obligations.[](https://rwc340b.org/boehringer-ingelheim-is-latest-manufacturer-to-file-a-lawsuit-against-hhs-on-contract-pharmacy-program/) Boehringer sued HHS in federal court, alleging the agency's contract pharmacy policy and related enforcement letters were arbitrary and capricious under the Administrative Procedure Act, seeking to vacate them and exemption from providing discounts to contract pharmacies.[](https://rwc340b.org/boehringer-ingelheim-is-latest-manufacturer-to-file-a-lawsuit-against-hhs-on-contract-pharmacy-program/) In March 2022, the 340B Health alliance referred Boehringer to HHS for penalties over alleged continued violations of 340B pricing requirements.[](https://www.340bhealth.org/newsroom/boehringer-ingelheim-referred-for-penalties-for-continued-violations-of-federal-law-on-340b-pricing/)\n\nInternationally, Boehringer Ingelheim encountered regulatory scrutiny for pricing-related anticompetitive conduct. In October 2023, the European Commission fined the company â‚¬2.2 million as part of a â‚¬13.4 million cartel settlement involving coordination on minimum sales prices for scopolamine butylbromide (SNBB), an active pharmaceutical ingredient used in Boehringer's Buscopan antispasmodic drug, from 2007 to 2015.[](https://ec.europa.eu/commission/presscorner/detail/es/ip_23_5104) The infringement decision followed an investigation into six firms fixing SNBB prices allocated to customers, including generic producers, thereby inflating input costs for downstream products.[](https://ec.europa.eu/commission/presscorner/detail/es/ip_23_5104) Separately, in January 2025, Romania's Competition Council imposed a â‚¬25.81 million fine on Boehringer for product hopping with its Spiriva Respimat inhaler, a strategy deemed abusive that involved reformulating the tiotropium bromide product and withdrawing the original dry powder version in 2015 to delay generic entry and sustain monopoly pricing, violating EU and national competition rules.[](https://www.vbb.com/insights/romanian-competition-authority-fines-boehringer-ingelheim-on-account-of-product-hopping) These cases highlight tensions between pharmaceutical pricing strategies and antitrust enforcement aimed at preventing artificial price maintenance."])</script><script nonce="MDFkNTc1MWYtZjA5OC00YWU2LWJmZGQtOTJjODZlMmExY2I0">self.__next_f.push([1,"8:[\"$\",\"$L1e\",null,{\"state\":{\"mutations\":[],\"queries\":[{\"dehydratedAt\":1761886112639,\"state\":{\"data\":{\"page\":{\"citations\":[{\"id\":\"1\",\"title\":\"Who we are - Boehringer Ingelheim\",\"description\":\"Boehringer has remained independent since the company's founding in 1885, which provides the freedom to take a long-term approach in achieving breakthroughsÂ ...\",\"url\":\"https://www.boehringer-ingelheim.com/us/about-us/who-we-are\",\"favicon\":\"\"},{\"id\":\"2\",\"title\":\"Boehringer Ingelheim | Company Overview \u0026 News - Forbes\",\"description\":\"Founded: 1885 ; Headquarters: Ingelheim, Connecticut ; Country/Territory: Germany ; CEO: Hubertus von Baumbach ; Employees: 52,000Â ...\",\"url\":\"https://www.forbes.com/companies/boehringer-ingelheim/\",\"favicon\":\"\"},{\"id\":\"3\",\"title\":\"Company History | Corporate Profile | Boehringer Ingelheim US\",\"description\":\"Click here to read more on the history of Boehringer Ingelheim, founded by Albert Boehringer in 1885. Today the company has become a global enterprise.\",\"url\":\"https://www.boehringer-ingelheim.com/us/about-us/who-we-are/history\",\"favicon\":\"\"},{\"id\":\"4\",\"title\":\"Boehringer Ingelheim reports strong growth in 2023 and accelerates ...\",\"description\":\"Apr 16, 2024 Â· Group net sales rose by 9.7%* to USD 27.7 billion (EUR 25.6 billion) in 2023, driven by 10.3%* growth in Human Pharma and 6.9%* growth in AnimalÂ ...\",\"url\":\"https://www.boehringer-ingelheim.com/us/media/boehringer-ingelheim-reports-strong-growth-2023-and-accelerates-late-stage-pipeline\",\"favicon\":\"\"},{\"id\":\"5\",\"title\":\"Facts and figures | Boehringer Ingelheim\",\"description\":\"Key product JARDIANCEÂ® grew currency-adjusted by 15%. The company also invested in R\u0026D, technology, and sustainability, with an increase of around 8% in R\u0026DÂ ...\",\"url\":\"https://boehringer-ingelheim.com/annualreport/2024/facts-and-figures/\",\"favicon\":\"\"},{\"id\":\"6\",\"title\":\"Boehringer Ingelheim to Pay $95 Million to Resolve False Claims ...\",\"description\":\"Oct 25, 2012 Â· Boehringer Ingelheim Pharmaceuticals Inc. has agreed to pay $95 million to resolve allegations relating to the improper promotion of the stroke-prevention drugÂ ...\",\"url\":\"https://www.justice.gov/archives/opa/pr/boehringer-ingelheim-pay-95-million-resolve-false-claims-act-allegations\",\"favicon\":\"\"},{\"id\":\"7\",\"title\":\"Boehringer Ingelheim accused of Orange Book violations\",\"description\":\"Mar 7, 2024 Â· Boehringer Ingelheim violated US antitrust law by improperly listing inhaler patents in the US Food and Drug Administration's Orange Book, a wealth fund hasÂ ...\",\"url\":\"https://globalcompetitionreview.com/gcr-usa/article/boehringer-ingelheim-accused-of-orange-book-violations\",\"favicon\":\"\"},{\"id\":\"8\",\"title\":\"History (1885-1948): Innovative beginnings - Boehringer Ingelheim\",\"description\":\"Everything started in 1885. This was the year Albert Boehringer (1861-1939) purchased a small tartar factory in the Rhine-Hessian village of Nieder-Ingelheim.\",\"url\":\"https://www.boehringer-ingelheim.com/about-us/who-we-are/history/1885-1948-innovative-beginnings\",\"favicon\":\"\"},{\"id\":\"9\",\"title\":\"1885-1948: Innovative Beginnings | Boehringer Ingelheim US\",\"description\":\"In 1885, Albert Boehringer purchased a small tartar factory in the Rhine-Hessian village of Nieder-Ingelheim. On 31 July, his company was included in theÂ ...\",\"url\":\"https://www.boehringer-ingelheim.com/us/about-us/who-we-are/history/1885-1948-innovative-beginnings-boehringer-ingelheim-us\",\"favicon\":\"\"},{\"id\":\"10\",\"title\":\"A history of... Boehringer Ingelheim - pharmaphorum\",\"description\":\"Oct 3, 2012 Â· In 1885, a man named Albert Boehringer purchased a small factory in the Rhine-Hessian village of Nieder-Ingelheim in Germany. Work began onÂ ...\",\"url\":\"https://pharmaphorum.com/views-and-analysis/a_history_of-_boehringer_ingelheim\",\"favicon\":\"\"},{\"id\":\"11\",\"title\":\"C.H. Boehringer Sohn - Encyclopedia.com\",\"description\":\"CH Boehringer Sohn is the holding company for Boehringer Ingelheim GmbH, which is among the top 20 international research-based pharmaceuticals manufacturers.\",\"url\":\"https://www.encyclopedia.com/books/politics-and-business-magazines/ch-boehringer-sohn\",\"favicon\":\"\"},{\"id\":\"12\",\"title\":\"Sage Reference - Boehringer Ingelheim\",\"description\":\"Boehringer Ingelheim, despite being located in a country (Germany) that was ravaged by two world wars, never interrupted its research andÂ ...\u003c|control11|\u003e\u003c|separator|\u003e\",\"url\":\"https://sk.sagepub.com/ency/edvol/the-sage-encyclopedia-of-pharmacology-and-society/chpt/boehringer-ingelheim\",\"favicon\":\"\"},{\"id\":\"13\",\"title\":\"History of C.H. Boehringer Sohn - FundingUniverse\",\"description\":\"Inspired by his older brother, Albert acquired a small chemical plant in Lower Ingelheim on the Rhine in summer 1885. On July 31 that facility was officiallyÂ ...\",\"url\":\"https://www.fundinguniverse.com/company-histories/c-h-boehringer-sohn-history/\",\"favicon\":\"\"},{\"id\":\"14\",\"title\":\"History (1948-1990): Going global - Boehringer Ingelheim\",\"description\":\"In 1948, three years after the end of the Second World War, the first foreign subsidiary is founded in Vienna under the name Bender \u0026 Co. GmbH.Missing:  ownership | Show results with:ownership\",\"url\":\"https://www.boehringer-ingelheim.com/about-us/who-we-are/history/1948-1990-going-global\",\"favicon\":\"\"},{\"id\":\"15\",\"title\":\"History (1990-2025): Value through Innovation - Boehringer Ingelheim\",\"description\":\"The company's goal is anchored in its mission statement, to this day: to help people and animals around the world by providing innovation.Missing:  war reconstruction 1946-1999\",\"url\":\"https://www.boehringer-ingelheim.com/about-us/who-we-are/history/1990-2025-value-through-innovation\",\"favicon\":\"\"},{\"id\":\"16\",\"title\":\"1988-2015: Value Through Innovation | Boehringer Ingelheim IN\",\"description\":\"Acquisition of microPartsBoehringer Ingelheim acquires the micro-technology company STEAG microparts GmbH from STEAG AG Essen, which since then has been basedÂ ...Missing:  key | Show results with:key\",\"url\":\"https://www.boehringer-ingelheim.com/in/about-us/who-we-are/history/1988-2015\",\"favicon\":\"\"},{\"id\":\"17\",\"title\":\"Boehringer Ingelheim Invests More Than $350 Million in 2011 U.S. ...\",\"description\":\"Nov 15, 2011 Â· ... Boehringer Ingelheim Fremont, Inc. The facility, acquired from Amgen, manufactures biological medicines, and consists of more than 300,000Â ...\",\"url\":\"https://www.prnewswire.com/news-releases/boehringer-ingelheim-invests-more-than-350-million-in-2011-us-expansion-projects-133899483.html\",\"favicon\":\"\"},{\"id\":\"18\",\"title\":\"Boehringer Ingelheim Reports A Successful Financial Year 2015\",\"description\":\"Apr 19, 2016 Â· Boehringer Ingelheim Reports A Successful Financial Year 2015 Â· Net sales rose to 14.8 billion euros (currency-adjusted: +4.1 per cent; +11.1 perÂ ...\u003c|separator|\u003e\",\"url\":\"https://www.biospace.com/boehringer-ingelheim-reports-a-successful-financial-year-2015\",\"favicon\":\"\"},{\"id\":\"19\",\"title\":\"Sanofi and BI Confirm Closing of Business Swap | BI US\",\"description\":\"Jan 2, 2017 Â· Sanofi and Boehringer Ingelheim confirmed today that the strategic transaction signed in June 2016, which consists of an exchange of Sanofi's animal healthÂ ...\",\"url\":\"https://www.boehringer-ingelheim.com/us/media/press-releases/sanofi-and-boehringer-ingelheim-confirm-closing-business-swap-january-1st-2017\",\"favicon\":\"\"},{\"id\":\"20\",\"title\":\"Vetmedica Inc to Sell Vaccine Portfolio | Boehringer Ingelheim US\",\"description\":\"Oct 5, 2016 Â· Boehringer Ingelheim Vetmedica Inc. Enters Into an Agreement to Sell U.S. Feline, Canine and Rabies Vaccines Portfolio to Elanco Animal Health.\",\"url\":\"https://www.boehringer-ingelheim.com/us/media/press-releases/vetmedica-inc-sell-vaccine-portfolio-boehringer-ingelheim-us\",\"favicon\":\"\"},{\"id\":\"21\",\"title\":\"Boehringer Ingelheim and Sarah Cannon Research Institute launch ...\",\"description\":\"Sep 29, 2016 Â· Boehringer Ingelheim and Sarah Cannon Research Institute launch strategic collaboration to develop novel immune-oncology therapies. PressÂ ...Missing:  present | Show results with:present\",\"url\":\"https://firstwordpharma.com/story/4238116\",\"favicon\":\"\"},{\"id\":\"22\",\"title\":\"Boehringer Ingelheim Expands Collaboration With Sarah Cannon ...\",\"description\":\"Oct 30, 2017 Â· Boehringer Ingelheim and Sarah Cannon Research Institute today announced an expansion of their strategic partnership to bring innovative treatments to cancerÂ ...\",\"url\":\"https://www.biospace.com/boehringer-ingelheim-expands-collaboration-with-sarah-cannon-research-institute-to-investigate-novel-immuno-oncology-combination-therapy\",\"favicon\":\"\"},{\"id\":\"23\",\"title\":\"Boehringer Ingelheim boosts immune-oncology pipeline through ...\",\"description\":\"Boehringer Ingelheim boosts immune-oncology pipeline through collaboration with ViraTherapeutics. New long-term collaboration to develop next generationÂ ...\",\"url\":\"https://www.prnewswire.com/news-releases/boehringer-ingelheim-boosts-immune-oncology-pipeline-through-collaboration-with-viratherapeutics-300335137.html\",\"favicon\":\"\"},{\"id\":\"24\",\"title\":\"Boehringer Ingelheim acquires all ViraTherapeutics shares\",\"description\":\"Boehringer Ingelheim announce that it had acquired all shares of ViraTherapeutics, which has developed the lead candidate VSV-GP.\",\"url\":\"https://www.drugdiscoverynews.com/boehringer-ingelheim-acquires-all-viratherapeutics-shares-12818\",\"favicon\":\"\"},{\"id\":\"25\",\"title\":\"BI Acquires Abexxa Biologics | Boehringer Ingelheim US\",\"description\":\"Sep 21, 2021 Â· Boehringer Ingelheim today announced the acquisition of Abexxa Biologics Inc., a biopharmaceutical company taking a new approach in the fields of immuno-Â ...Missing:  timeline | Show results with:timeline\",\"url\":\"https://www.boehringer-ingelheim.com/us/media/press-releases/boehringer-ingelheim-acquires-abexxa-biologics-further-expand-its-research-efforts-cancer-immunology\",\"favicon\":\"\"},{\"id\":\"26\",\"title\":\"List of 16 Acquisitions by Boehringer Ingelheim (Jul 2025) - Tracxn\",\"description\":\"Jul 18, 2025 Â· Boehringer Ingelheim has made a total of 6 acquisitions. These acquisitions span 6 sectors, including Oncology (8), Immunotherapy (6),Â ...\",\"url\":\"https://tracxn.com/d/acquisitions/acquisitions-by-boehringer-ingelheim/__ooKdHxXtEcyDITzNJ6ncOXIosHFWVdjBkDWzzeDMuNQ\",\"favicon\":\"\"},{\"id\":\"27\",\"title\":\"New partnership and significant pipeline progress\",\"description\":\"Jan 9, 2025 Â· In Mental Health, Boehringer entered new partnerships with Sosei Heptares (now Nxera Pharma) and the Broad Institute of MIT and Harvard toÂ ...\",\"url\":\"https://www.boehringer-ingelheim.com/us/science-innovation/human-health-innovation/new-partnership-and-significant-pipeline-progress\",\"favicon\":\"\"},{\"id\":\"28\",\"title\":\"Boehringer Ingelheim Obtains Novel Preclinical Oncology Program ...\",\"description\":\"Aug 10, 2025 Â· Boehringer Ingelheim Obtains Novel Preclinical Oncology Program from Accent Therapeutics. Agreement to acquire Accent Therapeutics' asset addsÂ ...Missing:  2016-2025 | Show results with:2016-2025\",\"url\":\"https://accenttx.com/news-events/boehringer-ingelheim-obtains-novel-preclinical-oncology-program-from-accent-therapeutics/\",\"favicon\":\"\"},{\"id\":\"29\",\"title\":\"\",\"description\":\"\",\"url\":\"https://www.tempus.com/news/tempus-enters-multi-year-strategic-collaboration-with-boehringer-ingelheim-to-advance-its-cancer-pipeline/\",\"favicon\":\"\"},{\"id\":\"30\",\"title\":\"Extended-release eye therapies-collaboration - Boehringer Ingelheim\",\"description\":\"Jul 28, 2025 Â· Boehringer and Re-Vana enter strategic collaboration to develop extended-release eye therapies, aiming to reduce injections and improveÂ ...Missing:  present | Show results with:present\",\"url\":\"https://www.boehringer-ingelheim.com/us/science-innovation/human-health-innovation/extended-release-eye-therapies-collaboration\",\"favicon\":\"\"},{\"id\":\"31\",\"title\":\"Boehringer Ingelheim Bets up to Nearly $1B in ADC Play ... - BioSpace\",\"description\":\"Oct 15, 2025 Â· Boehringer Ingelheim is paying up to $991 million for an antibody-drug conjugate asset from South Korea's AimedBio, in a pact that continuesÂ ...\",\"url\":\"https://www.biospace.com/business/boehringer-ingelheim-bets-up-to-nearly-1b-in-adc-play-with-aimedbio-deal\",\"favicon\":\"\"},{\"id\":\"32\",\"title\":\"Boehringer Ingelheim Reports Strong H1 2025 Growth and ...\",\"description\":\"Jul 28, 2025 Â· In the first half of 2025, Boehringer Ingelheim's Human Pharma business grew 5.7%* reaching EUR 11.3 billion (USD 11.8 billion) in net sales.Missing:  2023 | Show results with:2023\",\"url\":\"https://www.boehringer-ingelheim.com/us/media/press-releases/boehringer-ingelheim-reports-strong-h1-2025-growth-and-prepares-key-launches\",\"favicon\":\"\"},{\"id\":\"33\",\"title\":\"[PDF] GROUP MANAGEMENT REPORT\",\"description\":\"Founded in 1885, the family-owned company with its headquarters in Ingelheim am Rhein is today one of Germany's most research-intensive companies.\",\"url\":\"https://annualreport.boehringer-ingelheim.com/2022/downloads/2020/bi_fb_konzernlagebericht_2020_en.pdf\",\"favicon\":\"\"},{\"id\":\"34\",\"title\":\"2 of the world's richest families are tied to healthcare\",\"description\":\"Dec 8, 2023 Â· Boehringer Ingelheim Chairman and CEO Hubertus von Baumbach is the great-grandson of Mr. Boehringer, and his extended family serves as owners ofÂ ...\",\"url\":\"https://www.beckershospitalreview.com/finance/2-of-the-worlds-richest-families-are-tied-to-healthcare/\",\"favicon\":\"\"},{\"id\":\"35\",\"title\":\"Mathias Boehringer - Biography, Net Worth \u0026 Profile - RedCarpetLife\",\"description\":\"Sep 3, 2025 Â· Boehringer Ingelheim remains privately held, with ownership distributed among the extended Boehringer and von Baumbach families. This privateÂ ...\",\"url\":\"https://www.redcarpetlife.in/billionaires/profile/mathias-boehringer.html\",\"favicon\":\"\"},{\"id\":\"36\",\"title\":\"Leadership | Boehringer Ingelheim\",\"description\":\"Boehringer Ingelheim is an independently owned company governed by the Board of Managing Directors.Missing:  family structure\",\"url\":\"https://www.boehringer-ingelheim.com/us/about-us/who-we-are/leadership\",\"favicon\":\"\"},{\"id\":\"37\",\"title\":\"[PDF] 2024 Highlights - Boehringer Ingelheim\",\"description\":\"Independent and family-owned, we pursue a strat- egy that is aimed at securing our independence in the long term through the research, development, productionÂ ...\",\"url\":\"https://www.boehringer-ingelheim.com/annualreport/2024/files/downloads-and-archive/highlights-2024/BOE_Highlights_2024_EN.pdf\",\"favicon\":\"\"},{\"id\":\"38\",\"title\":\"Living Independence | Boehringer Ingelheim\",\"description\":\"As an independent family-owned business, the key focus at Boehringer Ingelheim is long-term, sustainable action. To achieve this goal, sound financing andÂ ...Missing:  structure | Show results with:structure\",\"url\":\"https://www.boehringer-ingelheim.com/about-us/who-we-are/history/living-independence\",\"favicon\":\"\"},{\"id\":\"39\",\"title\":\"Boehringer Ingelheim | Contract Pharma\",\"description\":\"Headcount: 54,500. Year established: 1885. Revenues: $27,910 (+5%) Pharma Revenues: $ 22,839 (+6%) R\u0026D Expenses: $5,951 (+9%).\",\"url\":\"https://www.contractpharma.com/top-company-profile/boehringer-ingelheim/\",\"favicon\":\"\"},{\"id\":\"40\",\"title\":\"Boehringer Ingelheim announces succession Chairmen\",\"description\":\"Apr 17, 2025 Â· The Shareholders' Committee has appointed Hubertus von Baumbach, currently Chairman of the Board of Directors, as his successor, effective July 1, 2025.\",\"url\":\"https://www.globenewswire.com/news-release/2025/04/17/3063157/0/en/Boehringer-Ingelheim-announces-succession-Chairmen-Shareholders-Committee-and-Board-of-Managing-Directors.html\",\"favicon\":\"\"},{\"id\":\"41\",\"title\":\"Succession Chairmen Shareholders' Committee and Board of ...\",\"description\":\"Apr 17, 2025 Â· The Shareholders' Committee has appointed Hubertus von Baumbach, currently Chairman of the Board of Directors, as his successor, effective July 1, 2025.\",\"url\":\"https://www.boehringer-ingelheim.com/about-us/who-we-are/leadership/succession-chairmen-shareholders-committee-and-board-managing-directors\",\"favicon\":\"\"},{\"id\":\"42\",\"title\":\"Leadership | Boehringer Ingelheim\",\"description\":\"### Current Members of the Board of Managing Directors\",\"url\":\"https://www.boehringer-ingelheim.com/about-us/who-we-are/leadership\",\"favicon\":\"\"},{\"id\":\"43\",\"title\":\"Boehringer Ingelheim announces appointments Board of Managing ...\",\"description\":\"Aug 30, 2024 Â· Shashank Deshpande, member of the Board of Managing Directors with responsibility for the Animal Health Business Unit, has been appointed toÂ ...\",\"url\":\"https://www.boehringer-ingelheim.com/about-us/who-we-are/leadership/boehringer-ingelheim-announces-appointments-board-managing-directors\",\"favicon\":\"\"},{\"id\":\"44\",\"title\":\"The data-driven digital journey defining Boehringer Ingelheim - CIO\",\"description\":\"Aug 22, 2025 Â· In short, family-owned German multinational pharma giant Boehringer Ingelheim's ... decision-making. And with cloud computing and adoptingÂ ...\",\"url\":\"https://www.cio.com/article/4043753/boehringer-ingelheim-a-digital-journey-with-a-focus-on-data.html\",\"favicon\":\"\"},{\"id\":\"45\",\"title\":\"Human Pharma Clinical Pipeline - Boehringer Ingelheim\",\"description\":\"We strive to improve the health of humans and animals - for generations. We work together with integrity and are guided by a shared purpose that defines whoÂ ...Download Pipeline Â· Oncology Pipeline Â· Cardiovascular-Renal... Â· PDE4B inhibitorMissing:  Division | Show results with:Division\u003c|separator|\u003e\",\"url\":\"https://www.boehringer-ingelheim.com/science-innovation/human-health-innovation/clinical-pipeline\",\"favicon\":\"\"},{\"id\":\"46\",\"title\":\"Human Health - Boehringer Ingelheim\",\"description\":\"Heart Diseases Â· Metabolic Diseases Â· Chronic Kidney Disease Â· Cancer Â· Lung Diseases Â· Mental Health Â· Retinal Diseases Â· Our Responsibility.\",\"url\":\"https://www.boehringer-ingelheim.com/us/human-health\",\"favicon\":\"\"},{\"id\":\"47\",\"title\":\"Boehringer Ingelheim half-year results 2025\",\"description\":\"Jul 24, 2025 Â· This performance was driven by strong demand for key products in Human Pharma, namely JARDIANCEÂ® with EUR 4.3 billion and OFEVÂ® with EUR 2.0Â ...\",\"url\":\"https://www.boehringer-ingelheim.com/about-us/who-we-are/boehringer-ingelheim-half-year-results-2025\",\"favicon\":\"\"},{\"id\":\"48\",\"title\":\"Animal Health \u0026 Veterinary Medicine | Boehringer Ingelheim US\",\"description\":\"Boehringer Ingelheim's animal-health portfolio includes some of the most highly regarded and broadly used vaccines, parasite-control products andÂ ...Meet our Team Â· Veterinary Public Health Â· Products Â· Our Responsibility\",\"url\":\"https://www.boehringer-ingelheim.com/us/animal-health\",\"favicon\":\"\"},{\"id\":\"49\",\"title\":\"Boehringer Ingelheim Animal Health: Homepage\",\"description\":\"Boehringer Ingelheim Animal Health offers vaccines, parasite control, and therapeutics, focused on preventing disease and innovation, with over 3,000 employeesÂ ...Our History Â· Cattle Â· Than Canine Health Â· Veterinary Public Health\",\"url\":\"https://bi-animalhealth.com/\",\"favicon\":\"\"},{\"id\":\"50\",\"title\":\"Veterinary Public Health - Boehringer Ingelheim\",\"description\":\"Through our Veterinary Public Health (VPH) Center, we partner with health authorities, governments and NGOs to provide vaccines and control solutionsÂ ...\u003c|separator|\u003e\",\"url\":\"https://www.boehringer-ingelheim.com/us/animal-health/veterinary-public-health\",\"favicon\":\"\"},{\"id\":\"51\",\"title\":\"Our History | Boehringer Ingelheim IN\",\"description\":\"Boehringer Ingelheim is one of the world's leading research-driven pharmaceutical companies. Click here to learn more information about our history.Missing:  timeline 2000s\",\"url\":\"https://www.boehringer-ingelheim.com/in/animal-health/our-history\",\"favicon\":\"\"},{\"id\":\"52\",\"title\":\"Boehringer Ingelheim acquires Saiba Animal Health, adding ...\",\"description\":\"Sep 3, 2024 Â· Boehringer Ingelheim acquires Saiba Animal Health, adding innovative technology platform to its pet therapeutics R\u0026D portfolio.\",\"url\":\"https://www.boehringer-ingelheim.com/science-innovation/animal-health-innovation/boehringer-ingelheim-acquires-saiba-animal-health-adding-innovative-technology-platform-its-pet\",\"favicon\":\"\"},{\"id\":\"53\",\"title\":\"Animal Health Products - Boehringer Ingelheim\",\"description\":\"Our aim is to provide advanced, preventive animal healthcare and develop smart and effective solutions for those who raise and care for animals.Missing:  Division | Show results with:Division\",\"url\":\"https://www.boehringer-ingelheim.com/us/animal-health/products\",\"favicon\":\"\"},{\"id\":\"54\",\"title\":\"Animal Health Products - Boehringer Ingelheim\",\"description\":\"Boehringer Ingelheim offers vaccines for diseases like Bursal and Marek's, and products like Ubrostar, Ubrolexine, and Frontline Plus.Missing:  key | Show results with:key\",\"url\":\"https://www.boehringer-ingelheim.com/in/animal-health/products\",\"favicon\":\"\"},{\"id\":\"55\",\"title\":\"Boehringer Ingelheim Human Pharma \u0026 Animal Health Products\",\"description\":\"See our extensive range of human pharmaceutical and animal health products, see how our medicals products are improving patient lives human or animal.Human Health Products Â· Products Â· ActilyseMissing:  Division | Show results with:Division\",\"url\":\"https://www.boehringer-ingelheim.com/products\",\"favicon\":\"\"},{\"id\":\"56\",\"title\":\"Building Successful Partnerships in Animal Health\",\"description\":\"At Boehringer Ingelheim, 8 out of our 10 top-selling products in animal health are anchored in external collaboration. These important partnerships are, andÂ ...\",\"url\":\"https://www.boehringer-ingelheim.com/partnering/animal-health-partnering/perspectives/building-successful-partnerships-animal-health\",\"favicon\":\"\"},{\"id\":\"57\",\"title\":\"More Health Overview - Boehringer Ingelheim\",\"description\":\"We are dedicated to investing EUR 250 million in partnerships and collaborations to combat infectious diseases in human and animal health.\",\"url\":\"https://www.boehringer-ingelheim.com/about-us/sustainable-development/more-health/more-health-overview\",\"favicon\":\"\"},{\"id\":\"58\",\"title\":\"Working Together in Animal Health | Boehringer Ingelheim US\",\"description\":\"BI's collaborations with partners who share our passion for improving the health and wellbeing of animals play an essential role in our ambitions.Missing:  Division | Show results with:Division\",\"url\":\"https://www.boehringer-ingelheim.com/us/partnering/animal-health-partnering\",\"favicon\":\"\"},{\"id\":\"59\",\"title\":\"2024 results research and development investment rise\",\"description\":\"Apr 2, 2025 Â· â€œIf we look at the past five years, Boehringer Ingelheim has invested approximately EUR 25 billion in R\u0026D,â€ said Frank HÃ¼bler, Member of theÂ ...\",\"url\":\"https://www.boehringer-ingelheim.com/about-us/who-we-are/2024-results-research-and-development-investment-rise\",\"favicon\":\"\"},{\"id\":\"60\",\"title\":\"Home | Boehringer Ingelheim\",\"description\":\"2023 milestones. Explore some of the company's accomplishments achieved in 2023. Visit story â†’. Net sales and net sales by business. Key Figures. Export.Magazine Â· Letters Â· Downloads Â· Artificial Intelligence serving...Missing:  products | Show results with:products\",\"url\":\"https://annualreport.boehringer-ingelheim.com/\",\"favicon\":\"\"},{\"id\":\"61\",\"title\":\"Our Innovation Strategy - Boehringer Ingelheim\",\"description\":\"A deep understanding of disease, identifying relevant mechanisms and choosing therapeutic modalities to address them is the core of our innovation strategy.\",\"url\":\"https://www.boehringer-ingelheim.com/science-innovation/human-health-innovation/our-innovation-strategy\",\"favicon\":\"\"},{\"id\":\"62\",\"title\":\"Advancing health: Our impactful R\u0026D investments\",\"description\":\"At Boehringer Ingelheim, we focus on developing innovative therapies that can enhance and extend lives. Our commitment to research \u0026 development (R\u0026D) andÂ ...\",\"url\":\"https://www.boehringer-ingelheim.com/about-us/sustainable-development/more-health/advancing-health-our-impactful-rd-investments\",\"favicon\":\"\"},{\"id\":\"63\",\"title\":\"Advancing Biomedical Innovation Through Open Collaboration\",\"description\":\"At Boehringer Ingelheim, this philosophy is embedded in our progressive R\u0026D strategyâ€”one that fosters collaboration, openness, and scientific creativity withinÂ ...\",\"url\":\"https://www.boehringer-ingelheim.com/us/science-innovation/human-health-innovation/science-focus/advancing-biomedical-innovation-through-open-collaboration\",\"favicon\":\"\"},{\"id\":\"64\",\"title\":\"Research Collaborations - Boehringer Ingelheim\",\"description\":\"As an oncology partner of choice, we are involved in long-term collaborations with many of the world's leading academic, industry and advocacy organizations.Missing:  R\u0026D | Show results with:R\u0026D\",\"url\":\"https://www.boehringer-ingelheim.com/research-collaborations\",\"favicon\":\"\"},{\"id\":\"65\",\"title\":\"New XSeed Labs Research Team Starts Activity in the U.S. in ...\",\"description\":\"May 16, 2024 Â· A new research team at XSeed Labs â€“ a collaboration between BioMed X and Boehringer Ingelheim, will develop disease models to understandÂ ...\",\"url\":\"https://bmedx.com/news-events/press-releases/new-xseed-labs-research-team-starts-activity-in-the-u-s-in-collaboration-with-boehringer-ingelheim-011574/\",\"favicon\":\"\"},{\"id\":\"66\",\"title\":\"Kicking off 2024 with five new R\u0026D partnerships\",\"description\":\"Jan 9, 2024 Â· Boehringer Ingelheim enters 2024 on a high note: Announcing five new R\u0026D partnerships ; The collaboration with Suzhou Ribo Life Science Co., Ltd.Missing:  major | Show results with:major\",\"url\":\"https://www.boehringer-ingelheim.com/science-innovation/human-health-innovation/kicking-2024-five-new-rd-partnerships\",\"favicon\":\"\"},{\"id\":\"67\",\"title\":\"LCRF announces new research collaboration with Boehringer ...\",\"description\":\"Jun 17, 2025 Â· $2.25 million research collaboration focused on understanding and treating lung cancers harboring HER2 mutations; call for proposals Â· NEW YORK,Â ...\",\"url\":\"https://www.lungcancerresearchfoundation.org/lcrf-bi-research/\",\"favicon\":\"\"},{\"id\":\"68\",\"title\":\"Tempus Enters Multi-Year Strategic Collaboration with Boehringer ...\",\"description\":\"May 14, 2025 Â· The new, multi-year collaboration builds on foundational work the two companies have conducted in the last few years, leveraging data and AI to further advanceÂ ...\",\"url\":\"https://www.tempus.com/news/tempus-enters-multi-year-strategic-collaboration-with-boehringer-ingelheim-to-advance-its-cancer-pipeline/?srsltid=AfmBOopfPOhnboHerN3khDHryfC_BqqwtHLh2og_qKYiFpMUDc8uSL2C\",\"favicon\":\"\"},{\"id\":\"69\",\"title\":\"Cue Biopharma Reports Strategic Collaboration with Boehringer ...\",\"description\":\"May 12, 2025 Â· Cue Biopharma, Inc. reported a strategic collaboration with Boehringer Ingelheim for their drug CUE-501, which includes a $12 million upfront payment andÂ ...\",\"url\":\"https://www.quiverquant.com/news/Cue%2BBiopharma%2BReports%2BStrategic%2BCollaboration%2Bwith%2BBoehringer%2BIngelheim%2Band%2BFinancial%2BResults%2Bfor%2BQ1%2B2025\",\"favicon\":\"\"},{\"id\":\"70\",\"title\":\"Translating Human Pharma Science into Animal Health Innovation\",\"description\":\"Translating human pharma innovation into animal health breakthroughs Â· Delivering innovation through shared knowledge Â· Shared diseases and disease mechanisms.\",\"url\":\"https://www.boehringer-ingelheim.com/partnering/animal-health-partnering/perspectives/translating-human-pharma-science-animal-health-innovation\",\"favicon\":\"\"},{\"id\":\"71\",\"title\":\"Boehringer Ingelheim details new R\u0026D strategy, with greater focus ...\",\"description\":\"... focus areas, where we explore emerging science, new indications and new technology to expand opportunities.\\\" Specifically, Boehringer Ingelheim explainedÂ ...\",\"url\":\"https://firstwordpharma.com/story/3240666\",\"favicon\":\"\"},{\"id\":\"72\",\"title\":\"With 2 planned launches, Boehringer Ingelheim looks to make a ...\",\"description\":\"Jun 10, 2024 Â· So far this year, Boehringer has also signed a T-cell anti-cancer therapy partnership with 3T Biosciences and a collab with Suzhou Ribo LifeÂ ...\",\"url\":\"https://www.fiercepharma.com/pharma/asco-boehringer-ingelheim-make-name-oncology-two-upcoming-launches\",\"favicon\":\"\"},{\"id\":\"73\",\"title\":\"Zongertinib (BI 1810631): HER2 Tyrosine Kinase Inhibitor (TKI)\",\"description\":\"Zongertinib (BI 1810631) is an irreversible HER2-selective tyrosine kinase inhibitor (TKI) currently being investigated in a phase III clinical trial.\",\"url\":\"https://www.boehringer-ingelheim.com/science-innovation/human-health-innovation/clinical-pipeline/zongertinib-bi-1810631-her2-tyrosine-kinase-inhibitor-tki-0\",\"favicon\":\"\"},{\"id\":\"74\",\"title\":\"HERNEXEOSÂ® (zongertinib tablets) gains accelerated approval\",\"description\":\"Aug 8, 2025 Â· HERNEXEOSÂ® (zongertinib tablets) is a kinase inhibitor indicated for the treatment of adult patients with unresectable or metastatic non-Â ...\",\"url\":\"https://www.boehringer-ingelheim.com/us/media/press-releases/hernexeos-zongertinib-tablets-gains-accelerated-approval\",\"favicon\":\"\"},{\"id\":\"75\",\"title\":\"Zongertinib 77 percent response rate advanced HER2 mutant NSCLC\",\"description\":\"Oct 17, 2025 Â· Boehringer's zongertinib demonstrated a 77% objective response rate in treatment-naÃ¯ve patients with advanced HER2 (ERBB2)-mutant NSCLC.\",\"url\":\"https://www.boehringer-ingelheim.com/human-health/cancer/lung-cancer/zongertinib-77-percent-response-rate-advanced-her2-mutant-nsclc\",\"favicon\":\"\"},{\"id\":\"76\",\"title\":\"Zongertinib in Previously Treated HER2-Mutant Nonâ€“Small-Cell ...\",\"description\":\"Apr 28, 2025 Â· Zongertinib showed clinical benefit with mainly low-grade adverse events in patients with previously treated HER2-mutant NSCLC. (Funded byÂ ...\",\"url\":\"https://www.nejm.org/doi/full/10.1056/NEJMoa2503704\",\"favicon\":\"\"},{\"id\":\"77\",\"title\":\"\",\"description\":\"\",\"url\":\"https://www.boehringer-ingelheim.com/science-innovation/human-health-innovation/clinical-pipeline/nerandomilast-bi-1015550-pde4b-inhibitor\",\"favicon\":\"\"},{\"id\":\"78\",\"title\":\"Phase 3 trials nerandomilast slowed lung function decline IPF and ...\",\"description\":\"May 19, 2025 Â· Global phase III trials demonstrate that nerandomilast slowed lung function decline in IPF and PPF, with similar discontinuation rates to placebo.\",\"url\":\"https://www.boehringer-ingelheim.com/human-health/lung-diseases/pulmonary-fibrosis/phase-3-trials-nerandomilast-slowed-lung-function-decline-ipf-and-ppf\",\"favicon\":\"\"},{\"id\":\"79\",\"title\":\"Nerandomilast in Patients with Idiopathic Pulmonary Fibrosis\",\"description\":\"May 18, 2025 Â· In this phase 3, double-blind trial, we randomly assigned patients with idiopathic pulmonary fibrosis in a 1:1:1 ratio to receive nerandomilastÂ ...\",\"url\":\"https://www.nejm.org/doi/full/10.1056/NEJMoa2414108\",\"favicon\":\"\"},{\"id\":\"80\",\"title\":\"\",\"description\":\"\",\"url\":\"https://www.boehringer-ingelheim.com/science-innovation/human-health-innovation/clinical-pipeline/survodutide-bi-456906-glp1-gcgr-agonist\",\"favicon\":\"\"},{\"id\":\"81\",\"title\":\"Survodutide US FDA Breakthrough Therapy phase 3 trials MASH\",\"description\":\"Oct 8, 2024 Â· Boehringer announced the initiation of two Phase III clinical trials for survodutide for the treatment of adults living with MASH and fibrosis (scarring).\",\"url\":\"https://www.boehringer-ingelheim.com/human-health/metabolic-diseases/survodutide-us-fda-breakthrough-therapy-phase-3-trials-mash\",\"favicon\":\"\"},{\"id\":\"82\",\"title\":\"Survodutide Phase III study weight loss - Boehringer Ingelheim\",\"description\":\"Aug 17, 2023 Â· Data shows nearly 19% weight loss in people with overweight or obesity in Boehringer Ingelheim and Zealand Pharma Phase II trial with survodutide.\",\"url\":\"https://www.boehringer-ingelheim.com/human-health/metabolic-diseases/survodutide-phase-iii-study-weight-loss\",\"favicon\":\"\"},{\"id\":\"83\",\"title\":\"[PDF] PRODUCT PORTFOLIO - Boehringer Ingelheim Annual Report\",\"description\":\"Boehringer Ingelheim's product portfolio includes human pharmaceuticals and animal health, with products for respiratory diseases like COPD and asthma.\",\"url\":\"https://annualreport.boehringer-ingelheim.com/2022/downloads/2020/bi_fb_produktportfolio_2020_en.pdf\",\"favicon\":\"\"},{\"id\":\"84\",\"title\":\"Products Human Pharma - Boehringer Ingelheim\",\"description\":\"Products Â· Alteplase Â· Aspirin / extended-release Dipyridamole Â· Tipranavir Â· Ipratropium Bromide HFA Â· Ipratropium Bromide Â· Clonidine Hydrochloride, USP.\",\"url\":\"https://pro.boehringer-ingelheim.com/products\",\"favicon\":\"\"},{\"id\":\"85\",\"title\":\"Human Pharma | Products \u0026 Information | Boehringer Ingelheim US\",\"description\":\"Boehringer Ingelheim offers innovative prescription medications, including Aptivus, Basaglar, and Jardiance, among others.\",\"url\":\"https://www.boehringer-ingelheim.com/us/human-health/products\",\"favicon\":\"\"},{\"id\":\"86\",\"title\":\"MicardisÂ® | Boehringer Ingelheim\",\"description\":\"Micardis is for treatment of hypertension to reduce the risk of heart attack, stroke or death from cardiovascular (CV) causes in patients 55 years plus.Missing:  Spiriva Pradaxa\",\"url\":\"https://www.boehringer-ingelheim.com/human-health/products/micardis\",\"favicon\":\"\"},{\"id\":\"87\",\"title\":\"PradaxaÂ® | Boehringer Ingelheim\",\"description\":\"Pradaxa is indicated for the prevention of strokes and blood clots in patients with atrial fibrillation, prevention of VTE and treatment of DVT or PE.Missing:  Spiriva Micardis\",\"url\":\"https://www.boehringer-ingelheim.com/human-health/products/pradaxa\",\"favicon\":\"\"},{\"id\":\"88\",\"title\":\"NexGard | Boehringer Ingelheim\",\"description\":\"NexGard is delivered in a highly palatable beef-flavored chew that kills fleas before they can lay eggs, ticks and mites, with monthly treatments.\",\"url\":\"https://www.boehringer-ingelheim.com/animal-health/products/nexgard\",\"favicon\":\"\"},{\"id\":\"89\",\"title\":\"\",\"description\":\"\",\"url\":\"https://www.statista.com/statistics/831366/boehringer-ingelheims-revenues-by-top-animal-health-products/\",\"favicon\":\"\"},{\"id\":\"90\",\"title\":\"NexGardÂ® PLUS All-In-One Parasiticide for Dogs\",\"description\":\"NexGard PLUS chews prevent heartworm disease, fight fleas and ticks, and treat and control roundworms and hookworms, all in one delicious, beef-flavored chew.\",\"url\":\"https://bi-animalhealth.com/pets/canine/products/parasiticides/nexgard-plus\",\"favicon\":\"\"},{\"id\":\"91\",\"title\":\"Boehringer Ingelheim Introduces NexGardÂ® COMBO (esafoxolaner ...\",\"description\":\"Apr 24, 2023 Â· It is the first-and-only feline broad-spectrum protection against fleas, ticks, roundworms, hookworms, heartworm disease and tapeworms.\",\"url\":\"https://www.prnewswire.com/news-releases/boehringer-ingelheim-introduces-nexgard-combo-esafoxolaner-eprinomectin-and-praziquantel-topical-solution-the-first-and-only-feline-broad-spectrum-parasite-protection-that-treats-tapeworms-301805098.html\",\"favicon\":\"\"},{\"id\":\"92\",\"title\":\"\",\"description\":\"\",\"url\":\"https://www.allivet.com/product/metacam-15-mg-ml-oral-suspension/16000.html\",\"favicon\":\"\"},{\"id\":\"93\",\"title\":\"Cattle Products - Boehringer Ingelheim Animal Health\",\"description\":\"All Antimicrobials, Nutritional Supplements, Parasiticides, Pinkeye and Clostridial Vaccines (Blackleg), Reproductive Hormones, Reproductive Vaccines,Â ...\",\"url\":\"https://bi-animalhealth.com/cattle/products\",\"favicon\":\"\"},{\"id\":\"94\",\"title\":\"Boehringer launches swine vaccine with advanced protection ...\",\"description\":\"Sep 3, 2025 Â· INGELVAC CIRCOFLEXÂ® AD is the first vaccine to combine both PCV2a and PCV2d antigens in a single dose for optimized pig herd health.\",\"url\":\"https://www.boehringer-ingelheim.com/us/media/press-releases/boehringer-launches-swine-vaccine-advanced-protection-against-pcv2\",\"favicon\":\"\"},{\"id\":\"95\",\"title\":\"Livestock Health, Vaccines \u0026 Medicine | Boehringer Ingelheim US\",\"description\":\"Boehringer Ingelheim focuses on keeping animals healthy, offering vaccines, parasite-control products, and pharmaceuticals for livestock and pets.\",\"url\":\"https://www.boehringer-ingelheim.com/us/animal-health/livestock\",\"favicon\":\"\"},{\"id\":\"96\",\"title\":\"Where to find us | Boehringer Ingelheim\",\"description\":\"Click here to view our biggest sites. With 52000 employees worldwide, Boehringer Ingelheim has a research and production network across the globe.\u003c|separator|\u003e\",\"url\":\"https://www.boehringer-ingelheim.com/us/about-us/where-find-us\",\"favicon\":\"\"},{\"id\":\"97\",\"title\":\"Biberach - Boehringer Ingelheim\",\"description\":\"The Biberach site, in the very South of Germany, is home to the largest research and development center within Boehringer Ingelheim's global network.Missing:  details | Show results with:details\",\"url\":\"https://www.boehringer-ingelheim.com/about-us/where-find-us/biberach\",\"favicon\":\"\"},{\"id\":\"98\",\"title\":\"biologicals-development-center - Boehringer Ingelheim\",\"description\":\"The largest research and development center of Boehringer Ingelheim is located in Biberach, Germany. It is one of the largest sites in Europe forÂ ...\",\"url\":\"https://www.boehringer-ingelheim.com/science-innovation/human-health-innovation/science-stories/biologicals-development-center\",\"favicon\":\"\"},{\"id\":\"99\",\"title\":\"Boehringer Ingelheim invests â‚¬350m in new biotech R\u0026D facility\",\"description\":\"Apr 25, 2023 Â· The new â‚¬350 million biopharmaceutical R\u0026D centre is Boehringer Ingelheim's largest single investment in Germany to date.\u003c|separator|\u003e\",\"url\":\"https://www.europeanpharmaceuticalreview.com/news/181845/boehringer-ingelheim-invests-e350m-in-new-biotech-rd-facility/\",\"favicon\":\"\"},{\"id\":\"100\",\"title\":\"Ridgefield Research and Innovation - Boehringer Ingelheim\",\"description\":\"Boehringer Ingelheim is a research-driven group of companies dedicated to the discovery, development, manufacturing and marketing of innovative health careÂ ...\u003c|separator|\u003e\",\"url\":\"https://www.boehringer-ingelheim.com/us/science-innovation/human-health-innovation/science-focus/ridgefield-research-and-innovation\",\"favicon\":\"\"},{\"id\":\"101\",\"title\":\"Boehringer Ingelheim Expands Research and Development in ...\",\"description\":\"Oct 24, 2024 Â· PRNewswire/ -- Boehringer Ingelheim announced the grand opening of its newly expanded research and development facility in Athens, Georgia.Missing:  details | Show results with:details\",\"url\":\"https://www.prnewswire.com/news-releases/boehringer-ingelheim-expands-research-and-development-in-athens-georgia-302286462.html\",\"favicon\":\"\"},{\"id\":\"102\",\"title\":\"Boehringer Ingelheim announces research and development facility ...\",\"description\":\"Oct 30, 2024 Â· Boehringer Ingelheim's recent expansion has made the facility the company's largest R\u0026D site within the United States and third globally. TheÂ ...\",\"url\":\"https://www.dvm360.com/view/boehringer-ingelheim-announces-research-and-development-facility-expansion\",\"favicon\":\"\"},{\"id\":\"103\",\"title\":\"Ingelheim, Germany | BI Facilities\",\"description\":\"The largest research and development center of Boehringer Ingelheim is located in Biberach, Germany. This site is also the largest site in Europe forÂ ...\",\"url\":\"https://www.boehringer-ingelheim.com/us/about-us/where-find-us/ingelheim\",\"favicon\":\"\"},{\"id\":\"104\",\"title\":\"Boehringer's Chemical Innovation Plant, Ingelheim, Germany\",\"description\":\"Jun 16, 2023 Â· Boehringer Ingelheim will build a new Chemical Innovation Plant (CIP) at its headquarters in Ingelheim, Germany, by 2026.\",\"url\":\"https://www.pharmaceutical-technology.com/projects/boehringers-chemical-innovation-plant-ingelheim-germany/\",\"favicon\":\"\"},{\"id\":\"105\",\"title\":\"Global Network | BioXcellence - Boehringer Ingelheim\",\"description\":\"Our network of manufacturing facilities spans across the globe â€“ from Fremont in the US to Biberach (Germany), Vienna (Austria) \u0026 Shanghai (China).\",\"url\":\"https://www.boehringer-ingelheim.com/partnering/boehringer-ingelheim-bioxcellence/our-global-network\",\"favicon\":\"\"},{\"id\":\"106\",\"title\":\"Boehringer Ingelheim Expands in St. Joseph\",\"description\":\"May 10, 2024 Â· Boehringer Ingelheim's St. Joseph location is a key site within the company's global operations. This location is primarily dedicated to theÂ ...\",\"url\":\"https://choosesaintjoseph.com/boehringer-ingelheim-expands-in-st-joseph/\",\"favicon\":\"\"},{\"id\":\"107\",\"title\":\"The Company Headquarters - Boehringer Ingelheim\",\"description\":\"Over the course of the 20th century, the company gradually expanded from Ingelheim to become one of the leading, research-driven biopharmaceutical companies inÂ ...\",\"url\":\"https://www.boehringer-ingelheim.com/about-us/where-find-us/ingelheim\",\"favicon\":\"\"},{\"id\":\"108\",\"title\":\"Boehringer Ingelheim Manages Complex Global Needs with ...\",\"description\":\"Workforce management technology helped Boehringer Ingelheim to optimize resources, enhance collaboration, and drive business success.\",\"url\":\"https://workforcesoftware.com/blog/boehringer-ingelheim-global-workforce-management-technology/\",\"favicon\":\"\"},{\"id\":\"109\",\"title\":\"Boehringer Ingelheim and Cognizant announce the launch of a ...\",\"description\":\"The launch of our One Medicine Platform revolutionizes our medicinal development processes and takes our operational efficiencies to the nextÂ ...\",\"url\":\"https://news.cognizant.com/2025-03-11-Boehringer-Ingelheim-and-Cognizant-announce-the-launch-of-a-unified-cloud-platform-to-bring-innovative-therapies-to-patients-faster\",\"favicon\":\"\"},{\"id\":\"110\",\"title\":\"Biopharma machine learning | BioXcellence - Boehringer Ingelheim\",\"description\":\"Driving operational excellence using machine learning. Utilizing data science for fast detection of influencing factors in biopharmaceutical manufacturing â€“Â ...Missing:  initiatives | Show results with:initiatives\",\"url\":\"https://www.boehringer-ingelheim.com/partnering/boehringer-ingelheim-bioxcellence/newsroom/biopharma-machine-learning-bioxcellence\",\"favicon\":\"\"},{\"id\":\"111\",\"title\":\"How Boehringer Ingelheim Develops Leaders Who Drive Employee ...\",\"description\":\"Oct 5, 2020 Â· Boehringer Ingelheim's leadership development process focuses on self-awareness and EQ to drive employee engagement and high performance.Missing:  productivity | Show results with:productivity\",\"url\":\"https://www.forbes.com/sites/kevinkruse/2020/10/05/how-boehringer-ingelheim-develops-leaders-who-drive-employee-engagement-and-high-performance/\",\"favicon\":\"\"},{\"id\":\"112\",\"title\":\"Boehringer Ingelheim 2024 sales up forex-adj 6.1% - Reuters\",\"description\":\"Apr 2, 2025 Â· Group sales reached 26.8 billion euros ($28.94 billion), the family-owned, unlisted drugmaker said in a statement. Keep up with the latestÂ ...\",\"url\":\"https://www.reuters.com/business/healthcare-pharmaceuticals/boehringer-ingelheim-2024-sales-up-forex-adj-61-2025-04-02/\",\"favicon\":\"\"},{\"id\":\"113\",\"title\":\"[PDF] 2023 Highlights | Boehringer Ingelheim Annual Report\",\"description\":\"Apr 18, 2024 Â· That is why we concentrate on developing innovative therapies that can improve and extend lives, generating net sales of EUR 25.6 billion in.\",\"url\":\"https://annualreport.boehringer-ingelheim.com/2023/download/BOE_AR23_Highlights_2023_EN_safe.pdf\",\"favicon\":\"\"},{\"id\":\"114\",\"title\":\"Jardiance and Ofev propel Boehringer's human pharma sales\",\"description\":\"Apr 16, 2024 Â· The German company announced that it had reached â‚¬20.8bn ($22.1bn) in human pharma sales in 2023, also achieving a 14.2% boost in research andÂ ...\",\"url\":\"https://www.pharmaceutical-technology.com/news/jardiance-and-ofev-propel-boehringers-human-pharma-sales/\",\"favicon\":\"\"},{\"id\":\"115\",\"title\":\"Boehringer reports 6% sales growth for 2024 | The Pharmaletter\",\"description\":\"Apr 2, 2025 Â· Boehringer Ingelheim, now Germany's largest pharma company, today reported a currency-adjusted 6.1% gain in full-year 2024 revenues,Â ...\",\"url\":\"https://www.thepharmaletter.com/boehringer-reports-6-percent-sales-growth-for-2024\",\"favicon\":\"\"},{\"id\":\"116\",\"title\":\"Top 20 pharma companies by 2024 revenue\",\"description\":\"Apr 21, 2025 Â· Boehringer Ingelheim. By Kevin Dunleavy. 2024 revenue: 26.8 billion euros ($29.0 billion) 2023 revenue: 25.6 billion euros ($27.7 billion)\",\"url\":\"https://www.fiercepharma.com/special-reports/top-20-pharma-companies-2024-revenue\",\"favicon\":\"\"},{\"id\":\"117\",\"title\":\"[PDF] Value through Innovation - AnnualReports.com\",\"description\":\"In 2021, Boehringer Ingelheim achieved net sales of 20.6 billion EUR. Our significant investment of more than 4.1 billion EUR in R\u0026D drives innovation, enablingÂ ...\",\"url\":\"https://annualreport.boehringer-ingelheim.com/2021/downloads/en/BOE_AR21_Financial-Report_EN.pdf\",\"favicon\":\"\"},{\"id\":\"118\",\"title\":\"Boehringer Ingelheim 2024: An independent course - PharmaLive\",\"description\":\"Oct 10, 2024 Â· In the first half of 2024, net sales rose 7.4 percent year-on-year to â‚¬12.9 billion ($13.9 billion) in the first six months of 2024, driven byÂ ...\",\"url\":\"https://www.pharmalive.com/boehringer-ingelheim-an-independent-course/\",\"favicon\":\"\"},{\"id\":\"119\",\"title\":\"Top 20 pharma companies by 2023 revenue\",\"description\":\"Apr 15, 2024 Â· Boehringer opened 2024 continuing its business development spree, committing $2 billion biobucks to affiliated Chinese companies Suzhou RiboÂ ...\",\"url\":\"https://www.fiercepharma.com/pharma/top-20-pharma-companies-2023-revenue\",\"favicon\":\"\"},{\"id\":\"120\",\"title\":\"Boehringer Ingelheim reports strong growth in 2023 and accelerates ...\",\"description\":\"Apr 16, 2024 Â· Research \u0026 Development (R\u0026D) investments increased by 14.2% to EUR 5.8 billion. R\u0026D investments were substantial, at 22.5% of net sales. GroupÂ ...\",\"url\":\"https://financialpost.com/globe-newswire/boehringer-ingelheim-reports-strong-growth-in-2023-and-accelerates-late-stage-pipeline\",\"favicon\":\"\"},{\"id\":\"121\",\"title\":\"With â‚¬7B pledge, Boehringer Ingelheim is going heavy on ...\",\"description\":\"Apr 7, 2022 Â· The German company has earmarked more than 7 billion euros ($7.6 billion) for capital investments through 2025, it said in its annual report Tuesday.\u003c|separator|\u003e\",\"url\":\"https://www.fiercepharma.com/pharma/boehringer-ingelheim-spend-eu7-billion-capital-improvements-through-2025\",\"favicon\":\"\"},{\"id\":\"122\",\"title\":\"Building blocks of our future - Boehringer Ingelheim\",\"description\":\"In a world where innovation is key, Boehringer Ingelheim is making significant strides through its Capital Expenditures (CapEx) projects.\",\"url\":\"https://www.boehringer-ingelheim.com/building-blocks-our-future\",\"favicon\":\"\"},{\"id\":\"123\",\"title\":\"Lawsuit claims Boehringer misused US patents to delay asthma ...\",\"description\":\"Mar 6, 2024 Â· German drugmaker Boehringer Ingelheim was accused in a federal lawsuit in Boston on Wednesday of improperly submitting patents to the US Food and DrugÂ ...\",\"url\":\"https://www.reuters.com/legal/litigation/lawsuit-claims-boehringer-misused-us-patents-delay-asthma-drug-rivals-2024-03-07/\",\"favicon\":\"\"},{\"id\":\"124\",\"title\":\"Boehringer Ingelheim Accused of Using Expired Patents to Control ...\",\"description\":\"Apr 30, 2024 Â· Boehringer Ingelheim, the world's largest private pharmaceutical company, was hit with an antitrust class action alleging that the company is using expiredÂ ...\",\"url\":\"https://www.law.com/ctlawtribune/2024/04/30/boehringer-ingelheim-accused-of-using-expired-patents-to-control-market/\",\"favicon\":\"\"},{\"id\":\"125\",\"title\":\"[PDF] boehringer-ingelheim-orange-book.pdf - Federal Trade Commission\",\"description\":\"Nov 7, 2023 Â· On September 14, 2023, the Federal Trade Commission (â€œFTCâ€) issued a Statement. Concerning Brand Drug Manufacturers' Improper Listing ofÂ ...Missing:  issues | Show results with:issues\",\"url\":\"https://www.ftc.gov/system/files/ftc_gov/pdf/boehringer-ingelheim-orange-book.pdf\",\"favicon\":\"\"},{\"id\":\"126\",\"title\":\"[PDF] RESPIMAT PHARMACEUTICALS ANTITRUST LITIGATION MDL No ...\",\"description\":\"Aug 7, 2025 Â· Defendants Boehringer Ingelheim Pharmaceuticals, Inc., and. Boehringer Ingelheim International GmbH (together, Boehringer) oppose centralizationÂ ...\",\"url\":\"https://www.govinfo.gov/content/pkg/USCOURTS-jpml-1_25-F-03154/pdf/USCOURTS-jpml-1_25-F-03154-0.pdf\",\"favicon\":\"\"},{\"id\":\"127\",\"title\":\"Romanian Competition Authority Fines Boehringer-Ingelheim on ...\",\"description\":\"Jan 13, 2025 Â· The Romanian competition authority (RCA) announced today that it imposed a fine of EUR 25.81 million on Boehringer-Ingelheim (BI) on account of product hopping.Missing:  issues | Show results with:issues\",\"url\":\"https://www.vbb.com/insights/romanian-competition-authority-fines-boehringer-ingelheim-on-account-of-product-hopping\",\"favicon\":\"\"},{\"id\":\"128\",\"title\":\"The Romanian Competition Authority fines a pharmaceutical ...\",\"description\":\"Jan 13, 2025 Â· The Competition Council has sanctioned Boehringer Ingelheim RCV Gmbh \u0026 Co KG (Austria) with a fine of 128,470,123 lei (25.81 million euros) forÂ ...\",\"url\":\"https://www.concurrences.com/en/bulletin/news-issues/january-2025/the-romanian-competition-authority-fines-a-pharmaceutical-company-for-abusing\",\"favicon\":\"\"},{\"id\":\"129\",\"title\":\"Victory for Boehringer Ingelheim in Zentiva case - JUVE Patent\",\"description\":\"Aug 14, 2025 Â· The Court of Appeal finds Zentiva at risk of imminent infringement and has granted Boehringer Ingelheim a PI for its respiratory drug Ofev.\",\"url\":\"https://www.juve-patent.com/cases/court-of-appeal-grants-final-victory-to-boehringer-in-pi-case-against-zentiva/\",\"favicon\":\"\"},{\"id\":\"130\",\"title\":\"Federal Court addresses treatment and formulation patent claims in ...\",\"description\":\"Aug 27, 2024 Â· The Federal Court (FC) has upheld the validity of a patent concerning treatment of idiopathic pulmonary fibrosis (IPF) and granted injunctive relief againstÂ ...\",\"url\":\"https://www.pharmainbrief.com/2024/08/federal-court-addresses-treatment-and-formulation-patent-claims-in-pmnoc-case/\",\"favicon\":\"\"},{\"id\":\"131\",\"title\":\"Boehringer Ingelheim Announces Comprehensive Settlement of ...\",\"description\":\"May 28, 2014 Â· Boehringer Ingelheim Announces Comprehensive Settlement of U.S. PradaxaÂ® (dabigatran etexilate mesylate) Litigation. News provided by.\",\"url\":\"https://www.prnewswire.com/news-releases/boehringer-ingelheim-announces-comprehensive-settlement-of-us-pradaxa-dabigatran-etexilate-mesylate-litigation-260907991.html\",\"favicon\":\"\"},{\"id\":\"132\",\"title\":\"Cross-Motions for Summary Judgment Filed in PRADAXA Patent ...\",\"description\":\"Oct 28, 2015 Â· Boehringer alleges in its Complaint that FDA violated the Administrative Procedure Act and the Hatch-Waxman Amendments when the AgencyÂ ...\",\"url\":\"https://www.thefdalawblog.com/2015/10/cross-motions-for-summary-judgment-filed-in-pradaxa-patent-term-extension-dispute/\",\"favicon\":\"\"},{\"id\":\"133\",\"title\":\"Settlement of U.S. PradaxaÂ® (dabigatran etexilate) Case | BI US\",\"description\":\"May 28, 2014 Â· Boehringer Ingelheim (BI) announced today that it has reached a comprehensive settlement of state and federal cases in the US litigation regarding PradaxaÂ® (Â ...\",\"url\":\"https://www.boehringer-ingelheim.com/us/media/press-releases/boehringer-ingelheim-announces-comprehensive-settlement-us-pradaxa-dabigatran-etexilate-mesylate\",\"favicon\":\"\"},{\"id\":\"134\",\"title\":\"In Re: Mirapex Products Liability Litigation - Content Details - GovInfo\",\"description\":\"07-1836 - In Re: Mirapex Products Liability Litigation. Summary; Document ... Boehringer Ingelheim Pharmaceuticals, Inc., MDL - Notice Only Steven BoermaÂ ...\",\"url\":\"https://www.govinfo.gov/app/details/USCOURTS-mnd-0_07-md-01836\",\"favicon\":\"\"},{\"id\":\"135\",\"title\":\"boehringer-ingelheim | Violation Tracker - Good Jobs First\",\"description\":\"Boehringer Ingelheim International, drug or medical equipment safety violation, 2014, private lawsuit-federal, $650,000,000 ; Boehringer IngelheimÂ ...\",\"url\":\"https://violationtracker.goodjobsfirst.org/parent/boehringer-ingelheim\",\"favicon\":\"\"},{\"id\":\"136\",\"title\":\"Pradaxa US Litigation settlement - Boehringer Ingelheim\",\"description\":\"Boehringer Ingelheim has reached a comprehensive settlement to resolve the remaining claims pending in the Pradaxa litigation.Missing:  patent | Show results with:patent\",\"url\":\"https://www.boehringer-ingelheim.com/pradaxa-us-litigation-settlement\",\"favicon\":\"\"},{\"id\":\"137\",\"title\":\"Mancini v. Boehringer Ingelheim Pharmaceuticals, No. 17-2204 (8th ...\",\"description\":\"Jan 10, 2019 Â· In action against the manufacturers of Mirapex, a dopamine agonist used to treat Parkinson's disease, alleging the should be liable forÂ ...\",\"url\":\"https://law.justia.com/cases/federal/appellate-courts/ca8/17-2204/17-2204-2019-01-10.html\",\"favicon\":\"\"},{\"id\":\"138\",\"title\":\"Gazal v. Boehringer Ingelheim Pharmaceuticals, et al., No. 10-3129 ...\",\"description\":\"Jul 28, 2011 Â· Plaintiff's decedent was on notice of his injury and of the causal link between compulsive gambling and Mirapex no later than 2005, and theÂ ...\",\"url\":\"https://law.justia.com/cases/federal/appellate-courts/ca8/10-3129/103129p-2011-07-28.html\",\"favicon\":\"\"},{\"id\":\"139\",\"title\":\"Ignacuinos v. Boehringer Ingelheim Pharmaceuticals Inc., No. 20 ...\",\"description\":\"Aug 6, 2021 Â· Plaintiffs, who were prescribed a metered-dose inhaler manufactured by defendant and approved by the FDA to alleviate symptoms of chronicÂ ...\",\"url\":\"https://law.justia.com/cases/federal/appellate-courts/ca2/20-3643/20-3643-2021-08-06.html\",\"favicon\":\"\"},{\"id\":\"140\",\"title\":\"King \u0026 Spalding Secures Another Victory for Boehringer Ingelheim ...\",\"description\":\"Feb 24, 2025 Â· King \u0026 Spalding secured another victory for client Boehringer Ingelheim in the Circuit Court of Cook County, Illinois in a consolidated retrial of two cases.\",\"url\":\"https://www.kslaw.com/news-and-insights/king-spalding-secures-another-victory-for-boehringer-ingelheim-in-zantac-related-retrial\",\"favicon\":\"\"},{\"id\":\"141\",\"title\":\"\",\"description\":\"\",\"url\":\"https://www.law.com/radar/card/ca-alamedacounty-613455-keys-v-boehringer-ingelheim-pharmaceuticals-inc\",\"favicon\":\"\"},{\"id\":\"142\",\"title\":\"Boehringer latest to sue US over drug price negotiation plan - Reuters\",\"description\":\"Aug 21, 2023 Â· Aug 21 (Reuters) - Boehringer Ingelheim sued the U.S. government in an attempt to block a program that gives the Medicare health insurance planÂ ...Missing:  disputes | Show results with:disputes\u003c|separator|\u003e\",\"url\":\"https://www.reuters.com/legal/boehringer-latest-sue-us-over-drug-price-negotiation-plan-2023-08-21/\",\"favicon\":\"\"},{\"id\":\"143\",\"title\":\"Boehringer Ingelheim Pharms., Inc. v. Dep't of Health \u0026 Hum. Servs ...\",\"description\":\"Aug 7, 2025 Â· A pharmaceutical company challenged the federal government's implementation of a new program created by the Inflation Reduction Act of 2022,Â ...\",\"url\":\"https://law.justia.com/cases/federal/appellate-courts/ca2/24-2092/24-2092-2025-08-07.html\",\"favicon\":\"\"},{\"id\":\"144\",\"title\":\"Boehringer Ingelheim loses Medicare drug price negotiation case\",\"description\":\"Jul 5, 2024 Â· A federal judge ruled against Boehringer Ingelheim's challenge to the new Medicare drug price negotiation program, handing the pharmaceutical industry itsÂ ...\",\"url\":\"https://www.statnews.com/2024/07/05/boehringer-ingelheim-loses-medicare-drug-price-negotiation-case/\",\"favicon\":\"\"},{\"id\":\"145\",\"title\":\"CMS Announces Manufacturer Participation in Second Cycle of ...\",\"description\":\"CMS Announces Manufacturer Participation in Second Cycle of Medicare Drug Price Negotiation ; Ofev, Boehringer Ingelheim Pharmaceuticals, Inc. ; Otezla, Amgen IncÂ ...Missing:  conflicts | Show results with:conflicts\",\"url\":\"https://www.cms.gov/newsroom/fact-sheets/cms-announces-manufacturer-participation-second-cycle-medicare-drug-price-negotiation\",\"favicon\":\"\"},{\"id\":\"146\",\"title\":\"Boehringer Ingelheim Expands its 340B Drug Pricing Restrictions\",\"description\":\"Aug 8, 2022 Â· Boehringer Ingelheim said on Friday that health centers will be subject to its limits on 340B pricing involving contract pharmacies startingÂ ...\",\"url\":\"https://340breport.com/boehringer-ingelheim-expands-its-340b-drug-pricing-restrictions/\",\"favicon\":\"\"},{\"id\":\"147\",\"title\":\"Boehringer Ingelheim Is Latest Manufacturer to File a Lawsuit ...\",\"description\":\"Boehringer's complaint alleges that HHS's contract pharmacy policy and HRSA's October 4th letter are arbitrary, capricious, and in violation of the FederalÂ ...Missing:  controversies | Show results with:controversies\u003c|control11|\u003e\u003c|separator|\u003e\",\"url\":\"https://rwc340b.org/boehringer-ingelheim-is-latest-manufacturer-to-file-a-lawsuit-against-hhs-on-contract-pharmacy-program/\",\"favicon\":\"\"},{\"id\":\"148\",\"title\":\"BOEHRINGER INGELHEIM REFERRED FOR PENALTIES FOR ...\",\"description\":\"BOEHRINGER INGELHEIM REFERRED FOR PENALTIES FOR CONTINUED VIOLATIONS OF FEDERAL LAW ON 340B PRICING. March 29, 2022 in 340B Health News Releases.Missing:  settlements | Show results with:settlements\",\"url\":\"https://www.340bhealth.org/newsroom/boehringer-ingelheim-referred-for-penalties-for-continued-violations-of-federal-law-on-340b-pricing/\",\"favicon\":\"\"},{\"id\":\"149\",\"title\":\"Commission fines pharma companies â‚¬13,4 million in antitrust cartel ...\",\"description\":\"Oct 18, 2023 Â· The European Commission has fined Alkaloids of Australia, Alkaloids Corporation, Boehringer, Linnea and Transo-Pharm a total of â‚¬13,4Â ...\",\"url\":\"https://ec.europa.eu/commission/presscorner/detail/es/ip_23_5104\",\"favicon\":\"\"}],\"images\":[{\"id\":\"27b9bc93727a\",\"caption\":\"Boehringer Ingelheim headquarters\",\"url\":\"./_assets_/Ingelheim_site%252C_of_Boehringer_Ingelheim.jpg\",\"position\":\"CENTER\",\"width\":0,\"height\":0},{\"id\":\"6eae6e905a81\",\"caption\":\"Albert Boehringer\",\"url\":\"./_assets_/AlbertB.jpg\",\"position\":\"CENTER\",\"width\":0,\"height\":0},{\"id\":\"74f85ee879eb\",\"caption\":\"Poster for Boeson baking powder, the first patented Boehringer Ingelheim product\",\"url\":\"./_assets_/Poster_for_Boeson_baking_powder%252C_the_first_patented_Boehringer_Ingelheim_product.jpg\",\"position\":\"CENTER\",\"width\":0,\"height\":0},{\"id\":\"27b9bc93727a\",\"caption\":\"Ingelheim site of Boehringer Ingelheim\",\"url\":\"./_assets_/Ingelheim_site%252C_of_Boehringer_Ingelheim.jpg\",\"position\":\"CENTER\",\"width\":0,\"height\":0}],\"fixedIssues\":[],\"slug\":\"Boehringer_Ingelheim\",\"title\":\"Boehringer Ingelheim\",\"content\":\"$1f\",\"description\":\"Boehringer Ingelheim\\n\\nBoehringer Ingelheim headquarters \\nBoehringer Ingelheim is a privately held, research-driven biopharmaceutical company headquartered in Ingelheim am Rhein,...\",\"metadata\":{\"categories\":[\"BI\",\"Boehringer\"],\"lastModified\":\"1761582740\",\"contentLength\":\"77494\",\"version\":\"1.0\",\"lastEditor\":\"system\",\"language\":\"en\",\"isRedirect\":false,\"redirectTarget\":\"\",\"isWithheld\":false},\"stats\":{\"totalViews\":\"133879\",\"recentViews\":\"133879\",\"dailyAvgViews\":4462.63330078125,\"qualityScore\":1,\"lastViewed\":\"1761886111\"},\"linkedPages\":null},\"found\":true},\"dataUpdateCount\":1,\"dataUpdatedAt\":1761886112552,\"error\":null,\"errorUpdateCount\":0,\"errorUpdatedAt\":0,\"fetchFailureCount\":0,\"fetchFailureReason\":null,\"fetchMeta\":null,\"isInvalidated\":false,\"status\":\"success\",\"fetchStatus\":\"idle\"},\"queryKey\":[\"page\",\"Boehringer_Ingelheim\"],\"queryHash\":\"[\\\"page\\\",\\\"Boehringer_Ingelheim\\\"]\"}]},\"children\":\"$L20\"}]\n"])</script><script nonce="MDFkNTc1MWYtZjA5OC00YWU2LWJmZGQtOTJjODZlMmExY2I0">self.__next_f.push([1,"c:{\"metadata\":[[\"$\",\"title\",\"0\",{\"children\":\"Boehringer Ingelheim\"}],[\"$\",\"meta\",\"1\",{\"name\":\"description\",\"content\":\"Boehringer Ingelheim is a privately held, research-driven biopharmaceutical company headquartered in Ingelheim am Rhein, Germany. Founded in 1885 by Albert Boehringer initially as a chemicals manufacturer producing tartaric acid and baking powder, it has grown into a global enterprise focused on developing innovative therapies for human and animal health. The company's independence from public markets allows a long-term perspective on research and development, with annual R\u0026D investments...\"}],[\"$\",\"meta\",\"2\",{\"name\":\"author\",\"content\":\"system\"}],[\"$\",\"link\",\"3\",{\"rel\":\"manifest\",\"href\":\"/manifest.webmanifest\",\"crossOrigin\":\"$undefined\"}],[\"$\",\"meta\",\"4\",{\"name\":\"keywords\",\"content\":\"BI, Boehringer\"}],[\"$\",\"meta\",\"5\",{\"name\":\"robots\",\"content\":\"index, follow\"}],[\"$\",\"meta\",\"6\",{\"name\":\"googlebot\",\"content\":\"index, follow, max-snippet:-1\"}],[\"$\",\"link\",\"7\",{\"rel\":\"canonical\",\"href\":\"https://grokipedia.com/page/Boehringer_Ingelheim\"}],[\"$\",\"meta\",\"8\",{\"property\":\"og:title\",\"content\":\"Boehringer Ingelheim\"}],[\"$\",\"meta\",\"9\",{\"property\":\"og:description\",\"content\":\"Boehringer Ingelheim is a privately held, research-driven biopharmaceutical company headquartered in Ingelheim am Rhein, Germany. Founded in 1885 by Albert Boehringer initially as a chemicals manufacturer producing tartaric acid and baking powder, it has grown into a global enterprise focused on developing innovative therapies for human and animal health. The company's independence from public markets allows a long-term perspective on research and development, with annual R\u0026D investments...\"}],[\"$\",\"meta\",\"10\",{\"property\":\"og:url\",\"content\":\"https://grokipedia.com/page/Boehringer_Ingelheim\"}],[\"$\",\"meta\",\"11\",{\"property\":\"og:site_name\",\"content\":\"Grokipedia\"}],[\"$\",\"meta\",\"12\",{\"property\":\"og:locale\",\"content\":\"en\"}],[\"$\",\"meta\",\"13\",{\"property\":\"og:image\",\"content\":\"https://grokipedia.com/icon-512x512.png\"}],[\"$\",\"meta\",\"14\",{\"property\":\"og:image:width\",\"content\":\"512\"}],[\"$\",\"meta\",\"15\",{\"property\":\"og:image:height\",\"content\":\"512\"}],[\"$\",\"meta\",\"16\",{\"property\":\"og:image:alt\",\"content\":\"Boehringer Ingelheim\"}],[\"$\",\"meta\",\"17\",{\"property\":\"og:type\",\"content\":\"article\"}],[\"$\",\"meta\",\"18\",{\"property\":\"article:modified_time\",\"content\":\"1970-01-21T09:19:42.740Z\"}],[\"$\",\"meta\",\"19\",{\"name\":\"twitter:card\",\"content\":\"summary\"}],[\"$\",\"meta\",\"20\",{\"name\":\"twitter:creator\",\"content\":\"@Grokipedia\"}],[\"$\",\"meta\",\"21\",{\"name\":\"twitter:title\",\"content\":\"Boehringer Ingelheim\"}],[\"$\",\"meta\",\"22\",{\"name\":\"twitter:description\",\"content\":\"Boehringer Ingelheim is a privately held, research-driven biopharmaceutical company headquartered in Ingelheim am Rhein, Germany. Founded in 1885 by Albert Boehringer initially as a chemicals manufacturer producing tartaric acid and baking powder, it has grown into a global enterprise focused on developing innovative therapies for human and animal health. The company's independence from public markets allows a long-term perspective on research and development, with annual R\u0026D investments...\"}],[\"$\",\"meta\",\"23\",{\"name\":\"twitter:image\",\"content\":\"https://grokipedia.com/icon-512x512.png\"}],[\"$\",\"link\",\"24\",{\"rel\":\"icon\",\"href\":\"/favicon.ico\",\"type\":\"image/x-icon\",\"sizes\":\"16x16\"}],[\"$\",\"$L21\",\"25\",{}]],\"error\":null,\"digest\":\"$undefined\"}\n"])</script><script nonce="MDFkNTc1MWYtZjA5OC00YWU2LWJmZGQtOTJjODZlMmExY2I0">self.__next_f.push([1,"11:\"$c:metadata\"\n"])</script><script nonce="MDFkNTc1MWYtZjA5OC00YWU2LWJmZGQtOTJjODZlMmExY2I0">self.__next_f.push([1,"22:I[61172,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"4684\",\"static/chunks/24cf1b50-159cca90b09285e0.js\",\"1829\",\"static/chunks/9ffa21ba-c069766d809bd4c7.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"7720\",\"static/chunks/7720-3a1e7e411adba2d3.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"600\",\"static/chunks/600-9a9fcafaaa6c1c4c.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"5448\",\"static/chunks/5448-2a3cfd853d899c9a.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"8\",\"static/chunks/8-8ca70ca619d8e099.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"6304\",\"static/chunks/app/page/%5Bslug%5D/page-540a27b6839afde5.js\"],\"PageEditorProvider\"]\n"])</script><script nonce="MDFkNTc1MWYtZjA5OC00YWU2LWJmZGQtOTJjODZlMmExY2I0">self.__next_f.push([1,"23:I[63493,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"4684\",\"static/chunks/24cf1b50-159cca90b09285e0.js\",\"1829\",\"static/chunks/9ffa21ba-c069766d809bd4c7.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"7720\",\"static/chunks/7720-3a1e7e411adba2d3.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"600\",\"static/chunks/600-9a9fcafaaa6c1c4c.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"5448\",\"static/chunks/5448-2a3cfd853d899c9a.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"8\",\"static/chunks/8-8ca70ca619d8e099.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"6304\",\"static/chunks/app/page/%5Bslug%5D/page-540a27b6839afde5.js\"],\"default\"]\n"])</script><script nonce="MDFkNTc1MWYtZjA5OC00YWU2LWJmZGQtOTJjODZlMmExY2I0">self.__next_f.push([1,"20:[\"$\",\"$L22\",null,{\"children\":[\"$\",\"$L23\",null,{\"slug\":\"Boehringer_Ingelheim\"}]}]\n"])</script></body></html>